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ABSTRACT
Background: Organs transplanted between discordant species such as pig-to- 
primate, undergo hyperacute rejection due to the presence of natural xenogenic 
antibodies. Hyperacute rejection xenograft rejection can now be controlled by 
various approaches, but other immunological barriers have yet to be overcome. 
Polyspecific HLA antibodies often crossreact with other HLA antigens through so 
called public and private determinants. Swine leucocyte antigens share 
approximately 75-87% homology with HLA and as such, it may be expected that 
some HLA antibodies would react with certain SLA antigens. In an attempt to 
evaluate this possible occurrence, sera were selected from individuals with varying 
panel reactive antibodies.
Methods: Naturally occurring anti-pig antibodies were absorbed using an excess 
of leucocyte depleted washed pig red blood cells (PRBC). Antl-HLA/SLA cross 
reactivity was investigated by 1) testing the pre and post-absorbed sera against a 
panel of out bred pig splenocytes; 2) HLA class I and II antibodies were absorbed 
out using pooled EBV cell and human platelets; 3) Human non-Gala1,3Gal 
antibody was adsorbed onto, then eluted from pig splenocytes. The presence of 
HLA specific antibody in the eluates was investigated.
Results. Natural anti-pig antibody adsorption was confirmed in all sera by flow 
cytometry against PRBC. Anti-HLA activity was still present and undiminished post- 
PRBC-adsorption. Some HLA specific sera still reacted against some pigs after 
removal of natural antibody and no reactivity was identical to any other. Upon 
absorption of the HLA antibodies, the majority of anti-pig reactivity was abrogated. 
The eluates showed that HLA class I and II antibodies were eluted from pig 
splenocytes. In addition, the presence of a non-HLA antibody was also found. 
Conclusions: The results show that there is cross reactivity between igG anti-HLA 
and pig lymphocytes.
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Chapter 1 : ___________________________________________________   Introduction
CHAPTER 1: INTRODUCTION
1.1 GENERAL INTRODUCTION
The critical shortage of allogeneic organs for transplantation has generated an 
interest in animals, particularly the pig, as a possible source of organs for 
xenotransplantation. However, organs from such discordant animals are subject to 
hyperacute rejection by humans (Cooper et al., 1988). Antibodies play a critical role in 
this process and studies have shown that IgG, IgA and IgM natural antibodies 
recognise the disaccharide gaiactose-al ,3-galactose-R (Galal ,3Gal) on swine 
endothelium (Good eta!., 1992; Platt eta!., 1991; Sandrin eta!., 1993).
Much research has focused on the removal or inhibition of these xenoreactive 
antibodies, which cause hyperacute rejection. The infusion of specific soluble 
sugars proved unsuccessful since the sugar used (Galal-6GaI) failed to bind to 
30% of the xenoreactive antibodies (Ye eta!., 1994). Depletion of the anti-Galal- 
3Gal using specific Galal-3Gal affinity columns has been used with success, and 
in experiments using pig kidneys transplanted into baboons hyperacute rejection 
was abrogated (Taniguchi eta!., 1996b). However, the reduction was transient and 
was followed by a rebound in the antibody. Nonetheless, although hyperacute 
rejection can be prevented in some models, this is followed by an influx of 
inflammatory mediators and natural killer (NK) cells.
In the allograft situation, it has been shown that positive crossmatches in renal 
and heart allografts due to pre-formed HLA specific antibodies cause hyperacute or 
acute rejection (Terasaki, Kreisler and Mickey, 1971). In xenotransplantation, a 
positive crossmatch would also be a contraindication to successful transplantation. 
Both IgG and IgM HLA antibodies have been described and there is still debate as to 
the role of IgM HLA antibodies and allograft outcome. However, IgG HLA specific 
antibodies have been found to lead to graft loss (Taylor et a!., 1989). Often these 
antibodies are multispecific and cross-react with other HLA antigens through so 
called public and private determinants. HLA and swine leucocyte antigens (SLA) 
show a sequence homology between 75-85%; (class I about 79% and between 74-
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87% for class II). On the premise that HLA antibodies can cross-react with other 
HLA antigens (and since there is homology between HLA and SLA) it is not 
unreasonable to speculate that HLA specific antibodies may cross-react with SLA 
antigens.
Several groups have looked at this cross reactivity using patient sera that 
have anti-HLA antibodies. One group absorbed out the xenoreactive antibodies 
using pig red blood cells (PRBC) and found that a pig reactive antibody was still 
present. This reaction was abrogated by absorbing the anti-HLA sera further with a 
pool of human platelets that express HLA class I only (Taylor et al., 1998). Another 
group purified SLA antigens, then western blotted and immunoenzyme developed 
them with purified IgG HLA antibody and found a 45kd band which is the same size 
as MHO class I molecule (Naziruddin et al., 1998).
1.2 GENETIC MANIPULATION TO PREVENT XENOTRANSPLANT
REJECTION
A possible mechanism to avoid hyperacute rejection and/or delayed 
xenograft reaction could involve genetic manipulation. Groups have focused on 
manipulating genes to prevent the expression of Galal ,3Gal carbohydrate. Although, 
in the absence of this carbohydrate, xenoreactive antibodies specific for epitopes 
other than Galal ,3Gal may still initiate rejection of porcine organs (Gaca et al., 2001 ; 
McCurry et al., 1997).
The major difference between pigs and humans in regard to expression of 
oligosaccharides on the vascular endothelium is the presence of Galal-3Gal in the 
pig where ABH oligosaccharides are expressed in the human (Section 1.7.4). 
Therefore, an option would be to insert or delete particular genes that would 
prevent the expression of the Galal,3Gal epitope, such as a1,2-fucosyltransferase 
(a1,2FT). This would result in the expression of an H antigen, to which humans do 
not raise natural antibodies. Other enzymes could also be used in remodeling the 
carbohydrate antigen (Cooper, Keren and Oriol, 1993; Koike et al., 1996;Koyota et 
al., 2001; Sandrin etal., 1995; Sharma etal., 1996; Tanemura etal., 1997b; 
Tanemura et al., 1997c). Mice transgenic for a l ,2FT have been bred that express
22
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high levels of H blood group epitopes and a marked reduction, (of 70%) In the 
Galal-3Gal epitopes (Sandrin etal., 1995; Sharma etal., 1997; Shinkel etal.,
1997; Tanemura et al., 1997a). However, the insertion of the a l ,2FT gene led to a 
rearrangement of glycosylation on the surface of the tissues leading to exposure of 
normally cryptic antigens such as sialylated Tn and Forssman antigens, to which 
humans have preformed antibodies (Shinkel et al., 1997).
An alternative approach to prevent the binding of the xenoreactive 
antibodies would be to produce a pig that would express lower levels of Galal- 
3Gal epitopes. As the Galal-3Galepitope is produced by the enzyme a 1,3 
galactosyltransferase (al ,3GT), this single gene could be "knocked out" to produce 
a Galal-3Gal deficient pig (Shinkel et al., 1997). Using this strategy, mice have 
been bred that do not express Galal -3Gal epitopes although hearts transplanted 
from these knockout mice still undergo delayed rejection when perfused with 
human plasma (Tearle et al., 1996). Thus, it was hypothesised that the absence of 
Galal-3Gal may expose the presence of underlying "cryptic" oligosaccharide 
epitopes against which humans also have antibodies or that there are other 
mechanisms provoking the rejection (Shinkel etal., 1997). Galal-3Gal knockout 
pigs have been produced through cloning procedures that inactivate the gene for 
a 1-3 galactosyltransferase (Betthauser et al., 2000) (Onishi et al., 2000). To date 
there have been no further publications regarding this work.
In the mid 1990s, pigs transgenic for human DAF (hDAF) were produced 
and their organs were used in the pig-to-cynomolgus monkey model. However, the 
validity of this model is questionable since some of the control animals (non- 
transgenic) did not undergo hyperacute rejection and grafts functioned for fifteen 
days suggesting that hyperacute rejection is not consistent in this combination 
(Zaidi etal., 1998). Further studies have been performed using the hDAF 
transgenic pigs-to-baboon model and have shown that organs from these 
transgenic pigs do not undergo hyperacute rejection but are subsequently lost due 
to acute vascular rejection (Schmoeckel et al., 1998). The almost consistent 
prevention of hyperacute rejection when hDAF organs have been transplanted
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demonstrates the therapeutic benefit of this approach, particularly when it is 
combined with extracorporeal immunoabsorption of Gala1-3Gai antibody.
If hyperacute rejection due to xenoreactive antibodies was prevented, there 
is still a potential for anti-HLA/SLA cross reaction because of highly sensitised 
patients. Therefore, either breeding or selecting pigs that express particular SLA 
class I and II antigens that lack private and public epitopes to which HLA 
antibodies cross-react would be advantageous.
1.3 MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)
The major histocompatibility complex (MHO) genes are encoded on 
chromosome six in man and were originally described in the mouse on chromosome 
17 by Gorer e ta l., in 1948 (Reviewed Brent, 1997). The locus was originally identified 
and named because of its role in tissue rejection following transplant and many of its 
genes have been shown to have important functions in the biology of the immune 
system. Although the MHC was originally identified via its influence on graft rejection, 
this is not its physiological role. These antigens present self-antigens in the thymus 
and foreign antigens in the periphery to T cells. They also play a role in the induction 
of an immune response and tolerance and induce antibody-mediated (B cell) immune 
responses. An individuals T cells recognise processed peptide via their T cell receptor 
(TOR). CD4* T cells recognise antigen in class II molecules, whilst CD8^ T cells 
recognise antigen in class I molecules. Other genes within the MHC such as DM 
(which causes the release of peptides within class I molecules that do not have 
optimal fit) and TAP (Transporter associated with Antigen Processing) located within 
the class II region, determine which antigens are processed and presented (Beck et 
a/., 1996b).
Vertebrates all seem to have MHC genes and it appears that the clustering of 
antigen processing and presentation is conserved in this area in mammals. No 
outbred species other than humans has been studied in sufficient detail to accurately 
define the number and nature of expressed MHC class I genes on a range of 
haplotypes. However, as work has progressed, it appears that the situation in humans 
(with 3 expressed class I genes on all haplotypes) maybe unusual. Mice (Wroblewski,
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Kaminsky and Nakamura, 1994), rats (Joly etal., 1996), cattle (Ellis etal., 1999), 
horses (Ellis etal., 1995), pigs (Chardon etal., 1999) and some primates, all 
demonstrate variety in the number of genes expressed and variation in their 
configuration. For example, none of the cattle class I genes are consistently 
expressed and the haplotypes differ from one another both in number and 
composition (Ellis et al., 1999). Since there is a lack of locus-specific characteristics 
within the coding region (in humans locus-specific characteristics within the coding 
region allow the straightforward assignment of class I genes) the interpretation of the 
cattle MHC class I sequences is difficult. The reason why cattle should exhibit a 
greater range of MHC haplotype configuration is not clear (data suggests there are at 
least 4 expressed class I loci compared to the three in humans) and the functional 
implication of these variations between the species is yet to be addressed.
The MHC genes in humans encode approximately 4 million base pairs and 
many of these regions are highly polymorphic, particularly the HLA class I and class II 
genes. These are the most polymorphic known in higher vertebrates and it is therefore 
rare for two individuals to have an identical set of MHC glycoproteins, making it 
difficult to perfectly match donor and recipients for organ transplantation in humans 
(apart from genetically identical twins) (Takiff et al., 1988).
The reason why the MHC is so highly polymorphic was identified after the 
discovery that MHC molecules function to direct the action of T lymphocytes towards 
those host cells that have foreign antigen on their surface, thereby inducing an 
immune response to eliminate the foreign body. The polymorphism within the MHC 
probably reflects selection (driven by external pathogens) balanced against the need 
to avoid harmful auto-immunity. This strategy provides the mechanism by which MHC 
molecules can bind many different peptides and present them to T cells, but as there 
are a limited number of MHC antigens that an individual inherits, they must be capable 
of presenting nearly all Independent antigens. However, since the MHC molecule 
determines how an antigen is presented to a T cell, it is the genotype of the individual, 
which determines the overall focus of the immune response (Meruelo, Deak and 
McDevitt, 1977; Katz etal., 1986).
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The MHC arrangement of class I, class II and class III appears to be fairly well 
conserved throughout the various mammal species as maps of this region all appear 
similar (Kronenberg, Brines and Kaufman, 1994). In most vertebrae species studied, 
the genetic polymorphism of the MHC class II molecules lies in the variable amino 
acid residues of the first domain of the p chain encoded by the second exon. In MHC 
class I molecules, it lies in the a1 and a2 domains encoded by exons 2 and 3.
1.3.1 Human MHC
The human MHC is located on the short arm of chromosome 6 and is 
subdivided into three classes based on certain functional characteristics of the 
genes in each class; class I, class II and class III (Klein and Figueroa, 1986). This 
complex spans 4-6 megabases of DNA (Figure 1.1).
The most centromeric MHC genes are the class II region containing the 
HLA-DP, DQ and DR loci. Between the DP and DQB loci are the HLA-DM and DO 
loci that function in quality control of peptide loading by the class II molecules (van 
Ham et al., 1996). In addition, TAP and the proteosome LMP loci are located here and 
the products of these genes play a role in loading class I molecules with peptide. The 
proteosome functions as a general proteolytic enzyme for the degradation of proteins. 
It produces the majority of antigenic peptides for presentation by the class I molecules 
at the cell surface. The molecules encoded by TAP are required for the transport of 
antigenic peptide to be ioaded into the class I molecule by tapasin, before the class I 
molecule travels to the cell surface. HLA-DP, DQ and DR molecules are found as 
pairs consisting of an a and a p chain that form the heterodimeric protein expressed 
at the cell surface. These are members of the immunoglobulin supergene family, 
which are specialised for presentation of antigenic peptide (derived from 
extracellular proteins), to the T cell receptor on CD4* cells. Since these molecules 
are closely associated on the chromosome and their genomic structures are similar, it 
has been suggested that this organisation arose by duplication of ancestral genes.
The class I region is at the telomeric end of chromosome 6 and contains the 
HLA-A, B and C regions and related loci spread over 2 megabases (Figure 1.1).
These genes are also members of the immunoglobulin supergene family and are,
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involved in presenting peptide from intraceliuiarly derived, processed antigens to 
CD8* cytotoxic T cells. MHC class I molecules form heterodimers with the non-MHC 
encoded p2 microglobulin and are expressed ubiquitously on most nucleated cells, 
except the brain cortex, cerebellum, sympathetic ganglia, parathyroid gland, 
thyroid, exocrine pancreas, hepatocytes, sperm, skeletal and smooth muscle cells 
(Daar etal., 1984a; Daaref a/., 1984b; Fleming etal., 1981; Natali etal., 1984).
Centromeric to the HLA-B locus, the loci for the variant, class l-like, molecules 
MICA and MICB are found. These genes are polymorphic but the other MIC genes 
named MICC, D and E are pseudogenes (Steinie, Groh and Spies, 1998). These 
molecules interact with a common receptor (NKG2D/DAP10) on yô T cells (gut 
mucosal T cells), CD8* T cells and NK cells (Bauer etal., 1999; Das et al., 2001; 
Groh et al., 2001 ; Groh et al., 1998). Telomeric to the HLA-B locus is the HLA-C 
locus, followed by the non-classical class I genes HLA-E. The classical HLA-A locus 
is situated centromeric to other non-ciassical HLA-G and HLA-F.
MHC class I molecules can also interact with NK cells to either prevent NK- 
mediated lysis or activate NK lysis (Moretta etal., 1997). These NK receptors can be 
activated by all the class 1 loci, but they appear to be restricted to conserved epitopes. 
In some cases, peptide bound within the class I molecule may also play a role as the 
nature of the peptide in the HLA-Cw molecule does not effect NK recognition whilst it 
does in HLA-B*2705 (Colonna, 1997). In addition, the non-classical HLA-G that is 
expressed on extravillous trophoblasts in placental tissue inhibits NK-mediated attack.
Between the HLA class II and class I regions is the class III region which 
occupies 1 Mb of DNA. It contains a miscellaneous collection of densely packed 
genes. Many of the genes have not been characterised fully at the functional level but 
a role for them in the innate response and inflammation has been postulated. Those 
genes with obvious roles in the immune response are members of the complement 
cascade C2, C4 and Bf (complement factor B) and the tumour necrosis family 
members, tumour necrosis factor (TNF), Leukotriene A (LTA) and LTB hydrolases. 
However, many of the genes in this region play no role in the immune response 
(Khanna and Campbell, 1996; Perlmutter etal., 1986; Rittner and Schneider, 1989; 
Sim and Cross, 1986).
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1.3.2 Swine MHC
The pig MHC SLA is situated on Sus scrofa chromosome 7 (SSC 7) and is 
disrupted by the centromere (Geffrotin et al., 1984)(Figure 1.2). Thus, the class I and 
III regions are located on the short q-arm and the class II on the long p-arm of the 
chromosome (Smith et al., 1995). This represents the first example of a clear 
separation between groups of genes, which are usually tightly linked. However, in 
some cattle haplotypes, the class II genes are clustered at least 17centimorgan (cM) 
apart from the main MHC region. The MHC of swine has been shown to have 
extensive similarities to its human counterpart in both structure and function 
(Thistlethwaite etal., 1984). These MHC genes control humoral and cellular 
responses and the polymorphisms appear to influence disease resistance directly. 
Certain porcine MHC haplotypes are associated with superior antibody responses 
(Mallard, Wilkie and Kennedy, 1989; Vaiman, Hauptmann and Mayer, 1978). 
Additionally, the immune responses to some vaccines have been reported to be 
under SLA genetic control (Rothschild et al., 1984a; Rothschild et al., 1984b).
The overall genetic organisation of the swine MHC closely resembles that of 
other mammals, showing three main regions - class I, class II and class III. 
However, the swine MHC displays several remarkable features. There is an 
unusually small number of detectable MHC class I sequences and the total size of 
the porcine class I region is half that of the human. Depending on the techniques 
used, the number of class I genes varies from 7-10 per haplotype in miniature lines 
as well as in commercial breeds. This is in contrast to humans and rodents who 
exhibit 20-30 class I genes. Many aspects of the pig MHC remain undeciphered, 
such as the characterisation of all the functional SLA classical and class I related 
genes in specific haplotypes.
Most of the swine class I and II genes of the inbred, dd haplotype NIH 
minipig have been isolated and either entirely or partially sequenced. Among the 
characterised class I genes, 3 classical class I polymorphic genes named PD1,
PD7 and PD14 have been described (Satz et al., 1985). The PD7 gene appears to 
be expressed at low levels. Distantly related class I genes have also been 
discovered including the PD6 which does not appear to be expressed at the cell
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surface (Ehrlich et al., 1987). Further work using the NIH minipig with aa and cc 
haplotypes showed alleles for the PI locus (named PA1, PCI and PD1), as well as 
alleles for the PD14 locus (named PA14, PC14 and PD14; Sullivan et al., 1997).
Velten (1998) described the first map of the SLA using a large white pig of 
the HOI haplotype. It was constructed by alignment of yeast artificial 
chromosomes using primer pairs based on PD1, PD7, PD14, PD6 and anchor 
genes mapped within the human MHC complex. From this work a number of 
related class I genes was shown. Nine different class I genes were partially 
sequenced. SLA-1 and SLA-10 were highly homologous to the classical PD1 gene 
with 9 and 6 nucleotide differences respectively. Two others, SLA-5 and SLA-9, 
resembled PD14 and PD7 with 10 and 9 nucleotide differences respectively. The 
SLA-6 gene had 6 nucleotide differences from the non-classical PD6. The 
sequence of the SLA-7 gene suggests it is a distinct member of the class I gene 
family with no homologues in the NIH minipigs (Velten et al., 1998). The SLA-4 
sequence had a base deletion at position 326 leading to a frameshift and 
premature termination. This was considered a pseudogene. The SLA-8 gene was 
only detected by southern blot analysis in this work but it was subsequently 
sequenced (Velten et al., 1999). These 10 identifiable SLA class I genes were 
located in two clusters of approximately 200kb each. One of the clusters comprised 
7 classical class I genes including pseudogenes and the other cluster contained 
class l-related genes. At present it is not known which genes of the classical class 
I genes are involved in the serologically defined SLA class I alleles. However, the 
recent work by Velten et al., (1999) has been able to provide clearer data on the 
order of the class 1 sequences in these clusters (Figure 1.2). They have discovered 
a new class 1 divergent gene located telomeric to the pig ZNF173 (zinc finger) 
gene. In mice an H2-related gene (H2-M5) was characterised between the ZNF173 
and the MOG (myelin/oligodendrocyte glycoprotein) genes. In humans the HLA-A 
locus is located between these two evolutionarily conserved genes. The new 
porcine class I gene may be closer to the H2-M5 than the classical class I locus as 
it was not amplified by class I primer pairs (Velten et al., 1999).
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The SLA-6 gene and the human, non-classical, class-1, HLA-E genes share 
common features. Both are mainly transcribed in quiescent T cells and have a 
300bp insert in intron 5 that is absent from other classical and non-classical genes.
Closest to the centromere are the class 111 genes, TNFA and BATI (HLA-B 
associated transcripts), then the cluster of three class-1 related genes SLA-6, 7 and 
8, followed by two MIC-like genes and SCI (cell growth regulated gene), P0U5F1 
(transcription factor containing a POD (pituitary-specific Pit-1, Octamer binding 
proteins and neural Unc-89) domain), S (S-protein) and the p52 genes. The partial 
sequences of the pig MIC genes show approximately 70% homology to the human 
MIC genes and less than 20% to the classical SLA class I or class l-related genes. 
In humans there appears to be 5 related MiC genes, whereas in the pig only 2 
have been identified so far (Bahram and Spies, 1996). Other species such as the 
goat, cow, primates, dog and hamster also have these genes but they appear to 
have been lost in mice (Bahram etal., 1994). The expression pattern of swine MIC 
genes and their interaction with human T and NK cells maybe of importance with 
respect to xenotransplantation. The SLA-2 and 4 genes are situated very close 
together and their order could not be clarified; centromeric to these lies the SLA-
11. The remaining 4 class I genes SLA-3, 9, 5 and 1, and a class l-related gene, lie 
telomeric to the SLA-2 and 4. The locations of RFB30 (ring finger protein) and 
ZNF173 match that found in humans and mice. From this study 12 class I 
sequences were defined in the pig HOI haplotype and it remains to be defined if 
there is a similar organisation in other SLA haplotypes. Transcription studies in 
fibroblasts homozygous for the HOI haplotype, showed 3 classical class I genes, 
SLA 1, 2 and 3 (Velten et al., 1999). Other SLA class I genes may also be 
transcribed but were not detected in these experiments. This finding was expected 
as the serological and biochemical studies in the pig HOI always led to the 
characterisation of three distinct SLA class I molecules. However, unexpectedly, 
the class l-related gene SLA-7 was also detected (Velten et al., 1999). It is of note 
that transcripts from this gene were not found in lymphocytes from a pig carrying 
the HOI haplotype from another origin.
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The pig class II DRA and KE6 genes are separated by about 450kb which is 
about half that of the corresponding human class II region (Chardon, Renard and 
Vaiman, 1999). Large variations in the size of the MHO class II regions do occur in 
other mammals. Additional rearrangements of the pig class II region may have 
occurred following disruption by the centromere.
This intra-species similarity may have emerged as a result of convergent 
evolution driven by the need to react with common pathogens. Analysis of class II 
sequences of SLA-DRB1 and DQB genes demonstrates that codons 21-25 and 51-55 
are highly conserved in these genes (Kanai et al., 1999).
Other work has indicated the presence of 3 SLA-DRB loci in the large white 
pig of the HOI haplotype, 2 of which are pseudogenes (Chardon, Renard and 
Vaiman, 1999). Close to these DRB genes is the DRA locus. Telomeric to the DRB 
genes is the DQA locus and subsequently, two other DQB loci, one of which maybe a 
pseudogene or a DQB-related sequence. Two DQB loci are also described in the NiH 
minipig but it is unclear if they are both functional (Gustafsson et al., 1990b; Pratt et 
al., 1990). It is thought that the DOB locus is close to the DQB locus followed by the 
LMP7, TAP, DMB and DMA, with the possibility of a DPA locus. Restriction fragment 
length polymorphism (RFLP) analyses show DQB and DRB to be polymorphic in NIH 
minipigs and also in the Swiss Large White and American Hampshire breeds (Sachs 
etal., 1988; Shia etal., 1995).
No pig DPB-like locus has been detected. However, a pig DPB sequence was 
previously recovered from a miniature pig SLA  ^genomic library but no transcriptional 
products of pig DP genes have been detected (Pratt et al., 1990). This variation in the 
detection of DPB between breeds may indicate the presence in variations of gene 
content between breeds. Thus, each individual pig may have as many as 10 
expressed SLA antigens, from a polymorphic collection of up to 100 alleles.
1.4 STRUCTURE OF CLASSICAL CLASS I AND II MHC MOLECULES
The HLA class 1 and II loci are highly polymorphic with many hundreds of 
allelic variants involved in antigen presentation. Both MHC class I and class II 
antigens are cell surface glycoproi;eins consisting of two-noncovalently associated
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polypeptides. An understanding of how the MHC molecules present antigen to T 
cells came about when the 3-D structure was described for the HLA-A2 molecule 
(Bjorkman et aL, 1987b; Saper, Bjorkman and Wiley, 1991). Later the structure of 
the HLA class II molecule was described by Brown et aL, (1993). As predicted, the 
molecules had two membrane-proximal, -immunoglobulin-like domains (a3 and P2 
microglobulin for class I and the a2 and p2 for class II). The non-immunoglobulin 
domains form a platform of eight p strands on top of which are the a helixes that 
bow upward in the centre. The most distinctive structural feature of the MHC class I 
and II molecules is the groove formed by the sides of the helixes and the floor of the 
p-sheet. Peptides are bound in this groove and presented to the immune system. 
This groove is lined with polymorphic amino acids, which are spread throughout the 
a1 and a2 in the class I and mainly the pi domains in the class II molecule. Upon 
folding of the molecule, most of the polymorphic residues are in the binding cleft. 
The protein domains that form the peptide-binding groove of these molecules allow 
particular alleles to bind a diverse but relatively distinct variety of peptides. The 
majority of peptides bound within these MHC molecules are derived from self­
proteins. The mechanism of peptide binding in both cases has evolved to allow the 
binding of a multitude of foreign peptides as well as self-peptides to a large but 
limited number of MHC molecules.
Sequence comparisons of the HLA class I and II genes have shown a high 
level of synonymous and non-synonymous base changes in these domains, which 
is not found in flanking regions (Beck et aL, 1996a). The maintenance of this 
polymorphism may indicate a strong selective element probably driven by 
resistance to pathogenic organisms. The non-classical class I molecules, HLA-E, - 
F and -G and the class II genes not directly involved in antigen binding (HLA-DM 
and DO) are less variable in their sequence, thus supporting the theory of 
polymorphism is a function of antigen binding. The non-classical class I molecules 
are expressed at lower levels on tissue than the classical class I molecules (Lury, 
Epstein and Holmes, 1990).
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1.4.1 Structure of the HLA class I Molecules
No other human genetic locus exhibits this degree of polymorphism. Over 100 
alleles have been identified at the HLA-A and -B loci, with yet more to be 
discovered.
HLA class 1 molecules are composed of two polypeptide chains consisting of 
a heavy chain (that is 345 amino acid residues long and spans the membrane 
bilayer) and the non-covalently bound P2 microglobulin (132^ ) light chain (Cresswell, 
Turner and Strominger, 1973). The smaller (32  ^are not encoded in the MHC but on 
chromosome 17. The heavy chain has 3 extracellular domains a1, a2, and a3, 
each of which is approximately 90 amino acids long and is encoded by a separate 
exon. The a3 and p2m are relatively conserved and show sequence homology to 
immunoglobulin constant domains.
The first 5 exons (separated by introns of various lengths) code respectfully 
for a signal peptide, the first, second, and third extracellular domains and the 
transmembrane region of the protein molecule. The cytoplasmic segment is 
encoded by part of the 5th, 6th and 7th exons. A major advance in the 
understanding of how MHC molecules present antigen to T cells came when the 3- 
D structure of HLA-A2 was resolved to 3.5 Angstrom (A) by X-ray crystallography 
and further elucidated when the molecule was resolved to 2.6À (Bjorkman et al., 
1987b; Saper, Bjorkman and Wiley, 1991). The protein crystal structure was like an 
open 3-D lattice with much of its volume being taken up with water molecules. The 
structure of other class I molecules such as HLA-A68, HLA-B27, HLA-B53, HLA- 
B35, and some of the mouse class I H-2 molecules have also been resolved 
(Garrett etal., 1989; Guo etal., 1992; Madden etal., 1991; Madden etal., 1992; 
Balendiran etal., 1997; Smith etal., 1996a; Smith etal., 1996b). The comparison 
of the various MHC class I molecules has shown that there are structural 
conformations shared between the molecules which contribute to their role in 
antigen presentation, but these conformations show variations that are unique to 
the particular class-l/peptide complex (Smith et al., 1996b).
The HLA class I molecule consists of two structurally similar domains, a1 
and a2, both which have the same tertiary folds as (32m (Figure 1.3). The a1 and
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a2 domains are nearly identical to each other in structure and each form a four 
stranded anti-parallel p-sheets proximal to each other forming an eight stranded 
sheet. The sheet has a left-handed twist of about 70 degrees between the 
outermost strands of a1 and a2 domains (Bjorkman et aL, 1987b). In the helical 
region of the a1 domain, a short helix (residues 58-84) precedes a longer curved a 
helix (residues 138-148). The longer helix in the a2 domains is kinked at residue 
162 followed by the short helix that connects the a2 to the a3 domains. This 
structure is supported by the immunoglobulin like structures of the a3 and p2m.
The binding cleft situated between the a1 and a2 domains is orientated away from 
the membrane allowing the interaction with the TCR, NK receptors and the CD8 
molecule (Bjorkman et aL, 1987b). This cleft is occupied generally by a peptide of 8 
to 11 or more amino acids depending on the particular class I molecule. There are 
hydrogen bonds in the a1 and a2 domains and a disulphide bond at residue 101 of 
the N-terminal p-strand connecting to the long helix at residue 164 of the a2 
domain. A series of salt-bridged hydrogen bonds crosslinks the p-strands and 
connects the p-sheet to the helices. Many of these salt bridges are conserved in 
class I sequences and appear to stabilise this region and the interaction with bound 
peptide. The loops of the p-pleated sheet of the a1 and a2 domains extend 
alternatively above and below the p-sheet and interact with the a3 domain and the 
p2m. All MHC class I molecules have an N-linked oligosaccharide complex 
attached at asparagine 86 that is in a loop connecting the a1 to the a2 domain 
(Saper, Bjorkman and Wiley, 1991). However, glycosylation at this site appears to 
be unnecessary for the molecules function or folding (Ploegh, Orr and Stominger, 
1981).
The interface between p2m and the a1 and a2 helices extends under the 
entire p-sheet. The Pam acts as a keystone and is an integral element in the 
stability of the a1 and a2 domain structure. By contrast, the a3 domain has a small 
interface with a1 and a2 domains, which is at the extreme edge of the domain. The 
top of the molecule presents itself to the outside environment and the TCR. The 
groove, which varies in width and depth between the two alpha helices, provides a
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binding site for processed peptide, which is then presented to the T cell (Saper, 
Bjorkman and Wiley, 1991).
The structure of the groove explains the high affinity of peptide-MHC 
interactions and how a single MHC molecule may bind a multitude of different 
peptides that share particular structural features. The amino acid side chains in the 
centre of the groove are the most polymorphic, whereas those at the narrower end 
of the groove are conserved (Saper, Bjorkman and Wiiey, 1991). Different HLA-A 
alleles differ from each other by up to 20 to 30 amino acids and this polymorphism 
has the effect of changing the charge and shape of the cleft (Bjorkman et al., 
1987a). This flexibility allows the accommodation of a unique repertoire of peptides 
in distinct orientations. The N- and C- termini of the class I bound peptides are 
fixed at both ends of the binding groove and thus, are free to arch away from the 
floor of the binding cleft (Guo et al., 1992). The set of peptides bound by any given 
class I antigen tends to share a sequence motif which defines the preferred 
spacing and type of amino acid side chains for optimal binding (Corr et al., 1992; 
DiBrino etal., 1995). Peptides bound by the class I molecules are constitutively 
derived from endogenous and foreign proteins and might include between 2000 to 
20,000 different peptides being simultaneously presented by any one set of class I 
products on the cell surface.
Within the cleft are pockets, which are either at the junction of the p-sheet 
and the alpha helices or between the helices (Bjorkman et al., 1987a). These 
pockets tend to vary in size according to the antigen studied. The peptide has 
bumps and short side chain-like extensions, some which fit into these pockets. The 
six pockets, named A to F, in the cleft are of diverse shape and composition and 
are suited for binding the side chains of the antigenic peptide. The peptide is bound 
in the groove by hydrogen bonds and van der Waals forces interacting with the 
main chain atoms of the peptide. Structural studies of MHC and peptide complexes 
reveal that particular amino acid residues of antigenic peptides serve as anchors to 
specific pockets of the MHC. Sequence studies of peptides eiuted from MHC 
molecules revealed the conservation of particular residues at specific positions of 
the peptides (Falk, Rotzschke and Rammensee, 1990; Rotzschke et al., 1990).
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Pockets A to F lie at the two ends of the peptide binding groove and are highly 
conserved among the various class I molecules and accommodate the amino and 
carboxyl termini of the peptide. The residues of the peptide are numbered P1, P2, 
P3 etc. from the amino to the carboxyl terminus of the peptide. The amino terminus 
of the peptide is buried deep within the A pocket in an orientation that leaves the 
side chain at position P1 pointing upward into the solvent. There are distinct 
preferences for particular amino acids at the carboxyl terminus of the peptide 
depending on the chemical nature of the F pocket.
Some polymorphic sites do not appear to affect the binding of antigenic 
peptide such as position 71. Other polymorphic residues, which are not located on 
the helices or p-strands, may influence the binding site by conformational changes 
of the molecule.
Polymorphic residues located in the binding cieft have been identified as 
being critical for T cell recognition. A percentage of these polymorphic residues are 
concentrated towards the left end of the cleft, near the top surface of the helices 
and point up from the site (Bjorkman et a/., 1987a). In the HLA-A2 class 1 molecule 
some of the residues are on the top surfaces of the alpha helices and point up and 
project out and probably do not interact with antigenic peptides but interact with the 
TCR (Bjorkman etal., 1987a).
Four different TCR bound class I peptide complexes have been determined 
(Ding et al., 1998; Garboczi et al., 1996). In all structures, the TCR was found to 
bind in a similar diagonal orientation over the MHC/peptide complex (Figure 1.3). 
This orientation with the TCR Va-chain located over the N-terminal end of the 
peptide and the Vp-chain poised over the C-terminal region, allows the two 
hypervariable complementary determining region 3 (CDR3) loops in primarily 
contact over the centre of the peptide. The TCR-mediated activation of T cells is 
via the MHC-peptide complex on antigen presenting cells (ARC). This is enhanced 
by accessory molecules on both the T cell and the ARC (Vinay, Raje and Mishra, 
1996).
The expression of CD8 is a characteristic feature of T ceils that recognise 
the MHC class l-peptide complex. It functions in T cell activation by binding to the
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MHC on the ARC and by strengthening and prolonging the contact between the 
two cells (Norment et al., 1988). The CD8 molecule is non-polymorphic and a 
member of the immunoglobulin supergene family of proteins. It occurs on the 
surface of T cells as both a homodimer (CD8aa) and a heterodimer (CD8ap) 
(Leahy, Axel and Hendrickson, 1992). The ap heterodimer form is present on 
thymocytes and mature T cells whereas the aa homodimer is exclusively present 
on subsets of NK cells and intraepithélial lymphocyte cells of the intestine (Moebius 
et al., 1991; Terry et al., 1990). Studies showing the interaction between HLA-A2 
and CD8aa show a striking resemblance between this association and that of the 
antigen/antibody association. The CD8 molecule interacts with both the a2 and a3 
domains of MHC class I. Three residues (Glutamine 115, aspartic acid 122, and 
glutamic acid 128) in the a2 domain of class I are critical for the interaction with 
CD8 (Garcia etal., 1996; Sun, Leahy and Kavathas, 1995). The CDR-like loops of 
the CD8 molecule are clamped to an exposed loop in the non-polymorphic a3 
domain (residues 223-229) of the HLA-A2 (Salter etal., 1990). The CD8 CDR 
contact site with the HLA-A2 a3 domain is distinct from the peptide-binding groove 
and is also distinct from MHC class 1 sites that interact with the TCR. Two MHC 
class I molecules, HLA-Aw68.1 and HLA-Aw68.2, which do not bind CD8, have a 
valine residue at position 245 whereas all other HLA-A, B, C molecules have 
alanine (Salter et al., 1989). In addition, there is a conserved threonine residue at 
position 228 that is absent in swine MHC class i molecule, which is an important 
contact site for the CD8 molecule. Thus, complexes of CD8 and the T-cell receptor 
bound to the same class I major histocompatibility complex molecule seem to be 
necessary for T-cell activation.
In comparison to the vigorous T ceil response normally seen against 
allogeneic MHC molecules, T ceils recognize xenogeneic MHC molecules poorly. It 
appears that the CD8 molecule may interact with MHC class I in a species-specific 
manner, and that deficient CD8 interactions with the a3 domain of xenogeneic 
molecules may be an important contribution to poor xenoreactivity in some species 
combinations (Irwin, Heath and Sherman, 1989).
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1.4.2 Structure of the HLA class 11 Molecule
Loci within the MHC class II region are also extremely polymorphic and are 
formed through the non-covalent association of a 32kd a chain and a 29kd p chain.
MHC class II molecules bind peptides and are carried to the cell surface for 
presentation to CD4* T cells. HLA class II molecules are able to bind peptides from 
a broad spectrum of antigens and retain them at the cell surface long enough for T 
cell recognition to occur (Jensen et al., 1999). They are able to do this through a 
combination of structural biochemistry and the help of different molecular 
chaperones. These class II MHC/peptide complexes function in the generation of 
the humoral response as well as in a cytotoxic response, which are important in 
some autoimmune diseases.
The classical class II molecules, DR, DQ and DP, are expressed on B-cells, 
macrophages, monocytes, ARC and some activated T cells (Gerbase-Delima et al., 
1980;Jacobsen etal., 1980;McKinney etal., 1980). The class II antigens are 
encoded by distinct a and p chain genes; DRA, DRB, DQA, DQB, DRA and DRB 
respectively. The class II region also contains many pseudogenes that probably 
derive from ancestral gene duplication and mutation. The total number of class II 
loci, including pseudogenes, varies between different HLA haplotypes.
The three-dimensional structure of the class II molecule, DR1, has been 
determined and the a and p chains have similar overall conformation containing 
two extracellular domains (designated a l , a2, pi and p2 respectively) (Brown et 
al., 1993). The membrane distal domains, a l and pi, combine to form a single 
peptide-binding site composed of two a helical loops supported by a platform of 
eight anti-parallel p strands. A conserved disulphide bond connects the a helical 
region of the pi domain to a strand on the platform floor. The polymorphism in 
different MHC class II alleles is concentrated in these membrane distal domains 
and in the DR molecule it is in the p chain only. The a chain is conserved. This 
structure is very similar to that of HLA class I molecules. However, there are a 
number of important differences. Studies of peptides bound to MHC molecules 
show a size difference for class I and class II. The class 1 peptides are limited to a
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single size and terminate within the structure of the molecule whilst those bound to 
class II can vary in length at both ends, as the cleft that binds them is open. Unlike 
the kinked peptide bound in the class I, the peptide bound in the class II molecule 
is an extended and twisted structure. As in the MHC class I molecule some of the 
binding energy is provided by the interactions of the peptide side chains with the 
pockets within the molecule. There is a pattern of hydrogen bonding observed 
between the peptide backbone in the conserved amino acid side chains distributed 
along the length of the peptide binding groove rather than being clustered at the 
ends as In the class I molecule (Stern et al., 1994). This pattern of hydrogen 
bonding is remarkably conserved amongst the different alleles examined so far. 
Three asparagine residues (a62Asn, a69Asn, and p82Asn) are conserved in all 
class II molecules and are positioned to make hydrogen bonds with the peptide 
main chain. Other conserved residues (p81His and p61Trp) are positioned to form 
hydrogen bonds in the peptide main chain at the PI and P8 positions. The a l and 
pi alpha helical regions of most class II molecules are joined by a salt bridge 
formed between a76Arg and p57Asp. The primary role of this link is probably to 
stabilise the ap dimer, but these residues can also interact with the main chain of 
the RIO, resulting in additional hydrogen bonds near the C-terminal end of the 
peptide. The effect of these hydrogen bonds is to tightly constrain the peptide 
conformation to an extended helix. In this conformation, the peptide backbone 
twists along the length of the binding groove, progressing by about three residues 
with reached turn.
The binding groove is lined with polymorphic amino acids that form a series 
of pockets spaced to accommodate the side chains of the peptide. These pockets 
increase the specificity of the interaction of the peptide and also bury a substantial 
amount of the surface area. They also serve to align the peptide in the binding site 
so that the TCR can read each peptide sequence as a single unique determinant. 
Reptide binding often depends on just a few critical residues; this has allowed the 
definition of allele-specific peptide binding motifs. The class II peptide-binding 
groove is quite long and unfavourable interactions in one pocket may be overcome 
by more favourable interactions elsewhere along the peptide. Many examples exist
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of peptides that bind despite the fact they do not contain the consensus peptide- 
binding motif. Although these peptides often display high 'off-rates', they can still 
trigger T cells, as only a few peptide-MHC complexes are required for T cell 
recognition (Katzeta/., 1982).
MHC class II molecules are unstable in the absence of bound peptide and 
weakly bound peptide does not endure at the antigen presenting cell surface. 
Mechanisms within the cell limit the number of poorly loaded or empty class II 
molecules it presents to the immune system. The HLA-DM molecule appears to be 
able to cause the release of other peptides that display a less than optimal fit for the 
class II binding groove (van Ham etal., 1996).
The structure of peptide-MHC class II and TCR complex has been 
described using HLA-DRI plus influenza haemagglutinin peptide (Figure 1.3) 
(Hennecke, Carfi and Wiley, 2000). X-ray crystallography shows the binding is 
similar to that of peptide-MHC class I and TCR complex. Thus, both conserved and 
polymorphic residues are contacted. Although bound peptide within the MHC class 
II molecule extend out of both ends of the peptide-binding site, the TCR contact 
spans only 9 residues. This is only one more contact site than the peptide-MHC 
class I complex (Hennecke, Carfi and Wiley, 2000).
The T cell surface glycoprotein CD4 participates in antigen recognition by 
binding to conserved determinants on MHC class II molecules (Moebius etal.,
1992; Wang et al., 1990). This binding serves to increase the avidity of interaction 
during T cell receptor engagement. The CD4 molecule also functions as a signal 
transducer to the cell. X-ray crystallographic studies have revealed that the CD4 
molecule comprises four immunoglobulin-like domains, D1 - D4 (Ryu et al., 1990). 
The crystal structure shows the CD4 molecule interacts with both a2 and (32 
domains of the peptide-MHC class II molecule by residues Lys35, Phe43, Lys46 
and Arg59 of the D1 domain (Wang et al., 2001).
From functional studies, cell adhesion assays and peptide competition 
experiments, it is believed that a large area of CD4 (involving the D1 and the D2 
domains) form the primary MHC class il binding site (Konig, Fleury and Germain,
1996). The CD4 molecule binds to a loop in the MHC class II (3 domain between
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amino acids 137 and 143 (Cammarota et al., 1992). This loop in the p2 domain is 
structurally analogous to the CD8 binding loop previously identified in the MHC 
class I a3 domain (Gao et al., 1997). A separate region on the same face of the 
ciass II molecules also appears to be involved In CD4 binding, specifically residues 
42 to 56 of the (31 domain. Both these domains are highly conserved across 
species, particularly human and murine molecules (Brogdon etal., 1998).
1.4.3 Structure of the SLA class i and II Molecules
As yet no X-ray crystallographic structure for any of the SLA molecules has 
been defined. However, as both the human and murine MHC class I molecules 
have been determined it is assumed that the SLA molecule will be analogous in 
structure to other class I molecules.
It has been shown that papain solublised SLA class I molecules consist of 
two polypeptide chains, one which was 37kd to 43kd (heavy chain), and a 13kd 
chain, (32 microglobulin (Lunney and Sachs, 1978; Metzger etal., 1981). Porcine 
MHC class I genes consist of 8 exons separated by corresponding introns. As in 
humans, the protein encoding exons for the leader sequence show a variation 
between non-allelic class I MHC genes. The three exons encoding the extracellular 
domains, exons 2, 3 and 4 have the most polymorphism. These are found in 
clusters at amino acid positions 40-42, 66-70, and 75-82 (Satz et al., 1985). In exon 
3, where the largest sequence homology is seen, the nucleotide changes are 
scattered throughout the length of the exon and are not clustered as in exon 2. The 
highest degree of homology is found in exon 4. Two additional sites of homology 
between swine and human sequences are the cysteines at positions 101 and 164 
and at 203 and 259, which form disulphide bonds in both species. In addition, in the 
first extracellular domain, the N-iinked glycosylation consensus sequence at 
position 86-88 is conserved.
When comparing porcine SLA class I sequences with that of human, murine 
and rat, extensive homology is seen in exons 2, 3, 4 and 6. The remaining exons 
are less well conserved among the species, although swine and human genes are 
consistently more homologous in exons 1,5,7 and 8. A major difference between
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the swine PD1 gene and human A3 and Cw3 gene is the length of the first intron. 
The porcine intron is about 350bp compared to humans which all are 
approximately 100bp.
In the NIH minipig, the greatest polymorphism was found within the a1 and 
a2 domains, which corresponds to the human genes and correlates with the region 
of the ahelix that faces the antigen-binding groove of the MHC class 1 molecule 
(Sullivan et al., 1997). The sites of the polymorphisms of the al domain are 
residues 62-79. Unlike human genes in which polymorphism in the a2 domain are 
predominantly in the p-pleated sheet at sites 95, 97, 114 and 116; the SLA genes 
show the greatest polymorphism in the alpha helix of the a2 domain at positions 
156 and 163 (Parham, 1989; Sullivan etal., 1997).
As mentioned above, a significant difference occurs in the SLA class I 
molecule at position 228 compared to the human class I molecule. This residue is 
an important contact site for the GD8 molecule. Elucidation of the immune 
response mechanism against transplanted porcine tissue is critical for the success 
of xenografting in humans. However, human T cells and NK cells do recognize SLA 
antigens, and human receptors may bind to MHC antigens across species barriers 
(Horvath-Arcidiacono and Bloom, 2001; Kwiatkowski etal., 1999; Xu etal., 1999).
Molecular characterization of porcine MHC class I clones from two MHC 
class I loci (PI and P14) obtained from homozygous, inbred, minipigs of three 
haplotypes (aa, cc, and dd), revealed extensive conservation between loci, 
suggesting that the genes were products of duplication from a common ancestral 
sequence. The level of homology between loci was similar to that between the 
haplotypes at each locus, suggesting that there had been only limited divergence of 
these genes. Comparison of the alleles indicated that the polymorphism occurred in 
the a l and a2 domains of the class I heavy chain, while the a3 domain was highly 
conserved among the six genes analyzed. Amino acids in the a2 and a3 domains 
responsible for the binding of human CD8 to MHC class I, were largely conserved 
in the porcine genes, but several critical residues were altered. A comparison of 
sequences recognized by human NK cell inhibitory receptors revealed that the 
residues critical for recognition by these receptors were altered in the porcine
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genes. Thus, the porcine class I molecules would be unable to inhibit lysis by any 
human NK clones that have been characterized to date. This finding provides a 
likely explanation for the susceptibility of porcine cells to cytolysis by human NK 
cells. (Sullivan etal., 1997)
SLA class II molecules are made up of two distinct chains whose molecular 
weights are 32kd and 26kd. Experiments have demonstrated that two MHC class II 
molecules are expressed on the cell population studied (Chardon, Renard and 
Vaiman, 1981). Sequence analysis of SLA class II clones of the NIH minipig of the 
cc and dd haplotype has revealed that the MHC class II DRB genes had a striking 
amino acid homology between the first domain hypervariable regions of the DRB  ^
and the human DRB1*0101 and DRB1*0102 alleles (Gustafsson etal., 1990a). They 
differed only by 29% in the 17 residues of the first domain, whereas this value was 
66.2% when compared to other human DRB1* alleles. However, the number of silent 
substitutions between SLA-DRB^ and human DRB1*0101 and DRB1*0102 was high 
(73%) compared to other human DRB1* alleles (46.1%). The SLA-DQB sequence 
shows 80%(exon 2) and 87% (exon 3) identity to HLA-DQB sequences.
This intra-species similarity may have emerged as a result of convergent 
evolution driven by the need to react with common pathogens. Analysis of class II 
sequences of SLA-DRB 1 and DQB genes demonstrates that codons 21-25 and 51-55 
are highly conserved in these genes (Kanai etal., 1999). Amino acid sequences of the 
SLA class II pi domains is probably due in part to the polymorphism generated by 
combination of at least 3 structural segments of this domain which are derived from 
different ancestral alleles. It also demonstrates that the GC rich areas are hotspots for 
recombination.
1.5 DIRECT AND INDIRECT RECOGNITION IN THE IMMUNE RESPONSE
The immune response in allograft rejection is varied and complex in terms of 
the effector mechanisms employed and the nature of T cell recognition of the 
allograft antigens. Foreign antigens normally activate T cells in a self-restricted 
manner. In addition, T cells are selected for recognition of antigen only in the 
context of self-MHG. However paradoxically, they respond to MHC incompatible
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cells (Lindahl and Wilson, 1977). The TCR recognises an MHC molecule with a 
bound peptide and is biased towards recognition of foreign peptide with self-MHC 
as opposed to those bound in non-self MHC molecules (Garboczi et al., 1996; 
Kievits et al., 1989). It has been found that T cells specific for different foreign 
peptides bound within self-MHC molecules can also cross-react with allogeneic 
peptide bound in non-self MHC (Ashwell and Schwartz, 1986; Malissen etal.,
1988; Wilde etal., 1984). Allogeneic MHC molecules may directly trigger many 
recipient T cells as each may present a set of many different foreign peptides; a 
process called direct allo-recognition. At the same time, indirect recognition occurs 
activating CD4’*T helper cells when allogeneic MHC molecules (that are a rich 
source of foreign peptides) are presented by recipient MHC (Lechler and 
Batchelor, 1982).
1.5.1 Direct Antigen Recognition in the Immune Response
There appears to be no doubt that the direct pathway of allo-recognition plays 
a major role in acute rejection in allografts and produces a strong stimulus for the 
proliferative responses for delayed type hypersensitivity (DTH) reactions and for 
cytotoxic T ceil responses to the foreign cells of the graft (Hosken, Bevan and 
Carbone, 1989). The T cell response to allogeneic MHC molecules is vigorous; 10% 
of T ceils participate owing to the high frequency of T cells that recognise structurally 
related allo-MHC molecules. Two different theories, not mutually exclusive, have been 
proposed for the mechanisms involved:
1) The high determinant density modei
This model suggests that reactive T cells recognise the exposed polymorphic 
residues directly on the MHC molecule. The bound peptide is of secondary 
importance (Bevan, 1984). This suggests that there will be a high number of MHC 
ligands available (lOf per ceil) to which T cells may react. This implies that the TCR is 
relatively promiscuous due to the variation in the amount of allo-MHC plus peptide 
present per cell. This is in contrast to the density of MHC plus specific peptide when 
only a few hundred are displayed per cell. Experimental evidence shows that T cells 
can proliferate in response to MHC in the absence of peptide, thus not all allo-
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recognition is peptide-dependent (Elliott and Eisen, 1990; Smith etal., 1997). In 
addition, it appears that a single MHC-plus-peptide complex per target cell can 
activate T cell cytolytic function (Sykuiev etal., 1996).
2) Multiple binary complex hypotheses
This hypothesis proposes that the vigorous TCR response may be due to the 
activation of multiple T cell clones, each responsive to the same allogeneic MHC 
molecule bound with different peptide (Matzinger and Bevan, 1977). The set of 
peptides bound by an allogeneic MHC molecule will be substantially different to that 
bound by self-MHC. Support for this view has come from the observation that allo- 
reactive CD8* T ceils recognise specific allogeneic MHC peptide ligands (Dutz etal., 
1994; Udaka, Tsomides and Eisen, 1992).
Whichever hypothesis is correct, the potent response of allo-reactivity exists 
only because intact allogeneic MHC antigens are recognised directly by T cells 
without the requirement of being processed and presented by self-MHC (Bravery et 
al., 1995).
1.5.2 Indirect Antigen Recognition in the Immune Response
Although direct allo-recognition is a major mechanism in the allo-response, 
evidence suggests that indirect allo-recognition contributes a significant role in 
initiating and amplifying the rejection process (Auchincloss etal., 1993; Benichou et 
al., 1992). The indirect pathway leads to activation of CD4* T helper cells, which in 
turn activate immune effector mechanisms such as antibody production and isotype 
switching from IgM to IgG. The mechanism involves the recipients T cells recognising 
allogeneic MHC processed peptides that are presented by self-MHC antigens 
(Shoskes and Wood, 1994; Steele et al., 1996). Antigens shed from a graft are 
processed through the exogenous pathway and presented by the recipient APCs to 
CD4* T ceils (Neefjes and Ploegh, 1992). The activation of the T cell is dependant on 
the tri-molecular complex of TCR-MHC-peptide. Inflammatory cytokines assist the 
APC to process more antigen thus enhancing the activation of T ceils recognising 
MHC class II (DR) and bound peptides (Milton and Fabre, 1985). Donor MHC
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molecules are a major source of foreign epitopes generated by antigen processing 
and may possibly heighten the rejection response. However, evidence shows that the 
number of allo-determinants recognised by T cells Is relatively restricted, probably due 
to structural limitations of the host MHC class II molecule, which influences the 
number of allo-peptides that may be bound (Ciubotariu et ai, 1998; Harris, Liu and 
Suciu-Foca, 1992; Liu, Braunstein and Suciu-Foca, 1992; Liu et ai, 1997). 
Nonetheless, indirect allo-recognition by CD4* T cells of a limited number of peptides 
derived from the most polymorphic parts of the donor HLA molecules may play a 
pivotal role in both acute and chronic rejection (Benichou et at., 1992). Indirect 
recognition of allogeneic peptides in seif-MHC class II (and possibly also class I 
molecules) must involve recognition of the differences in the amino acid sequences of 
the self-MHC (Essaket et ai, 1990).
It has been reported that indirect allo-recognition by CD4^T cells of a limited 
number of peptides (derived from the most polymorphic parts of the donor MHC class 
II molecules) may play a major role in both acute and chronic rejection (Suciu-Foca et 
ai, 1998a). Most humans are heterozygous for HLA class II and as such, two 
immunodominant allo-peptides (derived from each allogeneic HLA-DR molecule) 
should occur. However, studies have shown that invariably the HLA class II molecule 
is limited to a single dominant determinant (Ciubotariu et ai, 1998; Colovai et ai,
1997; Harris, Liu and Suciu-Foca, 1992; Liu, Braunstein and Suciu-Foca, 1992; Liu et 
ai, 1997). This is due to differential transcriptional activities of the HLA class II genes 
that leads to a higher expression of one allelic product relative to the other (Louis et 
ai, 1994; Maffei et ai, 1997). However, an alternative mechanism could account for 
the single immunodominant determinant. During the manufacture of HLA class II,
CLIP (Class ll-associated invariant chain peptide) occupies the peptide-binding 
groove and is exchanged for exogenous peptide, assisted by HLA-DM (Denzin and 
Cresswell, 1995; Elliott et ai, 1994). The dissociation of CLIP allowing the loading of 
peptide is controlled by the polymorphic residues of HLA-DR molecule (Sette et ai, 
1995).
In patients transplanted with two DR mismatches, the indirect allo-response 
appears to target an immunodominant peptide of one of the mismatched antigens
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of the donor (Ciubotariu et ai, 1998; Liu et al., 1996). Over a period of two to three 
years post-transplantation, allo-reactivity spreads from the immunodominant 
determinant recognised during primary rejection to cryptic determinants of the 
allogeneic MHC molecule (intra-molecular spreading) (Benichou eta!., 1998; Suciu- 
Foca, Harris and Cortesini, 1998). in addition, reactivity may also develop to the 
second HLA-DR antigen (inter-molecular spreading). Epitope spreading and 
intermolecular spreading is associated with chronic rejection when T cells recognise 
new determinants of the other unrecognised HLA-DR antigen, after prolonged 
exposure to processed allo-peptides (Suciu-Foca eta!., 1998b; Ciubotariu et a!., 
1998).
1.6 T AND B CELL SPECIFIC IMMUNE RESPONSE
1.6.1 T cell Activation in the Immune Response
It is becoming clear that there are important reciprocal relationships 
between the innate (which is a pre-determined response and the first line of 
defence to protect the host from invading pathogens) and adaptive immune 
responses(Robertson, 1998). Thus, dentritic cells (DCs) are activated by innate 
stimuli and, loaded with foreign antigen, travel to lymph nodes to activate T and B 
cells of the acquired immune system. The survival of naïve as well as memory 
CD4* and CD8* T cells is dependant on MHC expression (Brocker, 1997; Rooke et 
a!., 1997; Takeda eta!., 1996). Antigen-specificT and B lymphocytes are essential 
for humoral immune responses to many antigens (Mitchison, 1971; Raff, 1970).
The change from naïve to primed effector ceils may result in cell-mediated 
immunity (in which T cells are involved) and humoral immunity (in which B cells 
effect their action through antibody production). In simple terms, there are three 
types of effector T cells: cytotoxic CD8* T cells (which kill their target cells); 
inflammatory CD4* T cells (which activate macrophages by the release of 
cytokines) and helper CD4* T cells (which help B cells produce antibody) (Smyth et 
a!., 1996; Yasukawa, Inatsuki and Kobayashi, 1988). Thus, T cells provide 
cytokines and co-stimulatory activation for B cells to produce antibodies (Clark and
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Ledbetter, 1994;Kupfer, Monks and Kupfer, 1994). Sustained T cell activation 
generally requires antigen/MHC and TCR interaction and co-stimulation between 
the ARC and T cells by various receptors and their ligands such as CD40/CD40L, 
CD80 (B7-1)/CD28 and CD86 (B7-2)/CTLA4 (Gill, 1993; Toes etal., 1998; Zhan et 
al., 2000a). For an effective B cell response, CD4* T cell help is mandatory and 
can also promote the clonal expansion of virus-specific CD8* cells.
T cells stimulated during a primary response are usually polyclonal (Cole, Hogg 
and Woodland, 1994; Horwitz, Yanagi and Oldstone, 1994). Recently it has been 
shown that T cells, like B cells, also undergo affinity maturation after repeated 
exposure to antigen resulting in T cells with increasingly restricted TCR repertoires 
that have higher antigen affinities (Busch and Pamer, 1999; Rees etal., 1999;
Savage, Boniface and Davis, 1999; KedI etal., 2000; van Bergen, Kooy and Koning, 
2001 ). High affinity T cells compete more effectively than low affinity T cells and 
respond to lower amounts of antigen on the surface of APCs. The interaction of high 
affinity T cells with APCs leads to a lowering of the amount of ligand on the ARC cell 
surface, which may inhibit the response of T cells with a lower affinity to the same 
antigen. This process favours proliferation of high affinity T cells resulting in them “out- 
competing” other T cell populations for both the same and different antigen 
specificities (KedI et al., 2002).
1.6.1.1 Activation of CD4  ^T cells
Numerous transplant studies have shown that CD4^ lymphocytes are the main 
subset responsible for the strength of cell-mediated response in xenografts (Section 
1.7.7). However, studies have shown that porcine islet xenografts are eventually 
rejected even in the absence of CD4* T cells (Mandel and Koulmanda, 1995; Yi et al., 
2000; Zhan et al., 2000b). Nonetheless, the triggering of CD4"^  T cells plays a crucial 
role in the initial steps of the adaptive immune response. Once activated, CD4* T cells 
co-ordinate various stages of the immune response. They produce numerous 
cytokines that activate specific immune ceiis such as B cells, eosinophils, mast cells 
and macrophages.
Antigen is initially presented to naïve CD4* T cells exclusively by DCs within 
the T cell areas of the secondary lymphoid tissues (Steinman, Pack and Inaba, 1997).
51
Chapter 1 :____________________________________________________________  Introduction
Upon stimulation, the antigen-specific CD4'  ^T cells proliferate in an IL-12 rich 
environment (released by DCs), and produce IL-2 and TNFa that induces rapid 
secondary immune responses.
One of the most important functions of the CD4* T cell is to recognise MHC 
class 11 plus peptide complexes on antigen-specific B cells and provide help for 
antibody production. The upregulation of the B lymphocyte chemoattractant (CXCR5) 
on stimulated CD4* T cells prompts them to leave the T cell area and move towards 
the B cell areas of the lymphoid tissue (Mueller, Jenkins and Schwartz, 1989; Kelsoe, 
1996; Cyster, 1999; Kim etal., 2001; Schaerli etal., 2000).
1.6.1.2 Activation of CD8  ^T celis
CD8* T cells that recognise foreign antigen presented by self-MHC class I 
molecules generally kill the cell by cytotoxic mechanisms. Those antigens recognised 
by MHC class I-restricted cytotoxic T lymphocytes (CTL) are usually derived from 
endogenously synthesised proteins. However, there is evidence that exogenous 
proteins can also provide a source of class I restricted antigens (Bevan, 1976). This 
'cross-priming' of CD8‘*‘ T ceils involves cognate recognition by CD4* helper T cells 
that must recognise antigen on the same ARC (Bennett at ai, 1997; Heath and 
Carbone, 1999).
CD4* T cell help is usually critical for CTL responses to many antigens such 
as viruses and allogeneic major histocompatibility antigens by providing growth 
factors such as IL-2 for the activation of CD8* cytotoxic T cells. Although help for the 
CD8* T cells is generally mediated by cytokines produced by CD4* T helper (Th) cells, 
help may be delivered through activation of the ARC via CD40-CD40L (Schoenberger 
et ai, 1998). Upon activation, naïve CD8* T cells differentiate into two distinct subsets: 
T helper (Th) 1-like cytotoxic T cells (Tel) and Th 2-like cytotoxic T cells (Tc2; Fitch et 
ai, 1995). Both these subsets kill by perforin/granzyme B lytic activity, the Fas 
pathways and via activation of the other cells through the release of cytokines (Smyth 
et ai, 1996). Unlike CD4^ Th2 cells that provide help for IgM and IgG synthesis from B 
cells. Tel and Tc2 do not induce any antibody production, as they can kill resting and 
activated B celis thus ruling out cognate help (Sad et ai, 1999; Mosmann, Li and Sad,
1997).
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1.6.2 B cell Activation
Early progenitor B cells rearrange their immunoglobulin heavy and light chain 
genes in the bone marrow. These immature B cells (IgM+ve IgD-ve) migrate to the 
red pulp of the spleen and colonise lymphoid follicles. These B cells express high 
levels of IgD and CD23 (Oliver et al., 1997).
The activation of B cells takes place in the secondary lymphoid tissue where 
antigen-specific B celis migrate to the edge of the lymph node follicles and present 
peptide MHC complexes to antigen specific CD4^ T cells post-activation by DCs 
(Section 1.5.1.1). The B cells proliferate in the follicles after receiving lymphokines 
and other signals from the T cells. Some of the activated B (and antigen-specific T 
cells) migrate into the follicles where they form immunoglobulin expressing germinal 
centre cells while others become antibody-secreting plasma ceils (Slifka et al., 1998). 
it is in the germinal centres that B cells undergo rapid clonal expansion, somatic 
hypermutation, isotype switching, and clonal selection (Liu etal., 1992; Tarlinton,
1998).
Cell surface markers on B cells such as CD40 and cytokine receptors play a 
central role in receiving signals from T cells for the required activation and 
differentiation (Liu and Banchereau, 1997). This ligation of CD40 on B cells is crucial 
for antibody production and the generation of B cell memory (Foy et al., 1994; Spriggs 
et al., 1993). Data from patients with X-linked hyper-IgM syndrome demonstrates that 
they have defective expression of the CD40L gene on T cells leading to very low or 
absent serum IgG levels (Aruffo et al., 1993). This data is corroborated in a 
transplantation animal model whereby the recipient CD4* T cells were depleted and 
alloantibody production was barely detectable. This group also showed that the 
absence of recipient MHC class II antigens led to the production of only IgM but not 
IgG antibodies (Steele et al., 1996).
T cell-dependent antibody production is related to the capture and 
internalisation of antigen by surface immunoglobulin that allows antigen-specific B 
cells to efficiently present peptide and MHC complexes to antigen specific T cells 
(Lanzavecchia, 1985). The B cell receptor (BCR) consists of membrane-bound 
immunoglobulin (mig), CD79a and CD79b. Upon BCR ligation, various signaling
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events occur. B cell activation is positively controlled by the co-receptors 
CD19/CD21 and negatively regulated by CD22 and FcyRII (Cyster and Goodnow, 
1997; Tedder, Inaoki and Sato, 1997). The resulting immunoglobulins, which maybe 
specific for MHC molecules or other alloantigens are released and the B cell 
undergoes affinity maturation. Due to the importance of this response in clinical 
transplantation, the requirements for primary and secondary stimulation of B cells by 
MHC antigen and the prevention of this signal have far reaching implications.
1.7 ROLE OF ANTIBODIES IN ALLOTRANSPLANTATION
1.7.1 Transplantation and Rejection
Sir Peter Medawar demonstrated that a second skin graft in the same animal 
was rejected more rapidly than the first and subsequently described the celis 
responsible for this process as lymphocytes or 'immunocompetent cells' (Reviewed 
Brent, 1997). Since this time the cells that are involved in this process have been 
characterised and a fuller understanding of their function elucidated. In addition, the 
importance of the humoral component in hyperacute rejection has been described 
and as such, the detection of circulating HLA specific antibodies prior to 
transplantation is a major requirement to avoid hyperacute rejection of the graft 
(Kissmeyer-Nielsen etal., 1966; Mullins etal., 1989; Ogura etal., 1992; Patel and 
Terasaki, 1969; Singh etal., 1983). Although a relatively small number of recipients 
for solid organ transplantation have preformed antibodies against HLA antigens, 
those that are sensitised present a major obstacle to successful kidney 
transplantation.
MHC class I HLA-A and HLA-B antigens are expressed on renal vascular 
endothelium; and this is the major site of antibody-mediated rejection leading to 
complement activation and thrombus formation (Ahern et al., 1982). Rejection of a 
solid organ transplant is seen initially as dysfunction of the organ, which is often 
reversible but can lead to extensive tissue damage and eventual loss of the graft. The 
cellular injury is accompanied by inflammation, but inflammation can also be seen 
without significant injury.
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Tissue damage may also play a role in the rejection process. Naïve cells 
interact poorly with non-activated endothelium but maybe attracted by endothelium 
activated by non-immune injury from the transplant process; e.g. prolonged cold and 
warm ischaemia (Kooijmans-Coutinho etal., 1996). Furthermore, antigen specificT 
cells probably interact with donor APCs in the organ or in the host lymphoid tissues 
for their primary stimulation. Endothelial cells (EC) are not passive bystanders in 
inflammation but act as APCs and respond to stimuli (Hirschberg, 1981). ECs also 
respond to many soluble inflammatory factors and interact with leucocytes through 
cytokine induced adhesion molecules (Mantovani, Bussolino and Dejana, 1992).
Kidney allograft survival has greatly increased over the past decade due to 
improved immunosuppressive therapy and superior methods for antibody detection 
before transplantation. However, despite HLA matching and improved 
immunosuppression cell-mediated rejection and antibody-mediated mechanisms 
continue to cause graft loss by acute rejection and/or chronic rejection.
1.7.2 Effect of HLA Matching in Allotransplantation
The role of HLA matching in organ transplantation is still a much-debated issue. 
It is well accepted that renal grafts from HLA identical sibling donors have far better 
survival than grafts from any other donor source. Their 91% three year and 74% ten 
year graft survival rate is an improvement of 16% over HLA matched cadaveric 
grafts. Whether an HLA haplotype matched kidney survives longer than a fully 
mismatched kidney, and whether matching for the HLA-A, B and DR molecules 
improves graft survival of kidneys from unrelated donors is a controversial issue 
(Opelz, 1997; Starzl and Fung, 1996; Terasaki etal., 1995). Recent data shows a 
clear effect of matching for the HLA-A, B and DR molecules on the frequency of 
acute rejection episodes in renal allograft survival (Opelz, Wujciak and Dohler, 1999). 
Data from European and United Kingdom sources indicates that matching for HLA- 
DR appears to be more important than matching for HLA-A and B in the first year. A 
superior outcome was achieved with kidneys that had no mismatches at HLA-A, 
HLA-B, and HLA-DR loci (000 mismatches). The next most favorable outcome was 
achieved with one mismatch at either A or B loci or one mismatch at both the A
55
Chapter 1 :_____________________________________________________  Introduction
and B, but no mismatch at the DR locus (100, 010, or 110 mismatches)(Morris et 
al., 1999). The effect of HLA matching is clearly seen ten years after 
transplantation; the graft survival rate of first cadaver kidney transplants with a 
complete mismatch (6 HLA-A+B+DR mismatches) was 17% lower than that of 
grafts with no mismatch (Opelz et al., 1999). Moreover, a significant effect of HLA 
matching is seen in renal graft survival for first and second grafts in both the 
sensitised and non-sensitised patient (Opelz, 1996). Matching for HLA-DP showed 
a significant effect in cadaver kidney retransplants, especially in the presence of 
preformed lymphocytotoxic antibodies. Heart graft outcome also shows a highly 
significant impact when organs are HLA matched (Opelz et al., 1999). However, 
the role of HLA matching in liver transplantation remains uncertain and a report has 
shown that repeat HLA mismatches appears to improve patient survival (Wong et 
al., 1996).
As the HLA molecules play a key role in the presentation of foreign peptides 
to T cells, the polymorphism of these antigens allows presentation of a large variety 
of foreign proteins to the immune system. As CD4* T cells are essential for the 
activation of B cells, MHC class II matched donor/recipient pairs would theoretically 
not induce specific T cell help. Nonetheless, MHC class I incompatibilities can still 
induce a specific response via the direct or indirect route (Essaket et al., 1990).
In patients transplanted with two DR mismatches, the indirect allo-response 
appears to target one immunodominant peptide of one of the mismatched antigens 
of the donor followed by intramolecular and intermolecular epitope spreading (Liu 
et al., 1996). This observation would indicate that matching for the HLA class II 
locus might have beneficial effects in reducing the occurrence of rejection episodes 
and re-transplantation.
As HLA class II molecules play a major role in graft survival, the correlation 
between DRB1 amino acid residue matching, the post-transplant humoral 
response and acute rejection episodes in renal transplants was investigated 
(Adorno et al., 1999). The absence of acute rejection correlated with DRB1 
compatibility, whereas the presence of one or more amino acid differences did not. 
The number of mismatches in the p-pleated sheet (codon 9 and 28) and the a-helix
56
Chapter 1 :_________________________________________________________________ Introduction
(codon 57) of the class II molecule I correlated with the number of rejection 
episodes. Also, rejection in patients with more mismatches in the a helix (codon 
58) was associated with class II specific antibody production. Thus it may be 
possible to define the existence of "permissive" or immunogenic" allele 
combinations which could increase the chances of a successful transplant.
1.7.3 Acute Allograft Rejection
Hyperacute rejection in allotransplantation is characterised by the binding of 
the recipients’ antibodies to the graft endothelium causing tissue injury. This leads to 
either complement dependent cytotoxicity or complement dependent (or 
independent) endothelial cell activation. This Induces a procoagulant state resulting in 
thrombosis (Kincaid-Smith etal., 1969). Direct complement-mediated cytotoxicity 
probably does not occur as most endothelial cells have complement regulatory 
molecules such as the complement receptor type 1 (CR1 ), decay accelerating factor 
(DAF) and membrane co-factor (MCP) (Weisman etal., 1990; Caudwell etal., 1990; 
Wang etal., 1991). It is possible that endothelial cell damage maybe caused by 
ischaemia and reperfusion injury, rendering the cells more sensitive than normal cells 
to complement activation via the classical pathway (Collard et al., 1997; Weiser et al., 
1996). This tissue injury may expose cryptic antigens (not otherwise seen) thus 
stimulating the immune response (Koenig, Barley-Maloney and Daniel, 1993).
Acute vascular rejection is often associated with the more severe forms of 
cellular rejection and possibly represents the end of a spectrum of immune 
damage. The prognosis of acute vascular rejection is poorer than acute cellular 
rejection. However, patients recovering from acute vascular rejection have similar 
long-term outcomes suggesting the antibody response can be transient if treated 
effectively (Delaney et al., 1988; Trpkov et al., 1996). Acute rejection is generally 
associated with de novo production of MHC class I donor specific antibodies (DSA) 
(Halloran etal., 1992; Halloran etal., 1990; Jeannet etal., 1970; Lobo etal., 1995). 
The risk of graft loss associated with antibody production is high, with first year 
survival rates varying between 15 and 50% (Halloran etal., 1992; Martin et al., 
1987). Nevertheless, the significance of DSA in the diagnosis of renal allograft
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rejection Is unclear, with 38 to 100% of reported patients with DSA suffering from 
rejection (Halloran e tal., 1990; Scornik etal., 1989; Utzig e tal., 1997). The 
variation in these figures probably reflects the variability and sensitivity of the 
methods used to detect donors’ specific antibody and the diagnosis of acute 
rejection on biopsy.
It was recently shown that the overall incidence of acute vascular rejection 
in patients was only 7.7% although 47% of patients received 2 DR mismatches and 
5% a zero DR mismatch (Crespo et al., 2001). In this study, biopsy sections were 
stained for the presence of the complement fragment C4d on the peritubular 
capillary, (which indicates activation of the classical pathway of complement) 
signifying rejection due to the presence of antibody.
The binding of antibody onto target cells in grafts may recruit Fc receptor- 
bearing killer cells to induce target cell damage (antibody dependent cellular 
cytotoxicity) contributing to inflammation such as DTH (Strom etal., 1975).
1.7.4 Chronic Allograft Rejection or Dysfunction
Chronic allograft nephropathy presents as a gradual loss of renal function. It is 
not clear if this is a distinct immunopathological state or is the result of continuing 
damage concurrent with previous destruction of nephrons and blood vessels 
(Hostetter, 1994). Chronic rejection accounts for 50-80% of renal failure post­
transplant and the diagnosis is not always clear-cut, but persistent allo-reactivity has 
been correlated with the development of chronic rejection (Ciubotariu et al., 1998; 
Yilmaz and Hayry, 1993).
There is evidence that indirect allo-recognition is involved in chronic graft 
dysfunction (SivaSai etal., 1999; Vella et al., 1997). Recently it has been shown in a 
murine transgenic model that sensitisation of CD4^ T cells precedes that of antibody 
production (Smith etal., 2002). This suggests that indirect allo-recognition led to 
chronic graft loss. Although the development of DSA after transplantation does occur, 
it is often without a detrimental effect for reasons which are unclear. It has been 
suggested that low levels of HLA-specific antibody do not represent a risk for 
hyperacute rejection if detected and treated early (Dafoe et al., 1991). Nonetheless
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the presence of these antibodies does have an overall effect on the graft outcome 
and is associated with acute and chronic loss of the graft (Davenport et ai, 1994; 
Halloran etal., 1992; Martin etal., 1987; Piazza etal., 2001; Saidman etal., 1994). In 
a study of chronic vascular rejection, it was shown that 61 % of patients had C4d 
staining on the peritubular capillaries (Mauiyyedi etal., 2001). Of these patients, 88% 
had anti-donor HLA present indicating that the presence of anti-HLA is eventually 
deleterious.
Though the indirect pathway is involved in rejection, the immunosuppressive 
drug cyclosporin A fails to inhibit the early antibody response to grafts in a small 
animal model, as it does not inhibit indirect T cell allo-recognition (Grosz et al., 1988; 
Sawyer, Daichau and Fabre, 1993). However, other immunosuppressive agents 
(such as the combination of tacrolimus and mycopheneolate mofetii) have been 
effective in suppressing long-term donor specific antibody production (Theruvath et 
a/., 2001).
1.7.5 Antibodies Involved in Ailograft Rejection
1.7.5.1 HLA Antibodies
Patients with greater than 85% HLA multispecific panel reactive antibodies 
represent a serious problem in organ transplantation and such patients may wait a 
long time for a compatible cadaveric donor resulting in an accumulation of sensitised 
patients on lists waiting for transplants.
Antibodies against HLA class I and class II antigens are generally produced in 
subjects by prior transfusions, deliberate immunisation, a failed transplant, or 
pregnancies (Dausset, 1954; Payne and Rolfs, 1958; Scornik etal., 1992b; Walford, 
Carter and Anderson, 1964). The probability of becoming highly sensitised following 
blood transfusions is low but the risk increases with each subsequent transfusion 
(Scornik et al., 1992a). The risk of sensitisation in multiparous women is higher 
particularly in rhesus negative women and those patients with failed grafts (Opelz et 
al., 1981). There are rare instances where HLA specific antibodies occur in non­
immunised individuals and the specificity of these antibodies has been predominantly 
anti-HLA-A2 and anti-HLA-B8. It is hypothesised that these antibodies are induced by
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viral agents or may reflect an anamnestic polyclonal immune response (Collins et al., 
1973; Lepage, Degos and Dausset, 1976; Tongio etal., 1985).
To further complicate matters, some antibodies detected do not appear to be 
harmful to graft outcome. Positive crossmatches by cytotoxic methods against donor 
lymphocytes do not always predict acute rejection. These cases are often found in 
patients with autoimmune diseases such as systemic lupus erythematosis or result 
from polyclonal activation during some viral infections. In a number of situations, 
these antibodies are autoreactive, but in other instances, they are not. The vast 
majority of these antibodies are of the IgM isotype, although IgG non-HLA antibodies 
have been reported (Barger etal., 1989; Bryan etal., 2001; Okuno and Kondelis, 
1978; Spees and McCalmon, 1990; Taylor etal., 1989). Whereas evidence indicates 
that most cytotoxic antibodies are a contraindication to transplantation, the 
identification of IgM HLA antibodies verses IgM non-HLA is difficult to determine 
(Iwaki etal., 1989; Taylor etal., 1989; Ting, 1989). Another controversial finding is 
that of antibodies reactive to B, but not T, ceils. When this is detected, early graft 
failure rates are generally not seen, unless the reaction is due to class I antibody, as 
there is a higher density of HLA class I antigens present on B cells (Pellegrino et al., 
1978). This may also be due to IgM non-HLA antibodies as they are often detected 
by B cells initially, rather than T cells (Taylor etal., 1989). Only certain 
immunoglobulin classes or subclasses of antibodies can cause cytotoxicity by fixing 
complement since not all are effective at complement fixation, e.g. lgG2 and lgG4 . 
Since some patients have only non-complement fixing antibodies these cannot be 
detected by complement-dependent tests and other methods must be employed, 
such as augmented anti-globulin reaction or flow cytometric analysis (al-Hussein et 
al., 1994; Karuppan, Ohiman and Moller, 1992).
There is no doubt that the presence of IgG HLA class I specific antibodies is a 
contraindication to clinical transplantation as they always cause hyperacute rejection 
and early immunological complications. However, the presence of HLA class II 
antibodies can also contribute to acute vascular rejection, although reports are 
conflicting (Taylor etal., 1987; Russ etal., 1987; Scornik eta/., 1992b; ten Hoor, 
Goopmans and Allebes, 1993). In some cases reported, the positive crossmatch
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maybe due to antibody against non-HLA antigens, which react preferentially with B 
cells.
Sensitised patients’ may be inherently high responders who are more likely to 
mount a de novo antibody response. There are several reasons why the immune 
response varies from one individual to another, such as variations in immune 
responsiveness and the degree of HLA matching between donor and recipient. It has 
been suggested that cytokine gene polymorphism's affecting expression may 
influence rejection or tolerance in transplants (Cavet et al., 2001; Hutchinson et al., 
1999; Sankaran etal., 1999).
1.7.6 Structural Interaction of Antibodies
The area of contact between antibody and antigen is between 700-800 A 
and involves about 15-22 pairs of amino acid residues (Colman, 1988; Laver et al.,
1990). Three-dimensional structures of antigen/antibody complexes show that up 
to 6 CDRs (three on the heavy and three on the light chain) of the antibody make 
contact with an antigen (Kabat, 1978; Kabat, Wu and Bilofsky, 1976). There are 
many residues on an antigen that bind with the antibody CDRs, but there are a few 
critical residues on any protein that provide a dominant interaction with one of the 
CDRs, with the remaining CDRs interacting with the protein to strengthen the 
reaction (Getzoff et al., 1988). It is conceivable that some antibodies may interact 
with the MHC in a similar manner as the TCR/MHC/peptide interaction (Section 
1.3.1). Thus, the first and second CDR of the antibody bind to the a helices of the 
HLA, whilst the CDR3 binds to the peptide and indeed one such monoclonal 
antibody has been described (Murphy et al., 1992). Also HLA antibodies recognise 
particular polymorphic amino acids of the MHC a l (positions 1-90) and a2 
(positions 91-182) helix, and a single amino acid substitution at a key site or even a 
buried site, may generate recognition by cytotoxic antibodies. Site directed 
muatgenesis studies have demonstrated that amino acid substitutions in positions 
distant from an antibody epitope can influence the binding between HLA antigen 
and antibody (Fu and Karr, 1994; McCutcheon et al., 1993). As many of the 
polymorphic residues occur on the floor of the p sheet, this raises the question as
61
Chapter 1 : __________ Introduction
to whether the peptide in the groove influences antibody binding to the MHC 
molecule. It is possible that this type of antibody recognition may account for the 
two HLA-B40 serological variants recognised by anti-HLA sera (Kennedy et al,, 
1989). Sequencing data demonstrated that these possible new variants 
corresponded to the same BM002 heavy chain found in the B61 antigen (Domena, 
Johnston-Dow and Parham, 1992). This was further supported by the observation 
of the serological specificities of HLA-B64 and B65, which differ by a single amino 
acid substitution at position 11. This amino acid is buried beneath the surface of 
the a l helix and it suggests that a B64 or B65 antibody would not be able 
recognise this specific epitope. Thus it may be that a single substitution may affect 
the conformation of other residues that directly interact with peptides or TCR and 
so influence antibody binding (Domena et al., 1993). Other groups have also 
demonstrated that peptide induces conformational changes in the MHC class I 
molecule, thus altering antibody recognition (Bluestone etal., 1992; Sherman et 
al., 1993). X-ray crystallographic studies have shown the potential conformational 
changes that may result from binding different peptides within the same MHC class 
I molecule (Fremont et al., 1992). This raises the possibility that HLA molecules 
may exist in different conformations on the cell surface, which hence would have 
implications for alio-recognition.
Mismatched HLA molecules expressed on grafts are targets for both the 
humoral and cellular arms on the immune response. Aiio-recognition starts from one 
foreign HLA molecule bearing an immunodominant epitope. Later, intermolecular and 
intramolecular ‘epitope spreading’ can take place (Ciubotariu etal., 1998; Liu etal., 
1996). This phenomenon has been reported in recipients transplanted with a graft 
differing by two HLA-DR alleles. It is thought that ‘epitope spreading’ may account 
for chronic rejection seen in cardiac allografts. As this phenomenon produces 
broader antibody specificities after exposure to a limited number of HLA-mismatched 
antigens in the host, the suppression of the indirect pathway would be a useful 
strategy to interrupt production of multiple alloantibodies.
Conversely it appears that not all patients produce HLA specific antibodies to 
donor mismatches and rarely do they form antibodies to all the HLA mismatches
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(Sanfllippo etal., 1982). Not all H LA-class I mismatched antigens appear to be 
immunogenic since in most cases, HLA antibody specificities are against one HLA 
antigen even when there is more than one HLA class I mismatch (Papassavas et 
al., 2000). The many polymorphic HLA genes products bear many epitopes (both 
private and public) that can induce an immune response. Each private epitope 
represents a unique site on one HLA molecule. Public determinants on the other hand 
represent an epitope shared by one or more HLA molecules and these public 
epitopes have been used to define major cross reactive groups (Dilioglou, Cruse and 
Lewis, 2001; Fuller, 1991; Rodey and Fuller, 1987). Peptides from private or public 
epitopes stimulate the aliopeptide specific Th cells that will provide the cytokines for 
the growth and differentiation of the anti-HLA class I secreting B cells (Steele et al., 
1996; Suciu-Foca et al., 1995). Allo-reactivity or nonreactivity of the recipients' 
immune system depends on which epitope is presented to the allo-reactive T cells 
with subsequent, cytokine secretion providing help for alloantibody production 
(Suciu-Foca etal., 1995).
The majority of sera from sensitised patients contain antibodies to cross 
reactive groups suggesting that shared public epitopes of the HLA molecule may 
induce a stronger response than private epitopes. It has been reported that patients 
do form HLA specific antibodies within their cross reactive groups, which would 
support the concept that HLA antigens carry both private and public epitopes 
(Dilioglou, Cruse and Lewis, 2001; Papassavas etal., 1999). Patients with intra-cross 
reactive group-mismatches do not seem to produce HLA class I specific antibodies 
against private epitopes that are shared between the recipient and donor 
(Delmonico et al., 1983; Rodey et al., 1994). However, matching for cross reactive 
groups does not appear to lead to better survival of transplanted kidneys (Stobbe et 
al., 2000).
Some HLA antigens may be more immunogenic than others as patients 
transplanted with HLA-A1 and -A2 develop antibodies that persist (Dilioglou, Cruse 
and Lewis, 2001). In contrast, exposure to antigens HLA-A23, B7 and B35 in a first 
failed transplant did not result in antibody production. HLA-A1 and A2 antigens 
beiong to the 1C and 2C cross reactive groups respectively (Table 1.1). The 1C cross
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TABLE 1.1 HLA class I classification by cross reactive groups or public 
epitopes.
[cross
reactive
group_
Associated private epitope
10 A1
66
3
68
11
69
23
74
24 25 26 29 30 31 32 33 34 36
20 A2 23 24 68 69 B57 58
50 B18
76
35
77
49
78
60 51 52 53 57 58 62 63 71 72 75
70 B7 8 13 54 55 56 27 60 61 41 42 47 48
80 B8 63 64 65 18 38 39 59
120 B44 45 49 50 13 60 61 41 47 48
40(Bw4) A24
52
23
53
25
57
32
58
34
59
Bw4
63
B13
77
27 37 38 44 47 49 61
60(Bw6) Bw6 Cw1 Cw3 B7 8 18 39 41 42 45 46 48 50 54
55 56 60 61 62 64 65 71 72 73 75 76
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reactive group contains three public epitopes (A10, A19 and A1, 3,11) that 
crossreacts with all HLA-A molecules except for A2, 23 and 24 (Rodey and Fuller, 
1987). This may account for the immunogenicity of HLA-A1. Private epitopes that 
cross react with members of the 1C cross reactive group may explain why a complex 
of different HLA-A antibodies can be formed after exposure to HLA-A1 antigen. The 
2C cross reactive group contains antigens shared with 1C such as A23, 24, 68 and 
A69. The sharing of antigens within the 1C and 2C cross reactive groups may 
increase the cross-reactivity of the A2 antigen. As peptides derived from public or 
private epitopes maybe presented through indirect allo-recognition-stimulating B 
cells, identification of the immunogenic peptides for transplantation could possibly 
allow matching at the epitope level.
It has been suggested that the specificity of antibodies could be a population 
phenomenon (DeFranco, 1993). Different B cells express specific immunoglobulin 
receptors possessing binding sites against the private and public epitopes. In 
addition, the genetic predisposition to antibody production may be driven by HLA- 
DR phenotypes (Fuller and Fuller, 1999; Heise, Manning and Thacker, 2001; 
Kreisler et al., 1988; Papassavas et al., 2002). These reports are conflicting. It has 
been reported that HLA-DR2 correlates with an antibody response to HLA class I 
antigens and shows a lower graft survival of mismatched kidneys. In another case 
antibody response to HLA-Bw4 epitope was restricted to DRB*01 and DRB*03. It 
would appear there is evidence that responder HLA linked genes exert both positive 
and negative influences over antibody production.
1.7.7 Non-HLA Antibodies in Aliotranspiantation
Those patients who have become sensitised to HLA antigens may also have 
alloantibodies directed against other antigenic determinants such as 
monocyte/endothelial antigens. A few examples were organs were acutely rejected 
in patients receiving fully matched grafts, maybe due to the presence of these 
antibodies (Ahern etal., 1982; al-Hussein etal., 1995; Cerilii etal., 1981; 
Kooijmans-Coutinho etal., 1996; Miltenburg etal., 1989; Paul etal., 1979a; Perrey 
etal., 1998; Sumitran-Karuppan etal., 1997; Wood etal., 1988; Yard etal., 1993).
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The occurrence of these non-MHC alloantibodies appears to be relatively low but 
nonetheless they have been reported to cause graft loss.
In animal models of chronic rejection, antibodies are produced against 
antigens associated with glomeruli and tubular basement membranes, mesangial 
cells, and vascular endothelial cells (de Heer et al., 1994; Mancilla-Jimenez et al., 
1977; Stuffers-Heiman, Gunther and van Es, 1979). Reports of these non-HLA 
antibodies are confusing as no cell surface molecule has been isolated and 
characterised. However, allo-antisera have been described that recognise 
polymorphic antigenic sites on endothelial cells and monocytes, but endothelial 
cells also possess antigens that are not present on monocytes (Moraes and 
Stastny, 1977; Perrey etal., 1998; Yard etal., 1993).
To date no antigen specificity has been fully characterised, although some 
proteins have been isolated, such as:
• A 92-1 OOkd kidney specific antigen that has been identified as a target for IgG 
from rejecting kidneys (Joyce, Flye and Mohanakumar, 1988).
• A 97-110kd endothelial target that is reactive with an IgM antibody that has 
been associated with hyperacute rejection (Sumitran-Karuppan et al., 1997).
• A 56-57.5kd endothelial cell target that has been associated with coronary 
artery disease following heart transplantation (Crisp et al., 1994).
• A 45-50kd (different from HLA class I), 53-55kd, 59-63kd and 66-67kd 
endothelial cell (IVEG) target that have been associated with renal graft failure 
(Suberbielle Boissel etal., 1998)
Other non-HLA target antigens that have been reported to be involved in 
transplant rejection are MICA and MiCB (Hankey et al., 2002). These antigens are 
polymorphic but less so than other class I genes and they are not associated with 
p2m or peptide ligands. As mentioned in Section 1.2.1 MIC molecules function as 
ligand receptors on NK cells, yôT cells and CD8^ T cells. The MIC antigens are 
constitutively expressed on gut epithelium but can be induced on other epitheliai cells 
by stress (Groh et al., 1996). Antibodies specific for MICA have been reported in the 
serum of some patients who had experienced rejection episodes in kidney aliografts 
as they are present on the tubular epithelium in the proximal and distal tubules of the
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kidney (Hankey et a!., 2002; Zwirner et al., 2000). However, the source of 
immunisation remains to be resolved. It is speculated that many of these patients 
may have formed these antibodies due to blood transfusions or pregnancy. In this 
situation, MIC expression may be upregulated due to the stress of graft rejection, 
possibiy as a consequence of an innate immune response rather than acquired 
immunity.
1.8 XENOTRANSPLANTATION
Xenotransplantation is defined as grafting tissues from one species of 
animal into another. It has a history almost as old as allotransplantation although 
much of this resides in mythology.
Early xenotransplantation research was driven by the mortality of end stage 
organ failure unless a suitable organ for transplantation was found. In the early 
1960s efforts to establish heterotransplants (later called xenotransplants) were first 
reported by Reemtsma when he transplanted two heavily immunosuppressed 
patients with kidneys from a rhesus monkey and a chimpanzee (Reemtsma et al., 
1964b). The rhesus recipient died on the 12th day and the graft showed some 
inflammatory cells present but the glomeruli were normal. The patient who received 
the chimpanzee organ succumbed to bronchopneumonia and died 9 weeks post 
transplant. Several other xenotransplants were performed by this group and one 
chimpanzee recipient survived for more than 6 months (Reemtsma et al., 1964a). 
Although these transplants were only moderately successful these experiments 
suggested that this type of transplant could possibly be successful in the future. 
Patients who were treated for liver failure (by ex vivo perfusion using animal livers) 
survived after their own organs regained function (Eiseman, Liem and Raffucci, 
1965; Hume, Gayle and Williams, 1969).
With the lack of human donor organs and the success of allotransplants 
there has been a renewed interest in xenotransplantation. An improved 
understanding of immune recognition and rejection of both allografts and 
xenografts has resulted in new therapies that can overcome hyperacute rejection 
and partially acute vascular rejection or delayed xenograft reaction (Bach et al..
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1995b). Much scientific progress has been made in the understanding of the 
various hurdles and the development of novel strategies in the field of clinical 
xenotransplantation.
1.8.1 Choice of Donor Species for Xenotransplantation
The choice of the donor animal for xenotransplantation is influenced by 
physiological, immunological, microbiological and ethical factors. Pigs and primates 
have been selected as the preferred species for xenotransplantation. Probably the 
best xenogeneic donor would be a species closely related to humans such as 
monkeys, but it is likely that there would be considerable public outcry over the use 
of non-human primates in large numbers for transplantation. Thus, for a variety of 
logistical and physiological reasons, the pig is currently the most favoured donor 
animal. This is because they have large litters, mature quickly (6 months), are easy 
to manage, their organ size is compatible, the risk of transmitting infection is low 
and their reproductive biology and the methods required for genetic manipulation 
are well understood. Pigs have an anatomy similar to humans and share 
characteristics with them such as size, haemodynamics and coronary artery 
distribution (Kirkman, 1989). By contrast, primates have single offspring which take 
a long time to reach maturity (5 years), they adapt poorly to captivity and the risk of 
transmissible diseases are high (Van der Riet et a/., 1987).
Although obtaining organs from swine would be unproblematic and they can 
be bred in a pathogen free environment, there are obstacles that need to be 
surmounted if xenotransplantation is to be successful. Zoonosis is a consideration, 
which has yet to be fully understood. Infectious agents from non-human primates 
are of potential pathogenic significance in humans especially the exogenous 
retroviruses. Many of these problems will be discussed below in more detail.
1.8.1.1 Physiological Barriers in Xenotransplantation
Experiments in the early sixty’s using primate donors and later work using
porcine donors, demonstrated that organs from animals can provide some level of 
physiological support for human and non-human primates (Alexandre etal., 1989; 
Sablinski etal., 1995; Zaidi etal., 1998). Nonetheless, even if the basic metabolic
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functions are similar between mammalian species, the organisation of 
communication and controi will determine the final outcome in xenotransplantation.
As solid organs rely on blood circulation the viscosity of the blood will play a 
role. The viscosity of blood in humans is lower than that of pigs, thus an increase in 
haemoperfusion will be expected when using pig organs. In addition, human 
erythrocytes are larger than those in pigs, which could lead to difficulties in the 
microcirculation, resulting in damage of the organ.
Although swine have similar haemodynamics to humans, the long-term 
outcome of transplanting organs from four legged animals to upright animals has 
yet to be clarified. Posture influences both blood circulation and organ function. In 
an upright position, blood pressure differences are greater between organs. Thus, 
post-lung transplantation, ventilation could be compromised, or oedema could 
develop within the organ leading to the death of the patient. Lung transplants from 
pig into non-human primates have been shown to function for oxygenation, gas 
exchange, and CO2 exchange (Daggett etal., 1998). However, these experiments 
were limited, due to severe vasoconstriction in the newly transplanted lung.
In allografting, matching for the ABO blood group system is a standard 
procedure due to the risk of hyperacute rejection by ABO incompatible antibodies. 
Swine only express blood group A and O and although the pig A antigen is not 
expressed on the vascular endothelium, it is expressed on the distal tubules, thin 
and thick tubules of Henie and the epithelium of the collecting ducts of the kidney 
(Oriol et al., 1993; Rydberg et al., 2001). However, this problem would be 
overcome by transplanting the ‘universal donor’ blood group O pig organs only.
1.8.1.2 Molecular Barriers in Xenotransplantation 
it is known that chimpanzee kidneys can support human life and that 
porcine insulin can regulate blood sugar levels in humans. However, there are 
reports that primates surviving with pig kidney transplants develop marked 
anaemia, raising the probability that erythropoeitin may not function correctly in 
primates (Régulier et al., 1997). Although kidneys from pigs may be adequate to 
support the renal function required by humans it is also reasonable to predict that 
deficiencies may develop if metabolically complex organs such as the liver are
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used for transplantation. Many enzymes require a carrier protein that is often 
albumin and as pig and human albumin share less than 65% homology, this may 
mean the enzymes will function differently (Hammer et al., 1998). Also, the body 
temperature of the pig is higher than in man and this may also affect enzyme 
function. Other factors such as production of bile salts and the effect of growth 
hormones on xenogeneic tissue will need to be considered. Renal parameters 
such as cholesterol and the electrolytes Ca & PO4 are also different, which could 
lead to possible electrolyte imbalance.
Other molecular compatibilities and incompatibilities between species are 
becoming known such as NK/T cell interactions and coagulant regulatory proteins 
(Goodman etal., 1996; Lawson and Platt, 1996; Rollins etal., 1994a; Rollins etal., 
1994b; Siegel etal., 1997; von Albertini etal., 1998). Many of these will be 
discussed below.
1.8.2 Hyperacute Rejection in Xenotranspiantation
Porcine heart and kidneys, when transplanted into non-human primates, 
reject hyperacutely, a process that occurs within 15 minutes to 1 hour post 
anastomosis -  this presents a major barrier to xenotransplantation. Work 
performed in the 1960s revealed that vascularised xenografts between widely 
disparate species experienced immediate destruction and histological studies 
showed this type of rejection was marked by extensive intravascular thrombosis 
and interstitial haemorrhage (Perper and Najarian, 1966). As this picture was 
similar to that recognised in blood group ABO incompatible allografts it was thought 
that preformed antibodies caused this xenograft rejection. This was later confirmed 
by passive transfer of antibody from goat to sheep (Perper and Najarian, 1967).
The target of these antibodies in hyperacute rejection is the vascular endothelium, 
which results in endothelial activation but no transcription of genes resulting in 
protein synthesis (type I endothelium activation), rather than cell death via 
complement activation. Due to the endothelial cell activation there is loss of the 
integrity of the endothelium resulting in oedema. Also there is loss of heparan 
sulphate from the cells leading to procoagulant changes (Platt et al., 1990a).
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Studies on xenotranspiantation in various species indicated that this 
hyperacute rejection occurred whenever there was a large species disparity. In 
1970, Caine suggested the term concordant to describe species combinations in 
which hyperacute rejection did not occur and discordant to describe combinations 
where it did.
1.8.3 Acute Vascular Rejection In Xenotransplantation / Delayed 
Xenograft Rejection
When hyperacute rejection is prevented, a delayed form of rejection usually 
occurs within 24 hours and leads to a more gradual graft failure even in the 
presence of heavy immunosuppressive therapy (Robson et al., 1995). Serial 
studies over several days after transplant show that histologically, xenografts 
undergoing delayed xenograft reaction demonstrate varying combinations of;
(1) focal deposition of IgM, IgG and C3
(2) progressive infiltration by activated macrophages and NK cells,
(3) platelet aggregation and fibrin deposition throughout the microvasculature and 
in the advanced phase interstitial haemorrhage and infarction,
(4) endothelial activation ieading to apoptosis and subsequently necrosis (Shimizu 
et al., 2000).
The histology of this type of rejection differs from those seen in hyperacute 
rejection. It is characterised by severe injury to vascular endothelial cells, and little 
cellular infiltrate with less haemorrhage but significant intravascular thrombosis 
(Hancock and Bach, 1994; Kobayashi et al., 1997). This picture is similar to that 
seen in acute vascular rejection in allografts (McPhaul, Stastny and Freeman, 
1981; Porter, 1992). The exact mechanism of this rejection is uncertain but it does 
appear that antibody and complement are involved and there is evidence that NK 
cells, macrophages and neutrophils play a role (Bach et al., 1995a; Fryer et al., 
1997; Goodman etal., 1997; Inverardi etal., 1992a). Like hyperacute rejection, the 
main target of acute vascular rejection is endothelial cell activation. This activation 
does not require complement and is seen in the discordant guinea pig-to-rat model 
and human decay accelerating factor (hDAF) transgenic pigs. It occurs slowly.
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allowing time for new gene transcription and protein synthesis (Schmoeckel et al., 
1998; Zaidi et al., 1998). This delayed endothelial activation is called type II 
activation, in contrast to the type I associated with hyperacute rejection. This 
endothelial cell activation leads to platelet activation, chemokine secretion and 
recruitment of NK cells and macrophages (Bach et al., 1996).
1.8.4 Xenoreactive Natural Antibody and Epitope
In pig-to-human transplantation hyperacute rejection is initiated mainly by the 
binding of human xenoreactive antibodies to the endothelium of the porcine organ. 
These are found in all immunocompetent individuals and consist mainly of IgM, 
some IgA and IgG (Rieben et al., 1995; Sandrin et al., 1993; Yu et al., 1996). The 
binding of antibody triggers activation of the complement system via the classical 
pathway leading to endothelial cell damage and activation, platelet clumping, 
thrombosis and infarction of the transplanted organ (Gewurz et al., 1966; Parker et 
al., 1994; Rosenberg and Tachibana, 1969). In some species combinations such 
as guinea-pig-to-rat or pig-to-dog, complement activation can occur through the 
alternative pathway even in the absence of preformed antibodies (Piatt et al.,
1991). Greater than 80% of xenoreactive antibodies that bind to porcine organs are 
antibodies directed against the single carbohydrate, galactose-al ,3-galactose- 
p1,4-N-acetyiglucosamine-R (Gala1-3Gal) which, has significant homology to the 
human blood group B (Cooper etal., 1993; Galiii etal., 1987; Good etal., 1992; 
Parker et al., 1999). The Gala1-3Gal epitope is formed by the addition of galactose 
to terminal lactosamine residues on glycolipids and glycoproteins by the enzyme 
a l ,3-galactosyltransferase (Figure 1.4). This enzyme exists in lower mammals and 
New World monkeys but is absent in Old World monkeys and humans due to the 
inactivation of the gene (Galiii and Swanson, 1991). Humans who either lack blood 
group A and/or B antigen develop ‘naturally occurring’ anti-B and/or anti-A 
antibodies respectfully, probably in response to normal enteric bacterial flora 
(Hayrinen, Pelkonen and Finne, 1989). In a similar fashion anti-Gala1-3Gal is 
believed to develop during the first weeks of life, possibly produced in response to 
gut bacteria, which express similar epitopes (Galiii et al., 1988).
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FIGURE 1.4 Structure of Gala1,3Gal antigen compared to human blood 
group A and B antigens.
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These natural Gala1,3Gal carbohydrate antibodies always include the IgM isotype 
and show very similar binding characteristics within the human population. They 
also have a high functional dissociation constant (10'®M) depending on the 
temperature (Parker et al., 1994; Lee et al., 1998). The concentrations of these 
antibodies are high in human serum, representing about 1-4% of total human IgM 
and are they continually produced (Hamadeh et al., 1995). The target Gala1-3Gal 
epitope is widely expressed on porcine cells, but is abundant on vascular 
endothelium, liver parenchymal and kidney cells (McKenzie etal., 1994). The main 
glycoprotein targets of these natural Gala1,3Gal antibodies have been identified as 
belonging to the integrin family, fibronectin and von Willebrand factor (vWF) 
(Holzknecht and Platt, 1995). There are likely to be many additional glycolipid 
targets.
Several approaches to overcome hyperacute rejection have been developed 
with some success. Some of these include:
1) The depletion or inhibition of the naturally occurring xenoreactive antibody.
2) Blockade of the complement cascade by depletion or inhibition.
3) The development of transgenic pigs that express human complement regulatory 
protein such as hDAF or the reduction of the Gala1-3Gal epitope expression on the 
donor organ.
1.8.4.1 Depletion/inhibition of Gala1 -SGal antibody to prevent 
hyperacute rejection in xenotransplants
One method that used the approach of inhibiting the Gala1-3Gal antibody 
was by the infusion of specific soluble sugars. These methods proved unsuccessful 
either due to large amounts of sugar required (which proved to be toxic), or the 
sugars used (Gala1-6Gal, Di-Gala1-3Gal and Tri-Gala1-3Gal) failed to bind to 
30% of the xenoreactive antibody (Ye et al., 1994; Romano et al., 1999).
The use of plasma exchange to deplete circulating antibodies or the use of 
protein A immunoadsorption columns has been effective in the removal of alio and 
xenoreactive antibodies (Branda etal., 1984; Fischel etal., 1991; Palmer ef a/., 1989). 
It has been shown that the depletion of xenoreactive antibodies by these techniques
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prior to the transplant of a pig organ delays rejection for some days but acute vascular 
rejection still develops. Depletion of the anti-Gala1-3Gal using specific Gala1-3Gal 
affinity columns has been used with success and experiments using pig kidneys 
transplanted into baboons show that reduction of the anti-Gaia1-3Gal (to a level 
whereby the antibody was no longer detected in vitro) abrogated hyperacute rejection 
(Taniguchi etal., 1996b). However, the reduction was transient and was followed by a 
rebound of the antibody and a >60-fold increase over a period of days or weeks. The 
use of immunosuppressive drugs in these experiments failed to prevent this rebound 
of the anti-Gala1-3Gal.
There is some heterogeneity within the anti-Gala1-3Gal repertoire and 
contains both low and high binding affinities (Lee etal., 1998; McKane etal., 1998; 
McMorrow et al., 1997). The low binding affinity makes it relatively difficult to inhibit 
these antibodies by soluble Gala1-3Gal disaccharides (Rieben etal., 1995). The 
binding of the Gala1-3Gal antibodies to endothelial cells appears to be dependent on 
antibody and antigen concentration and some anti-Gala1-3Gal cannot be dissociated 
by competitive inhibitors or by dénaturation with chaotropic reagents. The antibody 
could however, be dissociated by reduction of the disulphide bonds, which would 
suggest that the some of the antibody binds to the cell surface by a means other than 
a specific reaction with the epitope (Parker et al., 2001).
Another attempt to remove Gala1-3Gal antibodies was to target the B cells by 
removing them from the circulation and bone marrow in baboons by administration of 
monoclonal CD20 plus total body irradiation. This led to 100% depletion of B cells, 
which persisted for more than 3 months, but the absence of the Gaia1-3Gal antibody 
was not sustained for more than 2 days, suggesting depletion of plasma cells may 
also be required (Alwayn et al., 2001). Although the removal of Gala 1-3Gal antibody 
provides protection from hyperacute rejection, it is also likely that it plays a role in 
providing protection against various pathogens such as parasites, bacteria and 
viruses (Avila, Rojas and Galili, 1989; Towbin etal., 1987). Thus, the removal of anti- 
Gala1-3Gal may be detrimental to the well being of the patient.
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1.8.5 Role of Antibody in acute vascular rejection in 
Xenotransplantation
There is also evidence that donor antibodies play a role since acute 
vascular rejection is associated with allografts and concordant xenografts (Blakely 
eta!., 1994; Paul etal., 1979b; Perper and Najarian, 1967). In xenotransplantation 
it is thought that antibody binding is the most important factor responsible for type I 
endothelial activation. In pig-to-primate combinations, the level of IgG anti-Galal- 
3Gal increases rapidly following exposure to pig tissues. There is a striking 
correlation between the appearance of donor antibodies in concordant 
combinations and acute vascular rejection. The appearance of these antibodies 
appears to be T-cell independent. These antibodies may initiate the rejection by a 
number of different mechanisms such as;
1) the binding of antibody to antigen may activate complement which in turn 
activate the graft endothelial cells
2) the antibody binding may deliver signals via endothelial cell integrins leading to 
endothelial activation (Holzknecht and Platt, 1995).
3) circulating antibody may bind to effector cells via their Fc receptors and may 
serve as a means of recognition for NK cells (Inverardi et al., 1992b) and
4) increased immunogenicity of xenograft specific antigens (Galili et al., 1997).
Xenoreactive antibodies also bind to the glycocalyx (the carbohydrate rich 
zone on the outside surface of most eucaryotic cells) of porcine endothelial cells. 
When large amounts of glycocalyx are shed under cell stress or activation there is 
increased binding of the anti-Gala1-3Gal to the endothelial cells (Parker et al., 
2001). Thus, activation of the endothelium by complement causing the release of 
proteoglycans may initiate an increase in binding of xenoreactive antibodies (Platt 
et al., 1990b).
It has been shown that the removal of these Galal ,3Gal antibodies post­
transplant (by depletion or inhibition by immunosuppressive drugs) can delay the 
onset of acute vascular rejection (Chong et al., 1996; Lin et al., 1998; McCurry et 
al., 1995; Miyatake etal., 1998). Nonetheless, immunosuppressed primates 
transplanted with transgenic porcine organs synthesised 70-95% xenoreactive
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antibodies specific for the Galal-3Gal and 5-30% for other determinants (McCurry 
et al., 1997). However, blocking studies revealed these antibodies to other 
determinants were not to ‘new’ endothelial antigens.
1.8.6 Non anti-Gala1-3Gal Carbohydrate and Other Antibodies
Other non-anti-Galal -3Gal carbohydrate antibodies also appear to play a role 
in xenograft rejection but their exact role remains unclear. Some of the target 
molecules include Gal-a1,3-Le, Hanganutziu-Deicher (H-D), Tn, and Forssman 
antigens (Cooper, 1998). The H-D antigen with terminal N-glycolylneuramic (NeuGc) 
acid is widely expressed on endothelial cells of mammalian species except humans, 
at similar levels to Galal-3Gal epitopes. As baboons and monkeys also express H-D 
antigens, the pig to non-human primate experimental model cannot resolve the 
question of whether H-D antigens can elicit a humoral response in human recipients. 
Nonetheless, human patients, who have been exposed to porcine tissue, did not raise 
an antibody response to the H-D antigen (Kobayashi et al., 2000).
In addition to preformed natural antibodies, antibodies to protein determinants 
can also exist in potential transplant recipients as a result of prior exposure to foreign 
antigens (Michier et al., 1996).
Although there are studies in pig-to-baboon transplants and in humans 
exposed to pig hepatocytes, there was an increase in xenoreactive antibodies titres, 
but no de novo antibody was made. This indicates the lack of a humoral response 
against "new" endothelial antigens (Baquerizo etal., 1999; Cotterell etal., 1995; 
McCurry ef a/., 1997). Nonetheless, there are reports of non-Gala1-3Gal antibodies 
present that may play a roie in hyperacute rejection. An antibody against a low 
molecular weight protein was removed by perfusing human blood through a porcine 
lung. This antibody was not removed by Galal-3Gal affinity columns (Macchiarini ef 
a/., 1998). This experiment suggests that either there are specific antibodies reactive 
to lung tissue against a target other than Galal ,3Gal, or the columns used were 
ineffective in removing all the Galal ,3Gal specific xenoreactive antibodies.
Other workers have looked at IgG HLA sensitised human renal recipients and 
found that anti-HLA can cross react with pig lymphocytes suggesting that there may
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be cross reaction between anti-HLA and SLA (Barreau etal., 2000; Naziruddin etal., 
1998; Taylor etal., 1998). However, another group found that preformed IgG HLA 
specific antibodies against allogeneic MHC molecules are not an important factor in 
xenogeneic transplantation (Bartholomew ef a/., 1997).
It has also been reported that antibodies raised against other antigenic 
determinants may also play a role, as acute vascular rejection invariably occurs in 
the concordant models (McManus ef a/., 1991). In concordant combinations, anti­
donor antibodies aiso appear within several days after transplantation and their 
appearance appears to be T cell independent. The specificity of these antibodies 
has not been well characterised but it is thought they represent increased levels of 
natural antibody that normally is at a level that is either too low for easy detection 
or too low to trigger hyperacute rejection (Auchincloss and Sachs, 1998). In another 
study, the identity of the target molecules to which non-Gala1-3Gal antibodies are 
directed, has shown that some naturally occurring anti-agalactosyl antibodies not 
only bind to the terminal Galal-3Gal but also recognise other targets such as 
Galal-6Hexosepyrranosides. Also some of these anti-Gala1-3Gal do not bind In 
vitro to porcine xenografts (Parker ef a/., 1999). This obviously has implications in 
methods used when looking at the humoral response post transplant.
In Gothenburg, Sweden, when two human patients were perfused with pig 
kidneys, no novel antibody to non- Galal-3Gal or SLA was found (Rydberg ef a/., 
1996). Other in vitro experiments have demonstrated that pig aortic endothelial cells 
activated with TNF and IL-1 express new glycoproteins that are independent of 
Galal-3Gal epitopes (Vetr and Lipp, 1996). The stimulation of these new 
glycoproteins in vivo during acute vascular rejection is uncertain.
From the above experiments and observations, the evidence for the presence 
or absence of de novo xenoreactive is conflicting. It would appear that further work is 
required to elucidate the circumstances surrounding the existence of the antibodies. -
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1.8.7 Complement Depletion or Inhibition to Prevent Xenograft 
Rejection
During the 1990s, experimental studies identified that a critical mediator of 
hyperacute rejection in discordant xenografts was complement activation 
(Dalmasso, Platt and Bach, 1991; Platt etal., 1991). This usually occurs as a result 
of preformed antibody binding to antigen. The antibody constant regions bind in 
turn to the first component of the classical pathway. C l.
Purified cobra venom factor (CVF) has been shown to be effective in 
depleting complement and protects a discordant organ from hyperacute rejection 
(Leventhal et al., 1993). Nonetheless a picture of acute vascular rejection is seen 
2-3 days post-transplant similar to xenoreactive antibody removal, which leads to 
graft failure within a week. It has also been shown that CVF itself elicits a rapid rise 
in an anti-Gala1-3Gal response followed by a later anti-CVF response (Taniguchi 
et al., 1996a). It appears that the rise in Gala1-3Gal antibodies is probably due to 
Galal-3Gal residues present on CVF itself (Gowda et al., 1994). However, the 
depletion or inhibition of complement in the long term will have adverse effects on 
the patient, as this will increase the risk of infection. Indeed, even when 
complement is depleted or inhibited, acute vascular rejection may eventually occur 
(Loss et al., 2000).
The complement cascade is in a state of permanent low-level activity, in 
effect "ticking over" and complement regulatory proteins normally reduce or 
prevent inappropriate complement activation, such as DAF or CD55, MCP or 
CD46, and CD59 (protectin) (Figure 1.5). This mechanism explains why hyperacute 
rejection of blood-group incompatible allogeneic transplanted organs is a relatively 
weak and inconsistent reaction (occurring in only about 25% of cases), whereas 
hyperacute rejection of pig organs by primates is a rapid and aggressive event.
DAF is species-specific and as such porcine cells that express CD55 cannot inhibit 
human complement. CD59 and MCP, on the other hand, functions relatively 
efficiently across species. Porcine MCP is effective, expressed abundantly and in a 
similar pattern to human MCP (Dalmasso etal., 1991; Hanna et al., 1998; Perez de 
la Lastra, Hanna and Morgan, 1999).
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All these complement regulatory molecules have been used as targets for 
modifying pigs by transgenesis. However, both human MCP and DAF have been 
implicated as receptors for pathogens (Bergelson et al., 1994; Naniche et al.,
1993). Therefore it is possible that transgenic pig organs hyper-expressing human 
complement regulatory proteins present a particular risk of cross-species infection 
by viruses which utilise human complement regulators either as receptors or as 
resistance factors.
1.8.8 Cells involved In Acute Cellular Rejection
In allotransplantation, NK cells are rarely involved due to inhibitory signals 
that are generated when they bind to MHC HLA class I molecules. Porcine SLA 
molecules are not capable of producing inhibitory signals with human NK cells 
(Seebach etal., 1996). Furthermore, human NK cells express receptors such as 
NKG2 that recognise the GaIa1-3Gal molecule on the cell surface (Inverardi et al., 
1996). The finding that pig endothelial cells are less susceptible to lysis by human 
NK cells when they are transfected with a(1,2) fucosyltransferase gene is of 
interest as this may be exploited to prevent rejection (Artrip et al., 1999).
In an In vitro experiment it has been shown that NK cells were five times more 
efficient than T cells in killing porcine target cells which suggests the possibility of a 
rapid attack on xenografts by NK cells (Horvath-Arcidiacono and Bloom, 2001). 
This is supported by a study that showed that prolonged xenograft survival in a rat 
model was achieved by depletion of NK cells plus immunosuppression (Umesue et 
al., 1996). However, in another study in small animals showed that CD4'*' T cell 
depletion (without depletion of NK cells) causes prolonged graft survival, whilst the 
depletion of NK cells has no additional effect (Karlsson-Parra et al., 1996). In an 
allogeneic bone marrow transplant model, engraftment could be achieved by 
depleting T cells, but a xenogeneic engraftment requires additional anti-NK cell 
therapy (Sharabi et al., 1990). Thus, it would appear that T cells might be 
necessary to activate NK cells probably by cytokines such as IL-2 (Seebach et al., 
1996).
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Human T cells can respond to porcine endothelial cells through both direct 
and indirect pathways (Dorling etaL, 1996; Gill, 1992; Murray etal., 1994; Rollins 
et al., 1994b; Yamada, Sachs and DerSimonian, 1995a). Although the nature and 
intensity of T ceil responses to xenotransplantation is not completely known it is 
thought that it is likely that the intensity will be equal to or greater than that in 
allotransplantation (Brouard et al., 1999a). Early studies using some species 
combinations showed that the cell-mediated response was weak when measured 
in vitro. However, after graft rejection there was a strong T cell response In vitro 
that was dependent on the presence of host APCs, indicating the involvement of 
the indirect pathway of antigen presentation (Hines, Cowall and Lang, 1976; Moses 
et al., 1990). However, it is thought to be unlikely that direct recognition can occur 
by human CD8^ T cells, as they are unable to recognise and interact with 
xenogeneic SLA class I molecules as discussed earlier (Section 1.4.3). 
Nonetheless, it has been shown that human CDS’*" T cells are cytotoxic after 
stimulation with SLA class I molecules (Murray et al., 1994; Shishido et al., 1997).
In vitro research shows that cultured porcine aortic endothelial cells bind CTLA-4-ig 
and co-stimulate human T cells by both the GD2 and CD28 pathways (Murray et 
al., 1994). Other work indicates that human CD8^ T cells recognise distinct porcine 
peptides bound in SLA class I molecules and also human endogenous peptide plus 
SLA (Xu etal., 1999). Thus, although there are differences in MHC molecules 
between species, human TCR can recognise porcine SLA plus peptide complexes 
in a direct manner. In some species combinations, the molecular interaction 
between CD8^ T cells and MHC class I is intact. Alternativeiy, it may be that other 
molecular interactions or pathways are activated e.g. in small animal experiments, 
grafts from MHC knockout donors are always rejected rapidly (Markmann et al.,
1994). Thus, it can be argued that MHC antigen expression may not affect cell 
mediated xenograft rejection. Nonetheless, in other studies the human anti-porcine 
T cell response was similar to that of the allogeneic response as human T cells 
recognise SLA class II through the direct pathway involving the interaction of CD4 
accessory molecules (Kirk etal., 1993; Yamada, Sachs and DerSimonian, 1995b). 
This is likely to be due to the polymorphic regions of xenogeneic MHC molecules
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being similar to those of self-MHC molecules because there is conservation of the 
hypervariable regions of the molecule (Gustafsson etal., 1990a).
As the diversity of foreign peptides in xenografts is large, antigen 
presentation through the indirect pathway by recipient ARC may be potent. This 
pathway will probably dictate the extent to which humoral responses will ensue. 
Much work has concentrated on the direct and indirect presentation of peptides by 
MHC class I and class II molecules. These molecules can also present 
glycopeptides and the TCR can recognise the carbohydrate component (Deck et 
al., 1995; Harding etal., 1993).
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1.9 AIMS OF THE STUDY
The aim of this research was to:
1) To remove all anti-pig reactive antibodies by using pig red blood cells and 
demonstrate that any remaining xenoreactive antibody in the HLA specific 
anti- sera was not causing ‘false’ positive reactions against pig lymphocytes.
2) To test these anti-sera (some with the same/similar HLA specificity) would 
be tested against a panel of pig lymphocytes to examine if there was any 
pattern of reactivity of the HLA anti-sera against these cells.
3) The SLA class I alleles from these pigs wouid be sequenced in order to 
attempt to identify potential epitopes that these pigs may have in common 
with humans.
4) To remove the HLA specific antibodies present in the anti-sera by various 
means and study if the reactivity against the pig lymphocytes had been 
abolished.
5) To elute the antibody bound to the pig lymphocytes and attempt to 
characterise the antibody present in the eluate.
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CHAPTER 2: MATERIAL AND METHODS
2.1 CELL PREPARATION
2.1.1 Lymphocyte Preparation
Human peripheral blood lymphocytes (PBL) were isolated from 
anticoagulated blood (9 parts blood: 1 part 3.8% w/v trisodium citrate in distilled 
water; Sigma-Aldrich Company Ltd, Poole, Dorset) from random volunteers and 
splenocytes from cadaveric renal donors. These PBLs were used as targets in the 
standard complement-dependent lymphocytotoxic assay (GDC) and in flow 
cytometric assays. The cells were purified by density gradient centrifugation using 
Lymphoprep (Nycomed, Osio, Norway) at 1600g for 20 minutes (at room 
temperature, RT). Cells at the interface were harvested and washed twice at 700g 
for 2 minutes with phosphate buffered saline (PBS; ICN Biomedicals Inc. 
Basingstoke, Hampshire) and were resuspended in complement fixation test buffer 
(CFT; Oxoid, England) for the CDC assay or flow diluent (0.1% Bovine serum 
albumin (BSA); and 0.1% sodium azide dissolved in PBS; Sigma-Aldrich Company 
Ltd, Poole, Dorset) for flow cytometric assays.
Abattoir staff obtained pig PBLs and splenocytes from large white pigs 
(randomly selected) and staff at the Hammersmith Hospital, London, U.K. gave 
the spleen from NIH minipigs with cc and dd haplotypes for use. The PBLs 
were prepared as described above. Small pieces (1-2 mm^) of pig splenic 
tissue were placed into a petri dish and 10-15mls of 0.5% w/v 
ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich Company Ltd, Poole,
Dorset) in PBS was added. Using scissors and a scalpel the cut surface of the 
tissue was scraped to slough off cells and other tissue into the PBS. The 
separated spleen tissue was transferred into 30ml universal containers and was 
allowed to stand for 1-2 minutes to allow splenic particulate matter to settle to 
the bottom of the container. The supernatant was layered onto Lymphoprep 
and the process continued as described above. The pig splenocytes (blood 
group A or O, approximately 5 xIO^ cells per 1.2ml) were prepared, resuspended
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in freezing solution (see Section 2.1.1.1) and frozen under liquid nitrogen until 
required. The splenocytes were thawed into approximately 9mls of warmed 
(37°C) McCoys Medium (Life Technologies Ltd., Paisley, Scotland) and washed 
twice in PBS. If cells clumped, 5% w/v EDTA in distilled water was added to the 
McCoys medium (2mls EDTA plus 18mls McCoys). These cells were used as 
targets in CDC, flow cytometric assays and absorption techniques.
Pig splenocyte samples were numbered and pigs OxA and 41 was used in 
the series 1 experiments. Pigs 38, 42, 43,44 and 46 were used in series 2 
experiments. Pigs 43a, 46, 47, 48, 51, 52, 53, 54, 55, 56, 59, 60, 64, MPcc and 
MPdd were used in series 3 experiments.
2.1.1.1 Freezing cells
Lymphocytes were frozen in cooled freezing solution, (10% heat inactivated pig 
serum, 10% dimethylsulphoxide (DMSO; Sigma-Aldrich Company Ltd, Poole, 
Dorset)) made up in McCoys medium at a concentration of approximately 5 xIO^ cells 
per 1.2ml freezing vial. The vials were frozen down gradually using a Jencons ‘Handi- 
freeze' placed in the neck (the vapour phase of the liquid nitrogen) of a Taylor 
Wharton 35 VHC liquid nitrogen container. The vials were initially started at position 5 
and lowered by 16 turns anticlockwise after 45 minutes and left for a minimum of 3 
hours or overnight. The frozen cells were then filed into a rack in the liquid nitrogen 
itself.
2.1.2 Acid Treatment of Lymphocytes
Human cells when incubated for a short period in an acid buffer (pH 3.0) 
release (32-mlcroglobuIin from the HLA class I cell surface complex. This causes 
the selective reduction of surface HLA class I antigens, leaving the HLA class II 
and non-HLA antigens unchanged on the cell surface. Acid-treated cells tested in 
parallel with non acid-treated cells were used in the lymphocytotoxic antibody 
screening test for the detection and differentiation of HLA and non-HLA antibodies. 
Acid treatment of cells often results in a number of cells being killed, thus cell 
viability was checked before use.
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Cold acid buffer (0.5ml comprising equal volumes of 0.263M citric acid 
solution and 0.123M sodium phosphate solution (Na2HP0 4 : pH2.7-3.3; Sigma- 
Aldrich Company Ltd, Poole, Dorset) was added to a washed lymphocyte pellet of 
1-5 x10® cells/ ml. This was mixed and incubated for 3 min at 22°C. lOmIs of cold 
CFT was added to greatly dilute the acidity and samples were then centrifuged 
immediately at 700g for 3min. The supernatant was discarded and this wash step 
was repeated. The cells were resuspended in a small volume of CFT (0.3-1 ml) to 
give a final cell concentration of approximately 1x10® cells/ml.
2.1.3 Pig and Rabbit Red Blood Cell Preparation
Pig red blood cells (PRBCs) randomly taken from blood group O pigs were 
used for adsorption of xenoreactive natural antibodies. Whole blood was 
collected into anticoagulant (3.8% w/v trisodium citrate in distilled water) and 
washed four times in PBS. The buffy coat was removed after each wash.
Rabbit red blood cells (RRBCs) in citrate (as above) were obtained from the 
animal house at Imperial College, London, and washed three times in PBS.
2.2 SERUM SAMPLES
Patient serum samples were selected according to their panel reactive 
antibodies as determined by routine screening, as these patients would 
potentially be used for xenotransplantation in the clinical setting. Antisera used 
for serological HLA typing were selected because their specificity was very well 
defined and therefore could assist in defining epitopes on the SLA. (Tissue 
typing antisera were obtained either from other laboratories (both national and 
international) or locally and some had been submitted for international 
workshops on HLA). In addition, AB negative control sera were also included.
The majority of antisera that had anti-HLA antibodies were of the IgG isotype 
except sera 8-3, 9-3,16-3 and 27-3 in the series 3 experiments that were IgM 
only and serum 25-3 which had IgG anti-A2, 28 and IgM anti-A23 and 24.
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2.2.1 Series 1 Experiments
Twenty well defined anti-HLA class I typing sera, sera from two highly 
sensitised patient's serum with specificities against either/or HLA-A, B and C 
antigens and one negative control were selected (Table 2.1).
TABLE 2.1 Serum samples selected for the Series 1 experiments.
Serum
number Serum name HLA class 1 specificity
1 McColl A25,26,66,29,43,34wk
2 Holland A25,26,66,31,32,74,33,34,43,29wk
3 S21115/L Bw4,A23wk,24wk,32wk
4 Gibbens Cw4
5 Pinnington A23,24
6 Davey Cw2
7 Poole Cw4,6,7wk
8 O’Connell Cw5
9 Bowen B51,78
10 Bond Bw6,B52,49,57,51wk
11 Hutson B55,56,54,67,42wk
12 Dobson B7.8101
13 Tome A30,31
14 Cutting A2
15 Bright B57,58
16 Harvey Bw4,A23wk,24wk
17 Holt A1,36wk,11wk,B13
18 Who A24
19 I.F. (patient) A1,2,11,28, B8,13,+
20 J.R. (patient) 814,44,45,35,57,58,62,63,49,50,Cw1,+
21 Welsh A1,11
22 Pooled AB serum (negative control) Negative
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2.2.2 Series 2 Experiments
Eight well defined anti-HLA class I typing sera, nine sera from sensitised 
patients with specificities directed against either/or HLA-A, B and C antigens 
and one negative control were selected (Table 2.2).
TABLE 2.2 Serum samples selected or the Series 2 experiments.
Serum
number Serum name HLA class 1 specificity
21a Cutting A2
22a I.F. (patient) A1,2,11,28, B8,13,+
23 Gaffney B44,45wk,50
24 Hutchings B8,59
25 A.J. (patient) B44,45,13,7wk,60wk,61wk,49wk,50wk
26 L.L. (patient) B7,27wk,7wk,60wk,42wk
27 M.L. (patient) A2,B35wk,53wk,+
28 S.L. (patient) A1 Iwk
29 Lynch B44,45,+?Cw1
30 J.R. (patient) 814,44,45,35,57,58,62,63,49,50,Cw1,+
31 Roper A23wk
32 McColl A25,26,66,29,43,34wk
33 C.S. (patient) A1,B44wk,45wk
34 D.S. (patient) A30,31,26vwk
35 B.S. (patient) B8
36 Welsh A1,11
37 Ashdown Cwl
38 AB serum(negative control) Negative
2.2.3 Series 3 Experiments
Eleven well defined anti-HLA class I typing sera, 33 sera from patients 
with varying degrees of sensitisation with specificities directed to either/or HLA- 
A, B and C antigens and three negative control sera (AB negative) were 
selected. Antibodies against HLA class II specificities were also analysed 
(Table 2.3).
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TABLE 2.3 Serum samples selected for Series 3 experiments
iISerum name iin HLA class 1 specificity Isil HLA class II specificity
1-3 Abrahams 90 Bw6 72 DR52,(13)
2-3 AW (patient) 90 A1,2,649,61,++ 78 DR11,12,17,1,+
3-3 Ashdown 14 Cwl 41 DQ2
4-3 J.B. (patient) 100 A1,B35, +++ 100 Multispecific- undefined
5-3 B.B. (patient) 100 A1,2,3,11,28,++ 56 DR1,4,103,(10),Q2wk
6-3 R.B. (patient) 32 A2wk 28 DR16,16
7-3 G.B. (patient) 25 A3,B13,18,60vwk 13 DR4
8-3 W.B-1 (patient) 30 857,58 0 Negative
9-3 W.B-2 (patient) 30 657,58 0 Negative
10-3 W.B. (patient) 2 613 90 DR52,DQ2,DR15,16
11-3 J.C. (patient) 90 A2,3,11,23,24,28,857,58,++ 98 DR52,+
12-3 Ching 50 A23.24,32.25wk,B51,57wk 88 DQ2,DR17,18wk,13,14wk,1,10,103
13-3 CT (patient) 90 B7,+++ 99 Multi; ?DR15,16,51,13,14,++
14-3 Gaffney 25 B44,45wk,50 0 Negative
15-3 R.G. (patient) 90 A2,B7,44,45,++ 53 DR1.10,103,15,16,(51)
16-3 W.G. (patient) 64
A25.26wk,32,B49,52,44wk,57wk,58wk.
62wk,63wk,+ 0 Negative
17-3 Holt-1 43 A1,11,26 (ntB13) 53 DR15,16,51,11,12. +?52
18-3 Holt-2 46 A1,11,23,26.B8vwk 56 DR15,16,17,18,11,12
19-3 HGH (patient) 90 A2,644,57,++ 100 DR52,DQ2,+
20-3 Hutchings 20 68,59 78 DR52.DQ2
21-3 JAM (patient) 0 Negative CDC, positive by FlowPRA™ 26 DR11,13wk,+
22-3 M.J. (patient) 54 B51.52,57,58,49.62wk.44wk 56 DR17,18,13,14,8
23-3 A.J-1 (patient) 75 644,45,49,50,60,61,62,27,13 100 DR52,DQ1,2
24-3 A.J-2 (patient) 25 644,45,50 100 DR52,DQ1,2
25-3 LA (patient) 68 A2,28,24,23wk 28 DR4.53
26-3 L.L. (patient) 25 B7,27wk,13vwk,60vwk 75 DR15,16,1,103,10,+?4
27-3 M.L. (patient) 20 68 0 Negative
28-3 Lynch 25 644,45 78 DR15,16,51 ,DQ7,8,9,+
29-3 R.M. (patient) 90 A2,3,23,24,644,45,57,58,+ 75 DQ2,DR1,15,16
30-3 MU (patient) 82 67,13,27,60,61,41,55. A25,29,32,+ 100 DQ7,8,9,DR1,10,103,15,16,17,18
31-3 OK (patient) 25 A1 (ntA36) 63 DQ2
32-3 Parsons 86 A23,24,25,32,651,52,49,57,27,44wk 0 Negative
33-3 P.P. (patient) 90 A1,2,28,68,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+
34-3 M.P. (patient) 10 B44wk 0 Negative
35-3 Pugh 21 655,56,13,35wk 75 DR15,16,4,7,9,+
36-3 RA. (patient) 53
B51,62,49,50',B7,58wk,62wk,35wk,
71vwk,44wk 70 DR15,16,51,+
37-3 J.R. (patient) 53 614,44.45,35,57,58,62,63,49,50,Cw1,+ 81 DQ4,DR8,11,12,13,14,+?2,+
38-3 D.S. (patient) 11 A30wk,31wk 22 weak?
39-3 B.S. (patient) 100 A2,23,24,29,644,+ 100 Multi; ? DQ5,6,7,8,9,+
40-3 R.V. (patient) 0 Negative 88 DR53,DQ3wk
41-3 Welsh 50 A1,11,25,26 88 DR52.+
42-3 A.W. (patient) 90 A2,23,24,28,B44,+ 100 DR15,16,11,12,DQ2,+
43-3 H.W. (patient) 39 A1,11wk,24wk 72 DR15,16,+?1,10,103,+
44-3 R.W. (patient) 50 B14,8wk,+ 100 DR53,DQ3,+
45-3 AB serum 0 Negative 0 Negative
46-3 AB serum 0 Negative 0 Negative
47-3 AB serum 0 Negative 0 Negative
HLA class I specific antibodies highlighted In pink indicates IgM only.
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2.3 ABSORPTION OF XENOREACTIVE NATURAL ANTIBODIES
2.3.1 Absorption of Antl-pig Xenoreactive Antibodies
Since PRBCs do not express MHC molecules, these cells were used to 
adsorb xenoreactive natural antibodies without depleting potentially cross­
reactive HLA specific antibodies to SLA (Sandrin et al., 1993). An aliquot of 
unabsorbed sera was retained as a control. A ratio of one volume of packed 
PRBCs (Included blood group A and O) to one volume of human antiserum 
(series 1,2 and 3) was used for each absorption step. Equal volumes of serum 
and cells were mixed and incubated at 22°C for 60 minutes with an occasional 
mix. Tubes were centrifuged at 10,000g for Sminutes and the serum was 
transferred to the second aliquot of packed PRBCs and mixed. This was 
incubated at 4°C overnight and then centrifuged as above. Unabsorbed and 
absorbed sera were frozen until required.
2.3.2 Absorption of Antl-rabbit Renta Saccharide Reactive Antibody
RRBCs express Gaia1-3Gal|31-4GlcNAcp1-3Gaipi-4Gic (Penta­
saccharide) and if necessary (as judged by residual binding in a Galal-3Galp1- 
4GlcNAcp1-3Gaipi-4Glc- conjugated to human serum albumin (HSA) ELISA) 
sera were further absorbed twice by excess rabbit red cells, to ensure complete 
removal of anti-species antibody. Sera 6, 19, 20, and 21, from the series 1 
experiments, and sera 21a, 22a, 23, 24,27,28, 29,31, 33,35, and 36, from the 
Series 2 experiments were treated with RBCs, as they had remained positive in 
the anti-Penta-saccharide ELISA. Equal volumes of RRBCs and PRBC-absorbed 
sera were incubated at 4°C for 4 hours with an occasional mix. Tubes were 
centrifuged at 10,000g for Sminutes and the serum was tested for residual anti- 
Penta-saccharide by ELISA and flow cytometry against RRBCs and pig 
lymphocyte number 41 (Series 1) and number 43 (Series 2).
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2.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR GALa1-3
GAL SPECIFIC NATURAL ANTIBODIES
The presence of IgG and IgM xenoreactive natural antibodies was 
assessed in Series 1 and 2 experiments before, and after, PRBC absorption by 
ELISA specific for two oiigosaccharides based on the Gal a1-3Gal- saccharide 
(Dextra Laboratories, Reading, UK). The saccharides were conjugated to either 
BSA or human serum albumin (HSA; Cairns et al., 1995). ELISA plates (96- 
well) (PolySorp, Nunc, Roskilde, Denmark) were coated with 50pl of antigens 
Galal-3 Gal (Dl) and Penta conjugated to HSA at 10 pg/ml in 0.1 M bicarbonate 
buffer (pH 9.6) overnight at 4°C. Plates were washed four times with PBS plus 
0.05% w/v Tween (PBS-Tween, pH 7.4) and blocked with 2% w/v 
polyvinylpyrrolidone (Sigma-Aldrich Company Ltd, Poole, Dorset) for 4 hours at 
22°C. After washing the plates 4 times with PBS-Tween, 50 pi of each 
absorbed and unabsorbed serum sample (diluted 1:2 in PBS) were incubated 
for 1 hour at 22°C in both antigen and HSA coated wells. Plates were washed 4 
times with PBS-Tween and 50pl of peroxidase-conjugated F(ab')2  rabbit anti­
human IgG or IgM (DAKO, Ely, Cambridgeshire) diluted 1:1000 in PBS-Tween 
was added and incubated for 1 hr at 22°C. After plates were washed 4 times 
with PBS-Tween, they were developed with 50 pi of 1,2-phenylenediamine 
(DAKO Ltd., Ely, Cambridgeshire) per well and the reaction was subsequently 
stopped with 50 pi of 2M sulfuric acid (Sigma-Aldrich Company Ltd, Poole, 
Dorset). Optical density (O.D.) at 490nm was measured in an automated plate 
reader (Anthos Labtec). All tests and controls were performed in duplicate. 
Specific binding was calculated from the difference in OD between the antigen- 
coated and the BSA or HSA -coated wells. The cut off was an O.D. of 0.1 as 
determined by extensive assays performed in the laboratory by Janet Lee (The 
Brent Laboratory, St Mary’s Hospital, London W2).
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2.5 FLOW CYTOMETRIC ASSAYS
Flow cytometry allows the detection of antibody bound to its ligand on the 
surface of a cell by the addition an anti-immunoglobulin heavy chain conjugated to 
a fluorochrome.
Antisera before and after absorption using pig and RRBC and either human 
or porcine lymphocytes, were tested for binding of human immunoglobulin (IgG) to 
various ceils by flow cytometric assay. A ratio of one volume of serum to two 
volumes of cells (approximately 1x10 -^1x10® cells /tube) was added into Falcon 
tubes (ELKAY Lab Products Ltd, U.K.), including positive and negative controls, and 
mixed. The samples were then incubated for 30 minutes at 22°C and subsequently 
washed twice to remove unbound antibody, with 4mls of flow diluent at 700g for 3 
minutes. Four microlitres of rabbit anti-human polyclonal IgG (O.Spg) fluoroscein 
isothiocyanate (FITC) conjugate F(ab')2  (DAKO Ltd., Ely, Cambridgeshire) was added 
and the tubes were vortexed. The samples were incubated for 30-120 minutes at 
4°C. Following the washing steps as described above, the cells were re-suspended in 
200-400pi of flow diluent
2.5.1 Flow Cytometry Data Analysis
The flow cytometric analysis was performed on a Coulter Epics XL 
(Beckman Coulter, High Wycombe, U.K.) after the quality assurance procedure 
was carried out using flow-check beads. A known positive and negative control 
was always included in every assay and target populations were gated for 
lymphocytes by cell forward and side scatter characteristics. Data was collected 
on 5-10,000 events and histograms generated and analysed for surface IgG 
binding. Medium channel fluorescence (Mdx) was collected on the histogram of 
cell counts against the log of the FITC. These values are on a logarithmic scale.
The relative medium fluorescence (RMdx) was calculated by dividing the negative 
control value into the test value. This allows flow cytometric assays to be 
compared from different days. Histogram overlays were also analysed. An RMdx 
value of greater than 2.5 was considered positive.
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The RMdx cut-off value of 2.5 was based on the value of 2.3 that is used 
clinically for flow cytometric crossmatches for renai transplants. All histograms 
were overlayed and ‘eyebailed’ and based on experience with HLA antibody 
screening and crossmatching an RMdx cutoff of 2.5 was arrived at. This value Is 
probably conservative but it was important that serum samples reacting against 
pig lymphocytes were considered truly positive.
For these assays an RMdx value of up 5.0 was considered a positive result 
(as on the histogram analysis, values up to 5.0 indicated the amount of IgG (FL-1) 
binding fell into the first log decade along the X-axis). Those RMdx values above 
5.0 fell into the second log decade along the X-axis and were considered strongly 
positive.
2.6 STANDARD COMPLEMENT DEPENDANT MICRO-
LYMPHOCYTOTOXICITY TEST (CDC) (NIH) (n a t io n a l  in s t it u t e s  o f  h e a l t h )
2.6.1 CDC Test Against Human Lymphocytes
The CDC assay (Terasaki and McClelland, 1964) is a standard technique for 
HLA antibody screening and detects antigen/antibody reaction by the killing of the 
target lymphocyte.
In a 60 well Terasaki tray, 1pl of PBL or splenocytes (1-2 x 10®/ml) prepared as 
described in section 2.1.1 and suspended in CFT was incubated with 1pl of test serum 
under paraffin oil to prevent drying, for 30 minutes at 22°C. Five microlitres of rabbit 
complement (Cederlane, VH Bio Ltd., U.K.) was added and the trays were incubated 
for a further 90 minutes at 22°C. The cells were stained with 1 pi of the contrasting 
dyes, ethidium bromide and acridine orange (0.2mg/ml ethidium bromide (Sigma 
Chemical Co., Poole, Dorset) and 0.1 mg/ml acridine orange (Sigma Chemical Co., 
Poole, Dorset) dissolved initially in 1ml of 100% ethanol (Sigma-Aldrich, Poole,
Dorset) and then added to 15%w/v bovine haemoglobin (Sigma Chemical Co., Poole, 
Dorset) and 2.5%w/v EDTA dissolved in PBS). The lysed (killed) ceils stained red with 
ethidium iodide and the live cells stained green with the acridine orange. Background 
staining was quenched with the bovine haemoglobin. The continuation of
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complement-mediated iysis was prevented by the inclusion of 2.5% w/v EDTA with 
the stains. The piates were read with an inverted fluorescence microscope and the 
percentage lysis recorded in the standard NIH scoring system. A positive result was 
any lysis above the negative control. The scoring system ranged from 2 -8  whereby a 
score of 2 = 10-35% dead cells; 4 = 36-55%; 6 = 56-80%; 8 = 81-100% dead cells.
Although this method is used routinely In most tissue typing laboratories to 
characterise HLA antibody specificity, this technique has drawbacks. Some fresh 
human PBLs occasionally produce a background of cell death particularly after the 
addition of complement. Although this Is subtracted from the final score it is open to 
interpretation. As such weak reactions (cell death 10-35%) that maybe due to ‘non­
specific’ ceil death due to the fragility of the PBL is sometimes considered within this 
techniques error rate. For these experiments, if the cells used were less than optimal, 
weak reactions were not interpreted.
2.6.2 CDC Test Against Pig Lymphocytes to Demonstrate Anti-pig
Reactivity Present in Human Serum
2.6.2.1 Assessment of rabbit complement for use in CDC assay against 
pig lymphocytes
Two different batches of rabbit complement (TC2-41 and TC3-42) were 
evaluated for toxicity against pig lymphocytes. Unabsorbed pooled AB serum was 
titred in doubling dilutions from 1:8 to 1:1024 in PBS. One microlitre of pig 
lymphocytes was added and incubated at 22°C for 30 minutes. One microlitre of 
complement at neat, 1:2 and 1:4 dilutions in PBS was added and incubated for 
30minutes at 22°C. The wells were stained, read and scored as described in section 
2.6.1.
2.6.2.2 CDC against pig lymphocytes
One microlitre of PRBC-absorbed sera was added to 1 |j,l of cells and incubated 
at 22°C for 30 minutes. One microlitre of rabbit complement (batch TC2-41) was 
added at a 1:2 and 1:4 dilution in PBS and incubated for 30minutes at 22°C. The wells 
were stained, read and scored as described in section 2.6.1.
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In Series 3 experiment, PBLs from four pigs (60, 61, 62 and 63) were tested. 
Patient's serum samples were screened for the presence of IgG and IgM PRA pre- 
and post- PRBC-absorption by the technique described in section 2.6.1.
2.6.3 Dithiothreitol (DTT) Treatment of Serum
Dithiothreitoi (DTT) is a reducing agent used in the detection of IgM antibodies.
It breaks down the disulphide bonds; the intersubunit bonds of the IgM pentamer are 
more susceptible to cleavage than the interchain bonds of IgG or the IgM subunits. 
DTT at the appropriate concentration will inactivate IgM without affecting IgG activity.
A known positive and negative control was included with each test. Thirty-six 
microlitres of serum were mixed with 4pl of 0.1 M DTT (Sigma-Aldrich Company Ltd, 
Poole, Dorset) solution and used. The serum is tested by the standard 
microlymphocytotoxic technique as described in 2.6 with the deviation that 25pl of 
cysteine solution (0.1 M cysteine solution) (Sigma-Aldrich Company Ltd, Poole, 
Dorset) suspended in CFT) was added to each 1ml of rabbit complement used. 
Cysteine is added to inhibit further action by DTT.
2.7 DETERMINATION OF HLA CLASS I SPECIFICITY PRESENT IN PRBC 
ABSORBED AND UNABSORBED SERUM SAMPLES
The selected antisera described in Section 2.2 were retested pre and post 
PRBC-absorption. The HLA typing sera were chosen for their specificity as 
determined by CDC and patient’s serum samples had a high PRA and had been 
obtained from patients waiting for a kidney transplant. Their sera had been routinely 
screened for IgG and IgM antibody specificity every 2 months for over 5 years as 
described in Section 2.6.1 and 2.6.3, and their HLA specificity was well characterised. 
HLA class I antibody specificity for unabsorbed serum was determined using this 
panel and cumulative data from sequential antibody screening analyses.
In the Series 1 experiment, antisera were tested against a limited panel of human 
lymphocytes. In the Series 3 experiments, pre- and post-absorbed antisera was tested 
against a 'random' HLA typed panel of 49 fresh human PBLs, ensuring all known 
common antigen specificities to which monospecific antibodies may be raised were
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tested. The Terasaki plates were made up in batches of 63 and frozen at -20°C until 
required. Untreated and DTT treated sera were tested.
2.7.1 QUIK-Screen® class I Solid Phase ELISA for the Detection of 
Class I Antibodies
QUIK-Screen® class I solid phase ELISA (Quest Biomedical, Solihull, West 
Midlands) were carried out using the manufacturers instructions. The principle of 
the assay is purified HLA class I gycoproteins derived from the platelets of 40 
donors are each immobilized in different microtiter wells by means of a monoclonal 
antibody. Each plate is sufficient to test 10 specimens. Diluted serum and controls 
were added to the individual wells and incubated to allow antibody binding to their 
specific ligand. Post-incubation the plates were washed to remove residual 
antibody. A goat anti-human IgG antibody conjugated to alkaline phosphatase was 
added to each well and incubated further to allow the enzyme-labeled anti-IgG to 
bind to any HLA class I antibody bound to HLA class I antigen. A further wash step 
was carried out to remove any unbound enzyme-labeled anti-IgG. The remaining 
enzyme activity was measured by adding p-nitrophenol phosphate (PNPP) 
substrate and 3M sodium hydroxide (stop solution) to the wells and reading the 
absorbance at 490nm using an ELISA reader (Anthos Labtec). The amount of 
colour that developed during the incubation was proportional to the amount of 
bound conjugate.
2.7.2 FlowPRA™ (One Lambda, Inc) for the Detection of Class I and II 
Antibodies
2.7.2.1 Flow PRA™ (One Lambda, Inc) screening test
This test is designed for flow cytometric screening of PRA against HLA using 
a panel of microparticle beads (2-4|Lim in diameter) coated with purified HLA class I 
or class II antigens. The Flow PRA™ class I beads (One Lambda Inc., VH Bio Ltd., 
Newcastle, U.K) are non-fluorescent, whereas the class II beads are fluorescent 
and are excited at 488nm, and emit at 580nm, which is detected by the FL2
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channel. Thus, these beads can be run together or separately. The detection of 
bound IgG is by anti-human IgG FITC that is detected by the FL1 channel.
The method used was a modification of the manufacturers instructions, and 
validated as part of the routine work performed at The Brent Laboratory at St 
Mary’s Hospital, London. The sensitivity of the Flow PRA™ beads had also been 
shown to be slightly more sensitive than using human EBV transformed cell pools 
(van Dam etal., 2000). Ten microlitres of serum, including a positive and negative 
control, were incubated with 2pl of class I or class II beads for 30 minutes at 22°C. 
The beads were washed twice with 4mls of flow diluent at 1560g for 8 minutes.
Fifty microlitres of FITC conjugated goat anti-human IgG (Fey) at 1:100 (in flow 
diluent) was added to each tube and incubated for 30 minutes at 22°C. The tubes 
were washed with 4mls of flow diluent and resuspended in 300|il of flow diluent 
and analysed on a Coulter Epics XL. Target populations of beads were gated by 
bead forward and side scatter characteristics. Data was collected on 5-10,000 
events and histograms generated of bead counts against the log of the FITC. 
Histograms were analysed by eye for multiple peaks.
Data interpretation was not calculated as RMdx but observed for multiple 
peaks. This is because this assay tends to give false positive results due to IgG 
binding to the beads. However, if a single peak was observed and there was a 
large shift to the right, these sera were further analysed using control beads. If a 
result showed three or more peaks and had moved into the third log decade along 
the X-axis this was considered a three plus positive. A sample showing multiple 
peaks and a shift into the second log decade was assigned two plus, and a result 
with multiple peaks, which moved between the first and second log decade was 
assigned one plus.
2.7.2.2 Flow PRA™ Specific test for characterisation of HLA class II 
antibody
Flow PRA™ specific class I or class II are divided into 4 groups each. Each 
group contains eight different beads with different fluorescent properties, which 
can be detected on the FL2 channel. Since the eight different beads generate
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distinct FL2 channel shifts, each of the eight beads in a group can be separated 
on the FL2 channel. The testing procedure is the same as described in section 
2.7.5.1.
Results are interpreted as RMdx as described in section 2.5.4. The RMdx 
values are sorted in order of positivity and cutoff value is approximately 4.0.
2.8 ABSORPTION OF HLA ANTISERUM USING VARIOUS TARGETS
To demonstrate that HLA specific antibodies were crossreacting with porcine 
lymphocytes, these were absorbed out of the test sera using various targets. 
Human platelets express HLA class I but not class II, whereas human Epstein Barr 
Virus transformed cells express both HLA class I and II. The methods used are 
described below.
2.8.1 Platelet Adsorption of HLA class I-Specific Antibodies
HLA class l-specific antibodies were further absorbed from PRBC- 
absorbed patient sera using a pool of fresh human platelets. Expired pooled 
platelets were obtained from the blood bank, pooled and washed 4 times in 
PBS. One hundred microlitres of human sera (series 3) were mixed with 400pl 
of packed platelets and left at RT for 90minutes with an occasional mix and 
were then left overnight at 4°C. The serum platelet mixture was brought up to 
RT the following day, and centrifuged at 13,000gfor 5 minutes. The 
supernatant was removed and added to a further 400pl of packed platelets and 
left at RT for 90 minutes. The tube was centrifuged as above and the 
supernatant removed and tested for the presence of HLA class I antibody 
activity as described in section 2.6.1.3.
2.8.2 Absorption of HLA Antibodies Using Human Epstein Barr Virus 
(EBV) Transformed B Cell Lines
2.8.2.1 Preparation of cell line pools
Twenty ceil lines were used to cover as many HLA antigens as possible 
and were split into two pools of 10 cells each. The two pools contained all
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common HLA class I and II antigens, and thus any anti-pig splenocyte antibody 
that is due to HLA reactivity will be removed by the EBV pool.
The EBV transformed cell lines were obtained from the European 
collection of cell cultures (ECACC; Porton Down, Wiltshire) and the United 
Kingdom Transplant Special Services Authority (UKTSSA, Bristol) as frozen 
cultures. All procedures were carried out under sterile conditions. The frozen 
cells were thawed into approximately 9mls of warmed (37°C) RPM11640 with 
Glutamax I (Life Technologies Ltd., Paisley, Scotland) containing 10% heat 
inactivated foetal calf serum (PCS; Sigma-Aldrich, Poole, Dorset) and centrifuged 
at 400g for 5 minutes. The supernatant was discarded and the cells washed twice 
in 5ml of RPMI at 400g for 5 minutes. The cells were resuspended in RPMI, PCS 
plus antibiotic/antimicotic solution (Life Technologies Ltd., Paisley, Scotland) 
culture medium at a concentration of 1 x 10®/ml and transferred to a culture flask. 
The cultures were incubated at 37°C under an atmosphere of 5% CO2. Plasks 
were checked daily microscopically for cell growth and culture medium added as 
required until sufficient cells were present.
Cell pools were made by counting the cell lines and pooling equal numbers 
of the particular cell lines for that pool and frozen in a solution of 45% RPMI, 45% 
PCS and 10% DMSO until required.
2.S.2.2 Sera selected for absorption using EBV cell lines
Sera 7,13,14,32,34,45, (Series 3) which reacted against pig splenocytes 
and a negative and positive control were selected to be absorbed. Por the first 
absorption 1.4x10^ cells were combined with lOOpl of human sera and 
incubated at 22°C for 60 minutes. The cells and sera were centrifuged at 
10,000g for 5 minutes and the supernatant was removed and added to a 
second aliquot of EBV cells (8.6 x 10®) and incubated at 4°C for 4 hours. The 
supernatant was removed and tested by flow cytometry against pig 
lymphocytes (section 2.5).
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2.8.3 Adsorption of HLA Antibody Using Pig Lymphocytes.
Using sera previously treated with pooled PRBC to remove pig-specific 
antibody, the sera were absorbed with pig lymphocytes. This was to observe if 
these cells would remove the anti-HLA specificity.
Thirty microlitres of packed pig splenocytes were added to 120pt of PRBC- 
absorbed sera (series 2). These were incubated at 22°C for 30 minutes. The 
cell plus serum mixture was spun 10,000g for 5 minutes and the supernatant 
removed and added to a further 30pl of packed pig splenocytes. This was 
incubated at 4°C overnight. The supernatant was removed and tested against 
pig splenocyte 46 by CDC and flow cytometry.
2.9 ELUTION OF ANTIBODY BOUND TO 'PIG 64' SPLENOCYTES
Antibody was adsorbed then eluted using a low pH technique, from pig 
splenocytes using sera from series 3. Nine eluates were prepared from sera 4, 13, 
15, 23, 27, 29, 34, 39, and 42 that reacted against pig 64 lymphocytes by flow 
cytometry. Five negative controls were selected, two of which were AB serum (45 
and 46) and three, which were negative against pig cells but had a high PRA (5, 32 
and 33).
Pig splenocytes were obtained as previously described and 1.8 x 10® cells 
were mixed with 400pl of the sera (except for serum 4 and 15 where 9x10^ cells 
were mixed with 150j.il of sera and sera 27, and 33 where 1.3x10® cells were 
mixed with 300j.il of sera as there was insufficient serum to absorb 400pl). The 
cells and sera where incubated at 22°C for 3 hours with an occasional mix. The 
tubes were spun at 10,000gfor 5 minutes and the supernatant removed. The cells 
were washed twice in PBS and 200ul of 0.1 M glycine HCI, (Sigma Chemical Co., 
Poole, Dorset) pH2.3, was added. This was incubated at 4°C for 30 minutes. The 
tubes were centrifuged and the supernatant/eluate was transferred into a clean 
tube. The pH was adjusted to 7.0 with sodium hydroxide (Sigma Chemical Co., 
Poole, Dorset) and dialysed (dialysis tubing -  Visking size 5 diameter 19mm: 30m, 
pore size 12 -14kd (Medicel International)) against PBS for 3 hours. The eluates 
were back tested against pig 64 splenocytes by flow cytometry and CDC.
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2.10 DNA EXTRACTION
Pig splenocytes were prepared as described in Section 2.1.1. The white cell 
pellet was resuspended by flicking the tube and approximately 3mls of Nuclei Lysis 
Buffer (NLB; lOmIs of 1M Tris HCI pH 8.1 was added to ~500mls of distilled water, 
80mls of 5M NaCI, 4mls of 0.5M EDTA pH 7.5-8 and lOOg of SDS was added and 
made up to 1L) and mixed well. The tubes were placed in a water bath at 65°C 
overnight. After incubation the NLB and cell solution was transferred to a 
polypropylene tube and Iml of 6M NaCI, and 1ml of chloroform was added. The tube 
was capped and shaken until a homogenous milky solution was obtained. The tubes 
were centrifuge at 22°C for 20 minutes at 2000g. The top aqueous phase was 
aspirated into a clean tube. One to two volumes of 95% ethanol was added and the 
tube capped and inverted gently until all of the DNA had precipitated. Ethanol induces 
a structural transition in the nucleic acid molecules, which causes them to aggregate 
and precipitate from solution. The tube was centrifuged at 2000g for 5 minutes. The 
ethanol supernatant was discarded and the DNA pellet washed twice in 70% ethanol 
at 2000g for 5 minutes. Washing the precipitated pellet will effectively desalt the 
DNA, which is required, as the DNA will not effectively dissolve in high concentrations 
of salt. The DNA pellet was transferred into a sterile 2ml microtube and resuspend in 
an appropriate volume of autoclaved or sterile distilled water. Incubate the tube in the 
water bath at 56°C until the DNA is dissolved. Store the DNA at 4°C until use.
2.11 MEASUREMENT OF RNA/DNA CONCENTRATION
The final preparation of undegraded RNA/DNA free of proteins has a A260/A280 
ratio of approximately 1:8 -  2:0. Those samples with a ratio of ~1.5 will have 
approximately 50% protein contamination.
RNA or DNA samples were diluted 1:50 in distilled water and measured on a 
spectrophotometer (Pharmacia, Amersham Bioscience UK Ltd, Little Chalfont, 
Buckinghamshire) at an CD 260 and 280nm.
The concentration of RNA/DNA was calculation from the OD260 of a 1:50 
dilution: OD260 x 40 x 50(dilution factor) x volume in ml = total pg. Divide total pg by 
pi to obtain pg/pl.
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2.12 POLYMERASE CHAIN REACTION (PCR) OF GENOMIC DNA
This method uses Expand high fidelity PCR system from Roche Diagnostics 
(Roche Diagnostics, Welwyn Garden City, Hertforshire). Add together 5pl genomic 
DNA (50ng/pl), 5pl Expand buffer (containing MgCI at 1.75mM), 5pl DMSO, 0.75pl 
dNTP (lOOmM), 0.75pl Expand enzyme, 1 pi of each primer pair (10pM each) and 
make up to 50pl with distilled water. The sequences of the primers are shown in 
Table 2.4.
Primer pairs used were:
To amplify SLA-1
PI-1 PD1/7f+1 and PDIr+1452
PI-2 PD1/7f-3 and PDIr+1452
PI-3 PD1/7f-87 and PDIr+1452
To amplify SLA-7
P7-1 PD1/7f+1 and PD7r+1450
P7-2 PD1/7f-3 and PD7r+1450
P7-3 PD1/7f-87 and PD7r+1450
To amplify SLA-14
P14 PD14f+34 and PD14r+1182
2.12.1 Thermal Cycling Program
A Perkin Elmer thermocycler 960 (Perkin Elmer Life Sciences, Cambridge, 
U.K.) was used. The cycling times were 94°C for 2mins, 35 cycles at 94°C for 
lOsecs, 65°C for 45secs, 68°C for 3mins and finally 68°C for 7 minutes.
2.13 GEL ELECTROPHORESIS
Agarose gel electrophoresis is effective for separating and identifying 0.5- 
25kb DNA fragments. DNA molecules when exposed to an electrical field migrate 
towards the anode due to its negatively charged phosphates along the DNA 
backbone. The migration velocity is limited by the frictional force imposed by the 
gel matrix. While charge and/or size can affect the rate at which the 
macromolecules will pass through the gel, the charge to mass ratio is the same for
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DNA molecules of different lengths. Therefore it's the size of the DNA that 
determines the rate at which it passes through the gel, thereby allowing an 
effective separation of DNA fragments length mixtures by electrophoresis.
Agarose at 0.8% with 0.02% ethidium bromide added ( which binds to the DNA and 
can be 'photographed' by illumination with UV light (>2500pW/cm^) was made up 
and poured within 2mm of where the teeth on the combs join each other in a gel tray. 
This was allowed to set for 20-30 minutes. The tray was placed into the gel tank 
(Flowgen, Lichfield, Staffordshire, U.K.) containing 0.5 x Tris/Boric acid and EDTA 
buffer (TBE: 5.4g Tris base, 2.75g Boric acid and 0.2ml of 0.5M EDTA per litre; 
Sigma-Aldrich, Poole, Dorset). The agarose gel was covered to a depth of 0.1 and 
1cm of buffer. Five microlitres of each reaction plus lOpI of Orange G loading buffer 
(100ml of glycerol, 83.3ml of 2xTBE, 150ml of distilled water and 0.083g Orange G 
dye) was loaded into each well of the agarose gel. The gel was run at 70V for 60 
minutes. A 20bp DNA molecular weight marker was used to compare band sizes 
(FMC Bioproducts Europe, Rislngevej 1, Denmark). The product bands were 
visualised using a transiliuminator and recorded (UVP Ltd, Cambridge, U.K.).
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CHAPTER 3: REMOVAL OF XENOREACTIVE ANTIBODIES IN 
HUMAN ANTISERA
3.1 INTRODUCTION
The aim of this study was to investigate the anti-HLA cross-reactivity with 
SLA. Thus, it was imperative that the high concentrations of human anti-pig 
natural antibodies were removed prior to testing this hypothesis.
These natural antibodies are highly specific for glycoproteins and 
glycolipids bearing the terminal Gala1-3Gal residue (Good etal., 1992). Studies 
have shown that these Gala1-3Gal antibodies are a heterogeneous population 
and individuals may have antibodies that recognise either all or a combination 
of the three main Gala1-3Gal antigens (McKane et a!., 1998). The antigens to 
which individuals may have antibody against are, Di (Gala1-3Gal), Tri2 (Galal- 
3Gaipi-4GlucNAG) and Penta (Gala1-3Gaipi-4GlucNAC(31-3Gaipi-4Gluc). 
There is considerable diversity within the IgG isotype; this is in contrast with 
IgM, which shows little. This diversity is governed by the ABO blood group, and 
blood group O individuals have IgG antibody directed against all three Galal- 
3Gal epitopes, whereas blood group A, B or AB individuals may have a 
combination of these.
The removal of these natural IgG anti-pig antibodies in some individuals 
who have anti-Di, Tri2 and Penta oligosaccharide antibodies using a specific Di­
oligosaccharide column demonstrated that not all antibodies were removed 
(McKane et al., 1998). However, the Di-column does remove some Penta 
antibody indicating some crossreactivity within these antibodies, probably via 
the recognition of the common Gala1-3Gal epitope. The residual antibody 
would appear to require the terminal Gala1-3Gal oligosaccharide in a specific 
chain configuration to bind. The IgG anti-Penta specific antibody was the most 
difficult to remove from sera and investigations into this antibody showed 
heterogeneity within this antibody subset. Sera from some individuals with only 
anti-Penta saccharide react with pig kidney sections and rabbit red blood cells 
(RRBC) but fail to bind to pig lymphocytes, suggesting either further 
sophistication within the anti-Penta saccharide antibody or differential 
expression of the oligosaccharide on various tissues. This work demonstrates
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the complexity within the xenoreactive anti-pig antibody repertoire and has 
shown that oligosaccharide columns consisting of Di and Penta would be 
sufficient to remove the entire natural anti-pig antibody.
In the following experiments, a suitable matrix was sought to absorb out 
pig-specific antibody without removing any HLA specific antibody. Therefore, 
because PRBCs carry a full range of Gala1,3Gal proteins and lipids, they were 
used. Testing for the presence of these Gala1-3Gal antibodies was performed 
pre- and post-PRBG absorption by various techniques to show removal of these 
antibodies.
Three different series of experiments were performed and methods 
developed as the experiments evolved. The first set of experiments were 
named Series 1 where a small number of typing sera were selected followed by 
Series 2, which more patient samples were included. In Series 3 a larger 
number of human sera, including both typing and patient sera were selected. In 
this last set of experiments (Series 3), a larger quantity of sera was collected as 
some experiments in the first two series were limited by inadequate volume of 
serum samples.
To confirm the presence of xenoreactive antibodies in human sera used in 
these experiments, they were tested before their removal by a variety of 
methods. Gomplement dependent cytotoxicity was chosen as this method 
detects functional IgM and complement fixing IgG antibody. This assay was 
performed in the first Series and then later confirmed in the third Series. Flow 
cytometric assay were also chosen as this technique detects small amounts of 
antibody and non-complement fixing antibodies. This latter technique is not 
reliant on cell viability as freezing of the pig lymphocytes in particular always 
resulted in some cell death.
3.1.1 Pig PBL Tested by CDC Against Unabsorbed Human Serum
As expected all pre-absorbed sera that were tested against pig PBLs by 
GDG (Section 2.6.2) demonstrated varying degrees of reactivity indicating that 
an anti-pig specific antibody was present. In the Series 1 experiments, sera 
were tested against pig 41 lymphocytes and all were positive (data not shown). 
These sera were not screened for the presence of IgM antibody by inclusion of 
DTT in the sera. In the Series 3 experiments, all sera reacted versus pig
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lymphocytes 60, 61, 62 and 63 prior to DTT treatment (Table 3.1). In many 
cases, the sera agglutinated due to the IgM xenoreactive natural antibody.
Many of these sera also contained IgG antibody (DTT-treated serum). However, 
the CDC assay is not as sensitive as an ELISA or flow cytometry for the 
detection of IgG antibody, and so further examination of these antibodies was 
performed.
3.1.2 Pig PBLs Tested by Flow Cytometry Against Unabsorbed
Human Serum
In the Series 1 experiments unabsorbed human antisera were tested 
against pig lymphocyte OxA and 41 and Series 2 against pig lymphocyte 43 and 
44 by flow cytometry as described in Section 2.5 (Table 3.2). This table shows 
that all the human sera in the Series 1 experiment were positive (RMdx >2.5) 
versus pig lymphocytes for IgG anti-pig specific antibody pre-PRBC adsorption. 
In the Series 2 experiments, all antisera were positive except patient’s serum 
28, which was negative pre- and post-PRBC-adsorption for IgG anti-pig specific 
antibody versus pig lymphocytes. The sera in these experiments show a wide 
range of reactivity as indicated by the RMdx values. Serum 28 was also 
negative for IgG-anti-Di and Penta saccharide specific antibody as seen in 
Figure 3.2, which will be discussed in section 3.3.2.
3.1.3 PRBC tested by Flow cytometry Against Unabsorbed Human
Serum
Since PRBC were being used to absorb out anti-pig specific antibody, the 
presence of this antibody was determined by flow cytometry (Section 2.5) in the 
human antisera prior to absorption. These sera were later tested post-PRBC- 
absorption to confirm anti-pig antibody removal (Section 3.2).
Human sera used in the Series 2 experiments were tested for the 
presence of IgG and IgM anti-pig specific antibody against a pool of PRBCs 
pre-absorption by flow cytometry. Table 3.3 shows that all sera were positive for 
the presence of IgG and IgM anti-pig specific antibody and the IgG reactivity 
was generally stronger, indicating more antibody binding, than that seen against 
pig lymphocytes as seen in Table 3.2. Although serum 28 was negative pre- 
and post- PRBC-adsorption for IgG anti-pig specific antibody versus pig 
lymphocytes, the presence of both IgG and IgM was detected versus PRBCs.
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TABLE 3.1 Isotype of the xenoreactive antibody when tested by CDC 
(Series 3). Human sera were incubated with PRBC and tested for IgM and IgG 
for anti-pig reactive antibody by CDC as described in Section 2.6.2. These 
results illustrate that all anti-sera pre-PRBC-absorption contained IgM 
xenoreactive reactivity by CDC. Some anti-sera also showed IgG reactivity.
Serum
No. Serum name
Xenoreactive
antibody
Serum
No. Serum name
Xenoreactive
antibody
IgM IgG IgM IgG
1-3 Abrahams yes yes 25-3 LA (patient) yes yes
2-3 AW (patient) yes no 26-3 LL (patient) yes no
3-3 Ashdown yes no 27-3 M.L (patient) yes yes
4-3 J.B. (patient) yes no 28-3 Lynch yes no
5-3 B.B. (patient) yes no 29-3 R.M. (patient) yes no
6-3 R.B. (patient) yes no 30-3 Mu (patient) yes no
7-3 G.B. (patient) yes no 31-3 OK (patient) yes no
8-3 W.B-1 (patient) yes no 32-3 Parsons yes yes
9-3 W.B-2 (patient) yes yes 33-3 P.P. (patient) yes no
10-3 W.B. (patient) yes yes 34-3 M.P. (patient) yes no
11-3 J.C. (patient) yes no 35-3 Pugh yes yes
12-3 Ching yes yes 36-3 RA (patient) yes yes
13-3 CT (patient) yes no 37-3 JR. (patient) yes yes
14-3 Gaffney yes no 38-3 D.S. (patient) yes yes
15-3 R.G. (patient) yes yes 39-3 B.S. (patient) yes yes
16-3 W.G. (patient) yes yes 40-3 R.V. (patient) yes no
17-3 Holt-1 yes yes 41-3 Welsh yes no
18-3 Holt-2 yes no 42-3 A.W. (patient) yes yes
19-3 HGH (patient) yes no 43-3 H.W. (patient) yes no
20-3 Hutchings yes yes 44-3 R.W. (patient) yes yes
21-3 JA (patient) yes no 45-3 AB serum yes yes
22-3 M.J. (patient) yes no 46-3 AB serum NT NT
23-3 A.J-1 (patient) yes no
24-3 A.J-2 (patient) yes yes
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TABLE 3.2 Investigation of the presence of IgG anti-pig specific 
antibody by flow cytometry. Unabsorbed human anti-sera from Series 1 
and 2 experiments were tested against various pig lymphocytes for the 
presence of IgG anti-pig specific antibody by flow cytometry as described in 
Section 2.5. All positive results are shown in red (RMdx >2.5) demonstrating 
that an anti-pig specific antibody was present prior to absorption with PRBC.
Series 1 experiments Series 2 experiments
Pig splenocytes Pig splenocytes
OxA 41 43 44
No. NAME RMdx RMdx No. NAME RMdx RMdx
1 McColl 363.4 344.1 21a Cutting 12.5 2.8
2 Holland 390.7 435.3 22a I.F. (patient) 172.6 119.9
3 S21115/L 58.3 17.3 23 Gaffney 16.2 13.0
4 Gibbens 24.0 11.7 24 Hutchings 63.2 32.2
5 Pinnington 222.4 130.0 25 A.J. (patient) 71.4 56.5
6 Davey 122.8 808.9 26 L.L. (patient) 17.0 11.1
7 Poole 44.2 22.4 27 M.L. (patient) 46.3 19.2
8 O’Connell 6.9 3.4 28 S.L. (patient) 2.4 1.3
9 Bowen 147.4 99.0 29 Lynch 49.1 29.0
10 Bond 8.8 6.2 30 J.R. (patient) 32.7 29.3
11 Hutson 4.0 3.4 31 Roper 16.0 7.3
12 Dobson 130.0 65.9 32 McColl 122.8 69.9
13 Tome 62.4 42.5 33 C.S. (patient) 18.7 6.9
14 Cutting 26.1 18.5 34 D.S. (patient) 103.8 106.5
15 Bright 63,7 106.7 35 B.S. (patient) 42.7 36.9
16 Harvey 42.1 24.8 36 Welsh 12.3 7.3
17 Holt 44.0 11.8 37 Ashdown 59.1 50.8
18 Who 248.7 113.3 38 AB serum 31.2 17.1
19 I.F. (patient) 176.6 143.1
20 J.R. (patient) 175.0 74.8
21 Welsh 31.8 17.6
22 AB serum 94.7 77.0
Positive results are highlighted in red (RMdx >2.5). 
RMdx = relative medium fluorescence.
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TABLE 3.3 Investigation of the presence of IgG anti-pig specific 
antibody against PRBCs by flow cytometry. Unabsorbed human anti­
sera from Series 2 experiments were tested against PRBC by flow 
cytometry (Section 2.5). All positive results are shown in red (RMdx >2.5) 
demonstrating that an anti-pig specific antibody was present prior to 
absorption with PRBC.
Series 2 experiments
Pre-PRBC-
absorption
Serum
No. NAME
RMdx
IgG
RMdx
IgM
21a Cutting 38,00 206.80
22a I.F. (patient) 145.80 55.20
23 Gaffney 26.10 16.20
24 Hutchings 27.80 23.60
25 A.J. (patient) 149.20 79.80
26 L.L. (patient) 29.00 142.80
27 M.L. (patient) 105.50 122.00
28 S.L. (patient) 4.70 237.80
29 Lynch 115.70 73.10
30 J.R. (patient) 109.00 44.40
31 Roper 25.20 132.00
32 McColl 612.60 20.70
33 C.S. (patient) 15.80 34.30
34 D.S. (patient) 87.40 46.90
35 B.S. (patient) 11.40 25.00
36 Welsh 4.90 14.20
37 Ashdown 85.00 16.00
38 AB serum 33.70 32.00
Positive results are highlighted in red (RMdx >2.5). 
RMdx = relative medium fluorescence.
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3.2 FLOW CYTOMETRIC ANALYSIS OF PRBC ABSORBED HUMAN 
SERA FOR XENOREACTIVE NATURAL ANTIBODY
3.2.1 Flow Cytometric Analysis of Absorbed Human Sera Against
PRBCs
All human sera were back tested against PRBCs after absorption with 
PRBCs. This was to determine if the absorptions using PRBCs was successful 
in removing anti-pig specific antibody. The positive control was pooled AB 
serum pre-PRBC absorption. The results show (Tables 3.4a, b and c) that all 
IgG and IgM reactivity against PRBC was removed in every serum that was 
absorbed. Although, in Series 1 and 3, the antisera were not tested for the 
presence of anti-pig reactivity pre-PRBC absorption, the PRBCs used for the 
absorptions were tested for the presence of bound IgG and IgM antibody. In all 
cases there was some bound antibody detected on the PRBCs cell surface 
(data not shown). However, in Series 2 Table 3.3 (pre-PRBC absorption) and 
Table 3.4b (post-PRBC absorption) clearly shows that all anti-pig reactivity was 
removed. For example, serum 32, which had a very high concentration of an 
IgG RMdx of 612 (log scale) was reduced to a RMdx of 1.3.
3.3 ELISA FOR GALa1-3 GAL SPECIFIC NATURAL ANTIBODIES IN 
PRBC ABSORBED HUMAN SERA
The assay described in this section was performed by Janet Lee as part 
of her PhD thesis at the University of Portsmouth. The samples for the current 
study were included in her assays.
In the Series 1 experiments, this assay was included as it was thought 
important to confirm depletion of anti-Gala1-3 Gal antibodies, which may cause 
false positive reactions in the assays when testing for anti-HLA/SLA 
cross reactivity. In the Series 2 experiments, the ELIS As were performed to 
confirm the earlier findings. Due to the results found in Series 1 and 2, the 
ELISA experiments were not carried out on the sera in Series 3.
Human sera from the Series 1 and 2 were tested for IgG xenoreactive 
natural antibodies by ELISA specific for Gal-a1,3Gal Di- and Penta-saccharides 
(Section 2.4). It has been shown that the combination of these two sugars used 
in an immunoadsorbent column would be sufficient to remove the majority of
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TABLE 3.4a Investigation of human sera post-PRBC absorption for anti­
pig specific antibody by flow cytometry. Human sera were Incubated with 
PRBCs and examined by flow cytometry for the presence of IgG and IgM 
xenoreactive antibody as described in Section 2.5. All sera are negative for the 
presence of anti-pig reactive antibody.
Series 1 experiments
Post- PRBC-absorption, 
back tested against 
PRBCs (RMdx)
No. NAME IgG IgM
1 McColl 1.7 1.5
2 Holland 1.3 2.2
3 S21115/L 1.0 1.6
4 Gibbens 0.7 1.6
5 Pinnington 1.2 1.4
6 Davey 0.9 2.5
7 Poole 1.2 2.0
8 O’Connell 0.9 1.4
9 Bowen 0.9 2.0
10 Bond 1.0 1.7
11 Hutson 0.9 1.4
12 Dobson 1.4 1.8
13 Tome 0.9 1.8
14 Cutting 0.9 2.2
15 Bright 0.9 1.7
16 Harvey 1.3 1.5
17 Holt 0.9 1.5
18 Who 1.2 1.6
19 I.F. (patient) 1.3 1.6
20 J.R. (patient) 1.5 1.6
21 Welsh 1.2 1.6
22 Pooled AB serum 1.1 1.6
22 Positive control 73.3 77.1
Positive results are highlightes in red (RMdx.> 2.5).
RMdx = relative medium fluorescence.
Samples highlighted in blue are the same sera used in Series 1 and 2. The 
same samples used in Series 2 and 3 and the single sample in turquoise has 
been used throughout all the experiments.
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TABLE 3.4b Investigation of human sera post-PRBC-absorptlon for anti­
pig specific antibody by flow cytometry. Human sera were Incubated with 
PRBCs and examined by flow cytometry for the presence of IgG and IgM 
xenoreactive antibody as described in Section 2.5. All sera are negative for 
the presence of anti-pig reactive antibody.
Series 2 experiments
Post-PRBC-absorption, 
back tested against 
PRBCs (RMdx)No. WSME.................. IgG IgM
21a Cutting 1.3 1.3
22a I.F. (patient) 1.1 1.1
23 Gaffney 1.1 0.9
24 Hutchings 1.2 1.2
25 A.J. (patient) 1.3 1.0
26 L.L. (patient) 1.2 0.9
27 M.L. (patient) 1.1 1.2
28 S.L. (patient) 1.0 1.1
29 Lynch 1.1 1.0
30 J.R. (patient) 1.2 1.2
31 Roper 1.3 1.1
32 McColl 1.3 1.1
33 C.S. (patient) 1.1 1.1
34 D.S. (patient) 1.1 1.2
35 B.S. (patient) 1.2 1.2
36 Welsh 1.3 1.2
37 Ashdown 1.2 1.1
38 AB serum 1.3 1.2
38 Positive control 37.8 30.4
Positive results are highlightes in red (RMdx >2.5).
RMdx = relative medium fluorescence.
Samples highlighted in blue are the same sera used in Series 1 and 2. Those 
highlighted in green are the same samples used in Series 2 and 3 and the 
single sample in turquoise has been used throughout all the experiments.
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TABLE 3.4c investigation of human sera post-PRBC-absorption for 
anti-pig specific antibody by flow cytometry. Human sera were 
incubated with PRBCs and examined by flow cytometry for the presence of 
IgG xenoreactive antibody as described in Section 2.5. All sera are negative 
for the presence of anti-pig reactive antibody.
Series 3 experiments
Post-PRBC- 
absorption 
back tested 
against 
PRBCs 
(RMdx)
Post-PRBC- 
absorption 
back tested 
against 
PRBCs 
(RMdx)
No, NAME IgG No. NAME IgG
1-3 Abrahams 0.9 25-3 LA (patient) 1.1
2-3 AW (patient) 1.1 26-3 L.L. (patient) 1.1
3-3 Ashdown 1.0 27-3 M.L. (patient) 1.1
4-3 J.B. (patient) 1.2 28-3 Lynch 1.1
5-3 B.B. (patient) 1.1 29-3 R.M. (patient) 1.1
6-3 R.B. (patient) 1.3 30-3 MU (patient) 1.1
7-3 G.B. (patient) 1.2 31-3 OK (patient) 1.1
8-3 W.B-1 (patient) 1.1 32-3 Parsons 1.2
9-3 W.B-2 (patient) 1.2 33-3 P.P. (patient) 1.3
10-3 W.B. (patient) 1.1 34-3 M.P. (patient) 1.1
11-3 J.C. (patient) 1.1 35-3 Pugh 1.1
12-3 Ching 1.2 36-3 RA (patient) 1.1
13-3 CT (patient) 0.9 37-3 J.R. (patient) 1.1
14-3 Gaffney 1.0 38-3 D.S. (patient) 1.2
15-3 R.G. (patient) 1.0 39-3 B.S. (patient) 1.1
16-3 W.G. (patient) 1.1 40-3 R.V. (patient) 1.2
17-3 Holt-1 0.5 41-3 Welsh 1.1
18-3 Holt-2 1.0 42-3 A.W. (patient) 1.1
19-3 HGH (patient) 1.1 43-3 H.W. (patient) 1.2
20-3 Hutchings 1.1 44-3 R.W. (patient) 1.1
21-3 JAM (patient) 1.1 45-3 AB serum 1.0
22-3 M.J. (patient) 1.4 46-3 AB serum 1.0
23-3 A.J.-1 (patient) 1.1 Positive control 14.4
24-3 A.J.-2 (patient) 1.3 PRBCs only 0.3
PRBCs + FITC 0.8
Positive results are highlightes in red (RMdx >2.5).
RMdx -  relative medium fluorescence.
Samples highlighted in blue are the same sera used in Series 1 and 2. 
Those highlighted in green are the same samples used in Series 2 and 3 
and the single sample in turquoise has been used throughout all the 
experiments.
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polymorphic Gal-a1,3Gal antibodies (McKane etal., 1998). Thus, only the 
presence of Di- and Penta-saccharide antibodies was tested by ELISA.
In the Series 1 and 2 experiments, some sera were included in both 
series. They were: McColl Sample 1 and 32
Cutting sample 14 and 21a
Welsh sample 21 and 36
I.F. (patient) sample 19 and 22a
J.R. (patient) sample 20 and 30
These sera have been highlighted in blue in the tables. Serum samples from 
patients were not taken on the same dates.
3.3.1 IgG Anti-DI Saccharide ELISA Results
In the Series 1 experiment, two sera (1 and 20) were weakly positive (O.D. 
>0.1) post-PRBC-absorption (both had O.D. 0.17) against IgG Di-saccharide- 
BSA conjugate (Figure 3.1). This figure shows all the results of the serum 
samples that were tested for the presence of anti-Di and Penta saccharide 
conjugated to BSA by ELISA. The O.D values of the tests and control sera were 
the mean of duplicate tests (described in Section 2.4) and the cut-off value was 
an O.D. of 0.1. Both sera 1 and 20 were used in the Series 2 experiment and 
were negative against Di-HSA. Serum samples 1 and 20 were not tested 
separately for reactivity against BSA.
In the Series 2 experiments, Figure 3.2 shows the Di and Penta ELISA 
results for human antisera tested pre- and post-PRBC-absorption. The majority 
of sera had anti-Di activity removed by PRBCs but, sera 33, 35, and 36 
remained positive post-PRBC-absorption (O.D. 0.122, 0.406, 0.308 
respectively) for IgG Di-HSA conjugate. Serum 35 anti-Di reactive antibodies 
were not reduced, but serum 36s levels fell by 76%. Although the pre­
absorption result for sample 33 was negative, the post-PRBC absorption serum 
was positive. This discrepancy in the pre-PRBC sample was due the duplicate 
O.D. values not being reproducible, thus the mean value was lower than it 
should have been. Serum 36, which was positive (O.D. 0.308), was also 
included in Series 1 (number 21) and here the Di-BSA ELISA result was 
negative. However, although the ELISA results show residual Gala1-3Gal
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antibody present in some antisera, none of these sera reacted against PRBC 
post-absorption.
3.3.2 IgG Anti-Penta Saccharide ELISA Results
In Series 1 and 2 antisera 2, 3, 5, 6, 7, 9,10, 12, 13, 14, 17, 18, 20, 21, 
21a, 22 23, 24, 29 and 35 were positive for IgG-Penta saccharide post-PRBC- 
absorption as shown in Figures 3.1 and 3.2. However, absorption with PRBC 
did remove a large amount of IgG Penta antibody in samples 22a, 24,25, 26, 
27,29,30, 32, 33, 35, 36, and 38 as seen in Figure 3.2. Sera 21a and 23 anti- 
Penta reactivity did not fall, but sera 24,29 and 35, which were remained weakly 
positive fell on average by 87.7%.
Series 1 sera 1,14, 19 and 21 were also used in the Series 2 
experiments (32, 21a, 22a, and 36 respectively) and only serum 1 (also number 
21a) was positive in both Penta ELISA's. Serum 1 (also 32) remained negative 
in both ELISA's. The two samples that gave varying results (19 and 22a; 20 and 
30) were antisera from patients and the samples were not taken on the same 
day.
IgG anti-Di and Penta ELISAs were not performed for the Series 3 
experiments, as all the sera were negative when tested back against the 
PRBCs post-absorption as described previously in Table 3.4c. Moreover, the 
anti-Di and Penta-saccharide specific antibody was reduced post-absorption 
with the PRBCs and there was no correlation between the presence of these 
weak residual antibodies and reactivity against pig lymphocytes by flow 
cytometry. This data will be presented in Chapter 5 in Tables 5.2 and 5.3.
3.3.3 Removal of IgG Penta by RRBCS
Since some antisera remained positive for IgG anti-Penta specific antibody 
post-PRBC-absorption in the Series 1 and 2 experiments, the presence of this 
antibody was further investigated. To evaluate if any residual anti-Penta 
saccharide-specific antibody present in PRBC-absorbed antisera could cause 
reactivity with pig lymphocytes, serum samples that were Penta ELISA positive 
were absorbed and tested further (Section 2.3.2). As RRBCs express Penta­
saccharide, serum samples were initially tested by flow cytometry against 
RRBCs followed by absorption with the RRBCs and tested back against these 
cells (Eto etal., 1968).
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3.3.3.1 Series 1 experimental results for removal of IgG anti-Penta
saccharide antibody
Since six of the twenty-two sera (1,4,8, 11, 15,and 16) were negative for 
IgG Penta antibodies by Penta ELISA as shown earlier in Figure 3.1, they were 
not tested. Serum 11 was selected as a negative control as no Penta antibodies 
were detected in this serum. Table 3.5 shows that all the PRBC-absorbed sera, 
except serum 7, were positive (shown in red) when tested against RRBCs by 
flow cytometry for the presence of IgG reactive antibody. Although serum 7 did 
shift to right along the X-axis, indicating some IgG binding, this was under the 
negative cut-off (described in section 2.5.4), and thus was considered negative. 
Figure 3.3 showing an overlaid histogram of three test sera and the negative 
control, demonstrates that serum 7 could be considered weakly positive when 
compared to the negative control. Both sera 10 and 20 are strongly positive for 
IgG reactivity against the RRBCs.
As the quantity of antisera was limited, four IgG-anti-Penta positive sera 
(6, 19, 20 and 21) were selected for RRBC-absorption as described in Section 
2.3.2. Figure 3.4 shows the ELISA results post-PRBC-absorption and post- 
RRBC-absorption. This figure demonstrates that absorption of these antisera 
with RRBC removed the anti-Penta reactivity in three of the four samples. The 
reactivity in sample 20 was considerably reduced from O.D. 2.385 to O.D.
0.791. Further absorption with RRBC would probably have removed the 
residual activity but there was insufficient RRBC to perform this. The pig and 
RRBC-absorbed antisera was tested by flow cytometry against RRBCs as 
described in Section 2.5, to confirm if the anti-rabbit reactivity was removed 
(Table 3.5). This table demonstrates that all pig and RRBC-absorbed samples 
did not contain any residual anti-species antibody. This also included serum 20, 
which was positive in the Penta-ELISA as shown in Figure 3.4.
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TABLE 3.5 Flow cytometric analysis of PRBC-absorbed anti-sera that 
were anti-Penta postive tested against RRBC. Human anti-sera that were 
positive by ELISA for Penta-saccharide antibodies (Section 2.4) were 
absorbed using RRBC (Section 2.3.2) and back tested against RRBC pre- and 
post-absorption with RRBC for the presence of IgG antibody by flow cytometry 
(Section 2.5). These results show all the anti-rabbit specificity was removed 
after absorption with rabbit rbcs. Sera 1,4,8,15 and 16 were not tested as they 
were anti-Penta negative by ELISA. Serum 11 was used as a negative control.
Series 1 experiments
Versus RRBCs
Serum
No. NAME
post-PRBC-
absorption
(RMdx)
post-PRBC and 
RRBC- 
absorption 
(RMdx)
2 Holland 9.5 nt
3 321115/L 4.2 nt
5 Pinnington 21.5 nt
6 Davey 2.5 1.2
7 Poole 2.1 nt
9 Bowen 5.7 nt
10 Bond 3.9 nt
11 Hutson (Penta neg) 1.3 2.1
12 Dobson 8.4 nt
13 Tome 4.4 nt
14 Cutting 4.0 nt
17 Holt 32.5 nt
18 Who 5.1 nt19 I.F. (patient) 4.6 ......1.2
20 J.R. (patient) 17.8 1.3
21 Welsh 5.4 1.1
22 AB serum 3.0 nt
RRBC auto 1.0
Positive control 225/7
Samples labelled in blue have been used in both Series 1 and 2 experiments. 
Positive control was pooled AB serum pre-PRBC-absorption.
Post-PRBC = serum post-absorption with PRBCs.
Post-pig and RRBC = serum post-absorption with pig and RRBCs.
Positive results are highlightes in red (RMdx >2.5).
RMdx = relative medium fluorescence, 
nt = sample not tested
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FIGURE 3.4 IgG anti-Penta-BSA ELISA post-PRBC and RRBC-absorption.
(Series 1 experiment) Human anti-sera that were positive by ELISA for Penta­
saccharide antibodies were absorbed using RRBC (Section 2.3.2) and tested by 
ELISA for the presence of anti-Penta specific antibodies (Section 2.4). These 
results demonstrate that anti-Penta specific antibody was removed in three of 
the four samples by RRBC.
Cut-off value is an O. D. of 0.1.
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S.3.3.2 Series 2 experimental results for removal of IgG anti-
Penta saccharide antibody
Since the number of samples tested in the first series was small, this 
experiment was repeated in Series 2.
Only five (21a, 23, 24, 29 and 35) of the eighteen serum samples tested 
post-PRBC-absorption was positive for anti-Renta specific antibody as seen 
earlier in Figure 3.2. However, when all eighteen sera were tested against 
RRBCs, by flow cytometry (Section 2.5) all the samples were positive (shown in 
red in Table 3.6) except serum 29 and 37, which were below the RMdx cut-off 
value of 2.5. Nonetheless, when these samples were viewed on a histogram 
overlay in Figure 3.5, sample 37 was probably very weakly positive when 
compared to the negative control serum. Sera that were anti-Renta positive are 
marked with an asterix in Table 3.6. Serum 29 that failed to react against the 
RRBCs in this experiment did contain some anti-Renta reactivity as shown 
before in Figure 3.2.
This inconsistency between RRBC-absorbed sera being IgG anti-Renta 
ELISA negative and IgG flow cytometry against RRBC being positive, was not 
seen in the Series 1 experiments as the majority of the sera were positive for 
Renta antibody. Only serum 11 (used as the negative anti-Renta control), which 
was Renta ELISA negative, was also anti-RRBC negative. All the other sera in 
the Series 1 experiments that were Renta ELISA positive were also anti-RRBC 
positive. This is in contrast to serum 29 (Series 2), which was IgG anti-Renta 
ELISA positive but was negative by flow cytometry against RRBC for IgG.
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TABLE 3.6 Flow cytometric analysis of PRBC-absorbed anti-sera tested 
against RRBC. Human anti-sera that were positive by ELISA for Penta­
saccharide antibodies (Section 4) were absorbed using RRBC (Section 
2.3.2)and back tested against RRBC pre-and post-absorption with RRBC for 
the presence of IgG antibody by flow cytometry (Section 2.5).These results 
show all the anti-rabbit specificity was removed after absorption with RRBCs.
Series 2 experiments
Versus RRBCs
No. NAME post-PRBC- absorption (RMdx)
post-PRBC and 
RRBC-absorption 
(RMdx)
21a Cutting 4.0* 1.2
22a IF. (patient) 3.3 1.2
23 Gaffney 21.5* 1.2
24 Hutchings 10.8* 1.2
25 A.J. (patient) 4.4 nt
26 L.L. (patient) 3.4 nt
27 M L. (patient) 4.4 1.1
28 S.L. (patient) 5.3 1.0
29 Lynch 1.4* 1.0
30 J R. (patient) 3.0 nt
31 Roper 3.4 0.8
32 McColl 13.5 nt
33 C.S. (patient) 3.2 1.0
34 D.S. (patient) 7.2 nt
35 B.S. (patient) 7.1* 1.3
36 Welsh 2.6 1.2
37 Ashdown 2.4 nt
38 AB serum 6.3 nt
RRBC auto 1.0
Positive control 201.3
Samples labelled in blue have been used in both Series 1 and 2 experiments. 
Positive control was pooled AB serum pre-absorption.
Post-PRBC = serum post-absorption with RRBCs.
Post-pig and RRBC = serum post-absorption with pig and RRBCs.
Positive results are highlighted in red (RMdx >2.5).
RMdx = relative medium fuorescence.
nt = sample not tested * = anti-Renta ELISA positive
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CHAPTER 4: EFFECT OF RABBIT AND/OR PRBC 
ABSORPTION ON HLA-SPECIFIC ANTIBODIES
4.1 INTRODUCTION
Historically, the standard method for the detection of HLA class I and II 
antibodies has been by GDC (Terasaki and McClelland, 1964)(Section 2.6). 
However, the GDC assay does have some disadvantages; thus, excellent cell 
viability is essential for accurate assessment for the presence of HLA antibody.
The use of frozen cells often causes PBLs to be more fragile and thus susceptible 
to cell lysis, resulting in false positives. This method relies on complement 
activation occurring, resulting in cell death. To activate complement, either one IgM 
or numerous IgG molecules at a high enough concentration and in close enough 
proximity must be present (Borsos and Rapp, 1965). Therefore higher titres of 
lgGi or IgGs than IgM would activate complement. This also means that non­
complement fixing antibodies are not detected in this assay. In addition, this 
method cannot differentiate between HLA and non-HLA complement fixing 
antibodies (Taylor ef a/., 1989).
Flow cytometry is reported to be 32 to 254 times more sensitive than GDG 
and is not reliant on complement binding and as such can detect non-complement 
fixing antibodies (Daniel et a/., 1989; Iwaki et a/., 1986). This method is now used 
frequently for screening for the presence of HLA antibodies and for crossmatching 
for solid organ transplants (Harmer et al., 1993;Talbot et al., 1987) (Section 2.5). 
FlowPRA™ uses purified HLA molecules bound to microparticles and can 
selectively detect the presence of either HLA class I or II antibodies and their 
specificity (Section 2.7.5). The advantage of these beads is that they can 
distinguish between HLA and non-HLA antibodies and can easily determine 
antibodies directed against HLA class or class II.
Techniques using ELISA also use purified HLA molecules and the principle 
of the assay is similar to the FlowPRA™ beads. This will be discussed in Section 
6 .1.
Since the continued presence of the HLA specific antibodies in the 
selected antisera post-PRBG and/or RRBG-absorption was central to this study,
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all antisera were screened pre-and post-absorption studies for the presence of 
these antibodies.
In both the Series 1 and 2 experiments the continued presence of HLA 
class I antibodies were screened against a small panel of human lymphocytes 
as the quantity of sera available was also limited. In Series 1 fifteen sera were 
screened by CDC against four HLA typed PBLs and in Series 2, only six sera 
were screened against 2 human splenocytes using flow cytometry. However, in 
Series 3, all antisera were screened using both CDC and flow cytometry as 
sufficient serum was collected to ensure that full and comprehensive screening 
could be carried out. The results of these various screening methods are laid 
out below.
4.2 EFFECT OF PRBC-ABSORPTION ON HLA-SPECIFIC ANTIBODIES
BY CDC IN SERIES 1 EXPERIMENTS
Nineteen HLA typing sera were used routinely by CDC to tissue type 
individuals -  these sera had been used for over 10 years, and were thus well 
defined (Section 2.2). The two patients (19 and 20) were highly sensitised and 
were waiting for a kidney transplant and their sera had been routinely screened for 
IgG and IgM antibody specificity every 2 months over the last 5 years.
Samples were tested pre- and post-PRBC-absorption against a selected 
panel of four HLA-typed individuals by CDC using PBLs (Section 2.6). Although 
sera 1, 6, 8, 9, 11, 12, and 13 were not tested (because cells with specific 
antigens to their serum antibodies were not available) all other sera showed that 
their HLA class I activity was not diminished (Table 4.1). This table shows the 
various human antisera tested against the human PBLs and a score of 2 
(approximately 20% of dead cells) to 8 (approximately 80 -100% of dead cells), 
which is a positive result. Serum 19 failed to react with cells 1 and 2 post- 
PRBC-absorption, which maybe due to this serum’s HLA class I specificity 
being removed by the PRBC. Other reactions were enhanced post- PRBC- 
absorption, such as serum 1 versus cell 1, serum 10 versus cell 4, serum 20 
versus cell 2 and serum 7 versus cell 4. However, all these reactions were 
expected to be positive due to anti-HLA specific antibodies.
Nevertheless, the enhanced reactions of serum 21 versus cell 1 and 2 
may have been due to other HLA antibodies present in this serum, as this
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serum occasionally gives extra reactions against other human lymphocytes in 
routine use. These 'extra' reactions have been difficult to fully characterise. The 
result for anti-serum 4 versus cell 4, which reacts weakly, after PRBC- 
absorption is within the technique’s error. Both cell sample 2 and 4 produced 
enhanced reactions with the antisera they were tested against, which suggests 
these enhanced reactions may be due to fragility of these particular PBLs.
Since it was shown that absorption with PRBC did not remove HLA class 
I antibodies when tested by CDC against a limited panel of human PBLs in 
Series 1, antisera that were also absorbed with RRBC in Series 2 were 
assessed to determine if the RRBCs may have removed any HLA specificity.
4.3 EFFECT OF RABBIT AND/OR PRBC-ABSORPTION ON HLA- 
SPECIFIC ANTIBODIES BY FLOW CYTOMETRY IN SERIES 2 
EXPERIMENTS
In Series 2, there was insufficient quantity of serum to screen by CDC 
against a panel of human PBLs and viable cells were not available at that time. As 
such, frozen human spleen cells were used and tested by flow cytometry (Section 
2.5). CDC was not used with the frozen human splenocytes, as the cell viability 
was 70%, which would have made interpretation of this assay difficult.
The eight HLA typing sera were used routinely by CDC to tissue type 
individuals and thus were well defined. The nine sensitised patients were selected 
and screened as described in Section 4.2. All these sera had well defined HLA 
class I antibody specificity.
Due to the small quantity of PRBC and RRBC-absorbed sera available, 
six of the seventeen antisera were screened by flow cytometry using two human 
frozen spleen cells (147 and 156). In addition, all the sera in Series 2 were 
negative against pig lymphocytes 43 and 44 (as seen in Chapter 5, Table 5.2) 
and thus it was considered necessary to check if any anti-HLA activity was still 
present. Human splenocyte 147 had the tissue type A l l ,  26; B18, 44; Cw5, 7 
and cell 156 was A1, 2; B8, 50; Cw6, 7. These cells were selected as they had 
the appropriate HLA antigens with which a selection of pig and RRBC-absorbed 
sera would react.
Serum sample 28 (Anti HLA - A l l )  was selected because it was expected 
to react with cell 147 whilst sample 35 (anti-HLA-B8) was not. Antisera 21a (anti-
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HLA-A2), 22a (anti-HLA-A1,2,28,88,13, +), 27 (anti-HLA-A2, 835, 53, +) and 30 
(anti-HLA-B14,12,5,15,17,21,Cw1, +) were selected to react with cell 156.
The histograms shown in Figures 4.1a and 4.2b demonstrate substantial 
IgG binding to the human splenocyte 156 as indicated by the shift to the right along 
the X-axis. It is clear from these histograms that antisera 21a, 22a, 27, and 30 still 
contained anti-HLA specific antibody, however, the amount of IgG binding to cell 
156 had fallen on average by 28%. This is probably due to small dilutional effects 
caused by residual supernatant present on the packed RRBCs used for the 
absorptions.
Serum 28 (after absorption against PRBC and RRBC) was also positive for 
IgG antibody with splenocyte 147, whilst serum 35 was negative (Figures 4.2a and 
b). If the PRBC and RRBC- absorptions did not remove and HLA specific antibody 
this result would be expected as the anti-A11 would have bound to the HLA- 
A11 antigen expressed on the human splenocyte. Once again, there is a slight 
reduction in the amount of IgG binding to splenocyte 147. It is evident no HLA 
specific antibody had been removed by the additional absorption of the sera with 
RRBC.
In both the Series 1 and 2 the absorption of the anti-pig and anti-rabbit 
antibody did not remove any HLA class I specific antibody. However, this 
screening was very limited by the quantity of serum available, and thus not all 
antisera were tested. As some experiments were indicating that HLA class II 
antibody was playing a role in HLA/SLA crossreactivity it was important that in the 
Series 3 experiments, screening for HLA class II antibody was performed post- 
PRBC-absorption. The Series 3 experiment included a larger number of selected 
antisera and it was important to confirm using both CDC and flow cytometry that 
HLA class I specific antibodies were not removed by PRBC. As such, in the Series 
3 experiments a more comprehensive screening for both HLA class I and II 
antibodies were carried out on all the sera used.
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FIGURE 4.1a Human serum samples pre-PRBC-absorption tested against 
human splenocyte 156. Serum samples were Incubated with human 
splenocyte 156 (A1, 2; B8, 50; Cw6, 7) and tested by flow cytometry for the 
presence of IgG binding -FL1 (Section 2.5). This histogram result shows all the 
anti-sera were positive as expected. The HLA antibody present in the serum 
reacting with its HLA antigen expressed on splenocyte 156 is underlined in the 
legend below.
FITC-FL1
Negative control
Serum 21a - anti-A2 (RMdx 57.3)
Serum 22a - anti- A1.2. 11, 28, B 8,13,+ (RMdx 177.0) 
Serum 27 - anti-A2. 35, 53, + (RMdx 109.4)
Serum 30 - anti-814, 12, 21, 15, 17, 35, Cwl (RMdx 29.5)
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FIGURE 4.1b Effect of absorption with PRBC plus RRBC on human serum 
HLA activity. Serum samples were incubated with human splenocyte 156 (A1, 
2; B8, 50; Cw6, 7) and tested by flow cytometry for the presence of IgG binding 
-  FL1 (Section 2.5). This histogram result shows all the anti-sera were positive 
as expected. The HLA antibody present in the serum reacting with its HLA 
antigen expressed on splenocyte 156 is underlined in the legend below.
o 10^
FITC-FL1
Negative control
Serum 21a -  anti-A2 (RMdx 37.1)
Serum 22a -  anti-AI. 2 .11, 28, B 8,13,+ (RMdx 154.1) 
Serum 27 -  anti-A2. 35, 53, + (RMdx 73.4)
Serum 30 -  anti-B14, 12, 21, 15, 17, 35, Cwl (RMdx 20.0)
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FIGURE 4.2a Serum samples pre-PRBC-absorption tested versus human 
splenocyte 147. Serum samples were incubated with human splenocyte 147 
(A l l ,  26; B18, 44; Cw5, 7 and tested by flow cytometry for the presence of IgG 
binding -FL1 (Section 2.5). This histogram result shows anti-serum 28 was 
positive and serum 35 was negative as expected. The HLA antibody present in 
the serum reacting with its HLA antigen expressed on splenocyte 147 is 
underlined in the legend below.
FITC-FL1
Negative control 
Positive control (RMdx 69.2) 
Serum 28 -  anti-A11 (RMdx 41.2) 
Serum 35 -  anti-B8 (RMdx 2.1)
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FIGURE 4.2b Effect of absorption with PRBC plus RRBC on human serum 
HLA reactivity. Serum samples were Incubated with human splenocyte 147 
(A11, 26; B18, 44; Cw5, 7) and tested by flow cytometry for the presence of IgG 
binding -FL1 (Section 2.5). This histogram result shows anti-serum 28 was 
positive and serum 35 was negative as expected. The HLA antibody present in 
the serum reacting with its HLA antigen expressed on splenocyte 147 is 
underlined in the legend below.
I>uu
o
FITC-FL1
Negative control 
Positive control (RMdx 69.2) 
Serum 28 -  anti-A11 (RMdx 31.9) 
Serum 35 -  anti-B8 (RMdx 0.9)
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4.4 EFFECT OF PRBC-ABSORPTION ON HLA-SPECIFIC ANTIBODIES 
IN SERIES 3 EXPERIMENTS
In Series 3, serum 37-3 had been screened in Series 2 (serum 30) but for 
HLA class I antibody only. No other antisera in this Series had been previously 
tested to ascertain if absorption with PRBC would remove either HLA class I or 
II antibody. Therefore screening for the presence of these antibodies was 
performed as described in Sections 2.5 and 2.6.
4.4.1 Effect of PRBC Absorption on HLA-Specific Antibodies by
CDC in Series 3 Experiments
In these set of experiments a larger number and sample volume of sera 
was selected. Eleven well defined HLA typing sera and serum samples from 
thirty-three patients, with varying PR As and antibody isotype was selected (see 
Section 4.2 for serum selection and screening protocol).
The patient’s serum samples were screened for the presence of IgG 
and IgM PRA pre- and post-PRBC-absorption for HLA class I antibody using a 
panel of 49 human lymphocytes. These antisera gave concordant results 
when tested pre-and post-PRBC-absorption (results not shown) except 
serum 15-3, which failed to react with a HLA -A2 cell, in no situation did the 
PRBCs remove any HLA class I antibody, which may have occurred in 
Series 1 (Section 4.2). Serum samples 8-3, 9-3,16-3, 27-3 and 34-3 were 
selected because of the IgM HLA reactivity and post-PRBC-absorption all 
IgM anti-HLA activity remained. All other antisera with HLA antibodies, which 
were IgG pre-PRBC absorption, were still present post-PRBC-absorption.
Only serum samples 21-3 and 40-3 were negative for the presence of HLA 
class I antibody by CDC.
This technique does not detect the presence of HLA class II antibody 
as PBLs comprises of 85-95% T cells (that express HLA class I) and 5-15%
B cells (that express both HLA class I and II antigen). Screening for the 
presence of HLA class II antibody by CDC requires the antisera to be 
absorbed with platelets, which express HLA class I, to remove HLA class I 
antibody. As other techniques are available to screen and identify HLA class 
II specific antibody without the removal of HLA class I specific antibody, 
FlowPRA™ beads were used. Moreover, this technique is more sensitive
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than CDC, and thus was used for screening (but not identification) for the 
presence of IgG HLA class 1 antibody.
4.4.2 Effect of PRBC Absorption on HLA-Specific Antibodies by
Flow Cytometry in Series 3 Experiments
4.4.2.1 Screening for the presence of anti-HLA class I and II specific 
antibodies in patients serum samples
As many of the serum samples had not been screened for the presence of 
HLA class II antibody, this was performed by FlowPRA™ screening test. The 
screening for the presence of HLA class I and II antibody can be achieved in a 
single tube and all sera were screened pre- and post-PRBC absorption by the 
FlowPRA™ screening test (see Section 2.7.2.1). Table 4.2 represents 
interpretation of the screening results. Positive results are indicated by red 
crosses and if the histogram showed three or more peaks and had moved into 
the third log decade along the X-axis this was considered a three plus positive. A 
sample showing multiple peaks and a shift into the second log decade was 
assigned two plus, and a result with multiple peaks, which moved between the 
first and second log decade was assigned one plus. This assay only detects the 
presence of IgG anti-HLA antibodies and the majority of samples were positive 
for anti-HLA class I specific antibodies; sera 8-3, 9-3, 16-3, 27-3 and 40-3 were 
not. These results were expected because 8-3, 9-3, 16-3 and 27-3 all have IgM 
HLA antibodies as described in Section 4.3.1. Sample 40-3 was negative both 
by CDC and flow cytometry, indicating the absence of any HLA class 1 antibody. 
Sample 21-3, which was negative by CDC clearly had an IgG HLA antibody 
present as detected by flow cytometry. Either the HLA specific antibody was 
non-complement fixing, thus detected by flow cytometry and not CDC, or the 
antibody titre was too low to be detected by CDC. The majority of samples were 
positive for the presence of HLA class II antibody; serum samples 14-3, 16-3, 
27-3, 32-3 and 34-3 were negative.
4.4.1.1 Identification of anti-HLA ciass II specific antibodies in 
patients serum sampies
Those serum samples that were positive by the FlowPRA™ screening 
test for the presence of HLA class II antibody were further tested for the 
specificity of the antibody. Patients samples that had had their HLA class 
antibodies characterised were not re-tested because the serum samples
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TABLE 4.2 Investigation of human anti-sera for the presence of HLA 
class I and II antibody. Flow cytometric results of anti-sera tested for the 
presence of IgG anti-HLA by FlowPRA™ beads (Section 2.7.2.1).
FlowPRA™ 
class 1
FlowPRA™ 
class 1
FlowPRA™ 
class II
FlowPRA™ 
class II
Name
HLA class 1 antibody by 
CDC
pre-PRBC-
absorption
post-PRBC-
absorption
pre-PRBC-
absorpbon
post-PRBC-
absorption
1-3 Abrahams Bw6 + + + -F++ + + + + + +
2-3 AW (patient) A1,2,B49,61.++ + + + + + + + +
3-3 Ashdown Cwl + + + + ++ + +
4-3 J.B. (patient) A1.B35, +++ +++ -F++ + + + -F++
5-3 B.B. (patient) A1,2.3,11,28,++ + + + + + + +-F-F + + +
6-3 R B (patient) A2wk + + + + + + + + + + + +
7-3 G.B. (patient) A3,B13,18,60vwk + + + + + + + + + + + +
8-3 W.B-1 (patient) 857,58 - - - -
9-3 W.B-2 (patient) 857,58 - - - -
10-3 W.B. (patient) 813 •f + + ++ +-F-F
11-3 J.C. (patient) A2,3,11,23,24,28,857,58,++ + + + + + + + + + -F++
12-3 Ching A23,24,32,25wk,B51,57wk + + + -F++ + + + -#-++
13-3 CT (patient) 87,+++ + + + + + + +-F+ +-F+
14-3 Gaffney B44,45wk,50 + + + + + + - -
15-3 R.G. (patient) A2,B7,44,45,++ + + + + + + -F-F+ + + +
16-3 W.G. (patient)
A25,26wk,32,B49,52,44wk,
57wk,58wk,62wk,63wk,+
17-3 Holt-1 A1,11,26 (ntB13) + + + + + + + + + +
18-3 Holt-2 A1,11,23,26, B8vwk + + + + + + + + + + + +
19-3 HGH (patient) A2,B44,57,++ + + + + + + + + + +
20-3 Hutchings 88,59 + + + + + -F+-F
21-3 JAM (patient) Negative +-F + + + + + +
22-3 M.J. (patient) 851,52,57,58,49,62wk,44wk -f+4- + + + + + + +-F-F
23-3 A.J-1 (patient) 844,45,49,50,60,61,62,27,13 + + + -F++ + + + + + +
24-3 A.J-2 (patient) 844,45,50 ++-F + + + + + + + + +
25-3 LA (patient) A2,28,24,23wk + + + •F++ + + ++
26-3 L.L, (patient) 87,27wk,13vwk,60vwk ■F+-4- + + + + + + -F++
27-3 ML. (patient) 88 - - - -
28-3 Lynch 844,45 + + + + ++-F + + +
29-3 R.M. (patient) A2,3,23,24,844,45,57,58,+ + + + + + + + + + + + +
30-3 MU (patient) 87,13,27,60,61,41,55,+ + + + + + + + + + + + +
31-3 OK (patient) A1 (nt A36) + + + + + + + + + + + +
32-3 Parsons
A23,24,25,32,851,52,49,57,27. 
44wk + + + + + + _ -
33-3 P.P. (patient) A1,2,28,88,35,+ + + + + + + + + + + + +
34-3 M.P. (patient) 844wk,(45,49,50) +-F + + - -
35-3 Pugh 855,56,13,35wk + + + + + + + + + + + +
36-3 R A . (patient)
851,52,49,50,57,58wk,62wk, 
35wk,71vwk,44wk +-F+ + + + + + + + + +
37-3 JR. (patient)
814,44,45,35,57.58,62,63,49, 
50,Cw1,+ + + + + ++ + + + +-F+
38-3 D.S. (patient) A30wk,31wk + + + + ++ + + -f + + +
39-3 B.S. (patient) A2, 23,24,29,844,++ + + + + + + + + + + + +
40-3 R V. (patient) Negative - - + + + +
41-3 Welsh A1,11,25,26 + + + + + + + + + + + +
42-3 A.W. (patient) A2.28,23,24,844,+++ + + + + + + + + + + + +
43-3 H.W. (patient) A1,11wk,24wk + + + + + + + + + + + +
44-3 R.W. (patient) 814,8wk,+ ++-F -F-F+ + + + + + +
45-3 AB serum Negative - - - -
46-3 AB serum Negative - - - -
Positive results are highlighted in red.
HLA class I antibodies highlighted in pink are IgM only
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selected for these experiments were taken close to the date the HLA class II 
antibody specificity was determined.
Thirty samples were tested using the FlowPRA™ class II specific 
assay. The Flow PRA™ specific class II test is divided into 4 groups, 
comprising of beads with eight different fluorescence profiles. These were 
detected on the FL2 channel. The amount of IgG HLA antibody bound to 
the beads is detected on the FL-1 channel, i.e. the X-axis (Figure 4.3). The 
results were interpreted as RMdx and the values sorted in order of amount 
of FL-1 (IgG) present and antibody specificity recorded. Table 4.3 
demonstrates results from FlowPRA™ class II specific beads for serum 3-3 
where the RMdx was sorted in order of FL-1 reactivity against each bead 
population as seen in Figure 4.3. These results show that this serum 3-3 
contains an anti-HLA-DQ2 specific antibody. The results for each antisera 
tested has not been shown, but the interpretation of each serum sample is 
tabulated in Table 2.3.
4.5 ACID TREATMENT OF HUMAN LYMPHOCYTES
Ten samples of human PBLs were acid treated to remove HLA class I 
antigen as described in Section 2.1.2. As the panel of human PBLs used for this 
assay was small, not all HLA antigens were represented, therefore not all HLA 
class I specific antisera could react with PBLs. Antisera not tested for removal 
of HLA class I antigen were 8-3, 9-3, 10-3, 20-3, 27-3 and 38-3, as the cell 
panel did not include antigens to which these sera could react against. In all 
120 cases, HLA specific antisera were strongly positive against non-acid treated 
cells when reacted with their specific ligand by CDC (Section 2.6). However,
106 reactions were negative with acid-treated cells, indicating the antibody 
ligand was an HLA class I like structure.
Those sera that reacted with acid-treated cells are shown in Table 4.4. 
This table shows the six positive sera pre- and post-acid treatment and pre- and 
post-PRBC-absorption tested against a panel of acid treated human PBLs. Pre- 
PRBC absorbed serum 4-3 reacted with acid-treated cell 1, 4 and 7; serum 5-3 
reacted against acid-treated cell samples 1, 3, 6 and 7; serum 11-3 reacted with 
acid-treated cell samples 4 and 5; sera 23-3 reacted against acid-treated cell 
samples 4 only; 39-3 reacted with acid-treated cell samples 2, 4, 5 and 7. These
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FIGURE 4.3 Example of FlowPRA™ specific test for the characterisation of 
HLA class II antibody. Flow cytometric dot plot of serum 3-3 showing each 
group of four beads of the Flow PRA™ HLA class II specific test. In each group 
eight beads are separated along the FL-2 axis and the amount of IgG antibody 
bound is measured along the FL-1 axis that is measured as medium channel 
fluorescence and later calculated to RMdx.
Group 1
a
11 DR1,4,DQ5,7 
21 DR12.18.52.004,5
3] DR9.10,53,005,9
4] DR13,15,52.51.DQ5,6
5] DR8,17,52,002,6
6] DR4,7,53,DQ2,8
7] DR17,103.52,002,5
8] DR9,15,53,51,005,9
Group 2
§
PL 10*
1] 0R4,14,52,53.0Q7,9
2] DR1,17,52,51,002.5
3] DR11,13,52,006
4] OR12,15,52,DQ5
5] DR11,12,52,005,7
6] 0R4.16,53,51,004,5
7] 0R13,17,52,002,6
6] 0R14,16,52,51.005
Group 3
1] DR1,11,52,005,6
2] 0R9,15,53,51,002.6 
31 0R8,11,52,007
4] DR1.7,53,005,9
5] DR14,16,52,51,007 
61 DR7.10,53,002,5
7] DR8,14,52,DQ4,5
8] DR15,103,51,006,7
Group 4
10*
1] DR7,18,52,53,002,4
2] 0R4,12,52,53.0O7,8
3] DR13,17.52,DQ2,7
4] DR9,12,52,53,DQ2,5 
51 0R13,18,52,004,7
6] DR1,16,005
7] DR1,17,52,002,5
8] DR13,15,51,005,7
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TABLE 4.3 Interpretation of results from FlowPRA™ class II specific 
beads for serum 3-3. Results were sorted in order of RMdx (IgG) reactivity 
against each bead population. The results show this serum contains an anti- 
HLA-DQ2 specific antibody.
Serum 3-3 ASHDOWN
Group Bead ID DRB1 DRB1 DRB3 DRB4 DRB5 DQ DQ RMdx
2-2 E64450 1 17 52 51 2 5 42.9
4-7 C5001 1 17 52 2 5 42.1
4-3 E5093 13 17 52 2 7 41.2
1-5 G0087 8 17 52 2 6 29.2
2-7 G0167 13 17 52 2 6 21.3
1-7 E5610 17 103 52 2 5 15.5
4-4 E5668 9 12 52 53 2 5 15.1
3-6 G0102 7 10 53 2 5 13.8
1-6 C4615 4 7 53 2 8 11.3
4-1 El1678 7 18 52 53 2 4 9.6
4-5 G0079 13 18 52 4 7 8.2
4-8 C5020 13 15 51 5 7 8.2
3-5 G0183 14 16 52 51 7 7.9
3-2 E11883 9 15 53 51 2 6 5.7
1-2 C4630 12 18 52 4 5 5.2
3-3 E3825 8 11 52 7 3.0
2-4 G0142 12 15 52 5 2.8
3-7 G0086 8 14 52 4 5 2.6
1-4 C4613 13 15 52 51 5 6 2.5
2-5 E64450 11 12 52 5 7 2.3
3-8 E22237 15 103 51 6 7 2.3
1-3 G0099 9 10 53 5 9 1.9
4-2 G0150 4 12 52 53 7 8 1.9
1-8 G0069 9 15 53 51 5 9 1.7
4-6 E20339 1 16 5 1.7
1-1 G0264 1 4 5 7 1.6
3-1 E14072 1 11 52 5 6 1.4
2-6 E2934 4 16 53 51 4 5 1.3
3-4 El6092 1 7 53 5 9 1.3
2-1 C4722 4 14 52 53 7 8 1.1
2-8 C5003 14 16 52 51 5 0.7
2-3 E4538 11 13 52 6 0.5
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Chapter 4 :______________ Effect of Rabbit and/or PRBC Absorption on HLA Specific Antibodies
reactions indicate the target molecule in these cases may not have been HLA 
class I. However, post-PRBC absorbed serum 4-3 failed to react against acid- 
treated cell samples 1, 4 and 7. Similarly, absorbed serum 11-3 was negative 
with acid-treated cell samples 4 and 5 and absorbed sera 23-3 and 39-3 were 
negative against acid-treated cell sample 4. These reactions indicate the 
PRBCs appear to have absorbed out a non-HLA class I antibody reactivity.
On the other hand, pre-and post-PRBC absorbed serum 5-3 and 39-3 
reacted with acid-treated cell samples 1, 3, 6, 7 and 2, 5, 7 respectively. In 
these cases, it is possible that there is a non-HLA target, which PRBCs fail to 
absorb.
In one case pre-PRBC absorbed serum 15-3 failed to react with acid- 
treated cell sample 7 indicating this reaction was due to anti-HLA class I specific 
antibody. However, post-PRBC this serum sample was positive with acid- 
treated cell sample 7. This would indicate that the PRBC have removed an 
antibody, which has allowed another antibody present in this patient’s serum to 
react.
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CHAPTER 5: ANALYSIS OF ANTI-PIG ABSORBED SERA 
AGAINST PIG LYMPHOCYTES
5.1 INTRODUCTION
Swine MHC genes are similar in overall structure to the human MHC 
molecules in that they share similar length a1, a2 and a3 domains (Gustafsson et 
al., 1990; Sullivan et al., 1997). The a l domain of the MHC class I molecule 
shows the greatest polymorphism, which is similar to the human genes, but in 
the a2 domain SLA genes show polymorphism in the a helix, whereas in 
humans, polymorphism is predominantly in the p pleated sheet (Parham, 1989). 
Polyclonal HLA antibodies with polyspecific reactivity are often ‘cross reactive’ 
with HLA antigens, which share either a common or similar epitopes. As there is 
approximately 75% homology between HLA and SLA it might be expected that 
some HLA antibodies would react with certain SLA antigens.
It had been demonstrated in chapter 4 that anti-HLA specific antisera 
when absorbed with RRBC and/or PRBC to remove anti-species reactivity do 
not affect the HLA antibody specificity (Table 4.6, Figures 4.1 and 4.2). On the 
basis that HLA and SLA have a similar structure and sequence homology, the 
following experiments in this chapter, test the argument that anti-HLA specific 
sera can cross react with the SLA molecule. Antisera from the Series 1, 2 and 3 
were tested by flow cytometry against different pig splenocytes. In Series 1, the 
PRBC-absorbed antisera were tested against two pig splenocytes. Additionally, 
those sera that still contained residual anti-Penta specific antibody were 
absorbed with RRBC to demonstrate that any anti-pig reactivity was not due to 
residual anti-species antibody. In Series 2, an attempt was made to confirm that 
anti-Penta specific antibody was not causing the reaction between the PRBC- 
absorbed human sera and pig lymphocytes. Unfortunately, none of the PRBC- 
absorbed sera reacted against any of the pig lymphocytes tested. In addition, 
the panel of pig lymphocytes to which the PRBC-absorbed sera was tested 
against was expanded.
Since it had been shown that anti-Penta antibody was not causing false 
positive reactions against pig lymphocytes the ELISA experiments were not
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repeated in the Series 3 experiments. As Series 2 had shown limited reactivity 
of these PRBC-absorbed antisera against a panel of pig cells, this was 
expended further in the Series 3 experiments.
5.2 SERIES 1 : RRBC AND/OR PRBC ABSORBED HUMAN SERA
VERSUS PIG LYMPHOCYTES
Lymphocytes from pigs OxA and 41 were tested by flow cytometry 
(Section 2.5) against PRBC absorbed sera (Table 2.1) to evaluate if the 
remaining IgG anti-HLA specific antibody would bind to ligands on the pig 
splenocytes, shown in Table 5.1. This table shows there was only one positive 
reaction (5%) of the twenty-one PBRC-absorbed antisera with HLA class I 
antibody against pig lymphocyte OxA and 28.6% of the antisera (3, 6, 16, 19, 20 
and 21) reacted with pig 41. This table also demonstrates that those antisera 
positive for anti-Di-saccharide (1 and 20) and those positive for anti-Penta 
saccharide (2, 5, 7, 9, 10, 12, 13, 14, 17, 18, 21 and 22) (see Figure 3.1 for 
details) were negative against both the pig lymphocytes.
PRBC-absorbed antisera that were positive with pig lymphocyte 41 (6,
19, 20 and 21) were absorbed with RRBC to remove the residual anti-Penta 
activity. This absorption with the RRBC was to confirm that the positive reaction 
against the pig lymphocytes was not due to any anti-Penta specific activity.
After absorption with RRBC, these sera were tested by flow cytometry against 
pig lymphocyte 41 as described in Section 2.5. Antisera 3 and 16 were not 
tested, as there was insufficient serum. Figure 5.1a shows overlaid histograms 
of PRBC-absorbed human antisera tested against pig lymphocyte 41 by flow 
cytometry. All samples were positive. Figure 5.1b also demonstrates a 
histogram and shows that after absorption with PRBC and RRBC the antisera 
were still reactive against the pig lymphocytes. Antisera 6 was tested in a 1:2 
dilution with flow diluent as there was insufficient serum to be tested neat. The 
removal of anti-Penta specific antibody was confirmed by ELISA as described in 
Section 2.4 and discussed in Chapter 3, Figure 3.4. However, there was an 
overall decline (average 26%) in the amount of IgG binding to the pig 
lymphocyte. This is probably due to the dilutional effects of the absorptions as 
there was always some residual wash solution left on the RRBCs.
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TABLE 5.1 Flow cytometric results of PRBC-absorbed sera (Series 1) 
against pig lymphocytes. PRBC-absorbed human anti-sera were tested 
against two different pig lymphocytes, OxA and 41, by flow cytometry as 
described in Section 2.5 for IgG antibody binding. None of the PRBC- 
absorbed anti-sera was positive with pig OxA lymphocytes and six samples 
were positive with pig 41's lymphocytes. Those anti-sera that were positive 
for Di and Penta-specific antibodies post-PRBC absorption are shown.
Post-PRBC-
absorption
No. |{ItName HLA class 1 antibody specificity OxARMdx Pig 41 RMdx
1 + MCCOLL A25,26,66,29,43,34wk 0.7 2.1
2 + HOLLAND A25,26,66,31,32,74,33,34,43,29wk 0.9 1.2
3 + S21115/L Bw4,A23wk,24wk,32wk 1.3
4 GIBBENS Cw4 0.6 1.4
5 + PINNINGTON A23.24 1.1 1.1
6 + DAVEY Cw2 0.8
7 + POOLE Cw4,6,7wk 0.6 0.8
8 O'CONNELL Cw5 0.5 0.6
9 + BOWEN B51.78 0.9 1.6
10 + BOND Bw6,B52,49,57,51wk 0.9 1.7
11 HUTSON B55,56,54,67,42wk 0.6 0.9
12 •f DOBSON B7.8101 0.7 1.1
13 + TOME A30.31 0.9 1.1
14 + CUTTING A2 1.9 2.2
15 BRIGHT B57.58 0.9 1.3
16 HARVEY Bw4,A23wk,24wk 1.1 ÈëÊÊM
17 + HOLT A1,36wk,11wk,B13 1.2 1.3
18 + WHO A24 1.1 1.4
19 + I.F. (patient) A1,2,11,28, B8,13,+ 1.4
20 + + J R. (patient) 614,44,45,35,57,58,62,63,49,50,Cw
21 + WELSH A1,11,25,26,+ 2.1
22 + AB Serum Negatiye 1.0
positiye control
RMdx = relative medium fluorescence.
Orange boxes indicate RMdx between 2.5 and 5.0. Red box indicates a 
RMdx >5.0.
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FIGURE 5.1a Investigation of PRBC-absorbed human anti-sera tested 
against pig lymphocytes by flow cytometry. Pig lymphocytes and human 
anti-sera were tested by flow cytometry as described in Section 2.6 for IgG (FL- 
1) antibody binding. This was to examine if any antibody present in human 
serum would react against pig lymphocytes. This histogram demonstrates that 
PRBC-absorbed sera 6, 19, 20 and 21 from the Series 1 experiments did react 
with pig lymphocytes 41. All these serum samples also contained residual anti- 
Penta antibody.
FITC-FL1
Negative control 
Serum 6 (RMdx 4.0) 
Serum 20 (RMdx 7.7)
Positive control (RMdx 62.4) 
Serum 19 (RMdx 6.1)
Serum 21 (RMdx 6.6)
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FIGURE 5.1b Investigation of PRBC and RRBC-absorbed human anti-sera 
tested against pig lymphocytes by flow cytometry. Pig lymphocytes and 
human anti-sera were tested by flow cytometry as described in Section 2.6 for 
IgG (FL-1) antibody binding. Renta positive serum samples 6, 19, 20 and 21 
were absorbed with RRBC to remove the Renta reactivity and tested back 
against the pig 41 lymphocytes and by Penta ELISA. This histogram 
demonstrates that PRBC and RRBC-absorbed sera continues to react with pig 
41 lymphocytes, thus the anti-Penta antibody was not causing the positive 
result seen in Fig 5.1a and b.
r
>LU
O
FITC-FL1
Negative control 
Serum 6 dll 1:2 (RMdx 3.7) 
Serum 20 (RMdx 4.5)
Positive control (RMdx 62.4) 
Serum 19 (RMdx 4.2)
Serum 21 (RMdx 4.8)
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Given that the work described above had demonstrated that the presence of the 
anti-Penta antibody was not causing false positive reactions against the pig 41’s 
lymphocytes, this experiment was repeated. This was performed not only to 
confirm this finding but also to investigate, using different antisera and a larger 
panel of pig lymphocytes, if different HLA specific sera reacted with different pig 
lymphocytes.
5.3 SERIES 2: RRBC AND/OR PRBC-ABSORBED HUMAN SERA
VERSUS PIG LYMPHOCYTES
In an endeavour to confirm the findings in Series 1 that the anti-Penta 
specific antibodies present in PRBC-absorbed antisera were not causing the 
positive reaction with pig lymphocytes, a selection of antisera were absorbed 
with RRBCs. A number of PRBC-absorbed antisera, 21a, 22a, 23, 24, 27, 28, 
29, 31, 33, 35,and 36 (including four that had anti-Penta activity, 21a, 24, 29 
and 35) were absorbed with RRBCs as described in Section 2.3.2. These 
PRBC and PRBC plus RRBC absorbed sera were tested against pig 43 and 44 
lymphocytes by flow cytometry. The following tables (5.2 and 5.3) demonstrate 
the various PRBC and/or RRBC-absorbed antisera tested against a panel of pig 
lymphocytes. All results are shown in RMdx (log) values. Values above 2.5 
were considered positive. The above experiments were performed on the same 
day and unfortunately, as seen in Table 5.2, no PRBC-absorbed antisera 
reacted with the pig lymphocytes, thus no PRBC plus RRBC-absorbed sera 
reacted either. However, further experiments shown in Table 5.3 shows that 
PRBC-absorbed, Penta positive antisera 21a and 29 did not react with any of 
the five pigs tested. This was also seen for serum 35, but only against the three 
pigs tested (pigs 43, 44 and 46). This serum was not tested against pigs 38 and 
42. PRBC-absorbed, Penta positive serum 24 was weakly positive with pig 42 
and negative against the other five pig lymphocytes. This would indicate that 
the anti-Penta antibody was not playing a role in causing positive reactions 
between PRBC-absorbed anti-HLA specific sera and pig lymphocytes. PRBC- 
absorbed antisera that still had anti-Di saccharide (33,35 and 36) activity did not 
react with any of the pig splenocytes either.
In order to examine if there was a pattern of reactivity of HLA class I 
specific sera, lymphocytes from pigs 38, 42, 43, 44, 46 and OxA were tested by
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flow cytometry against the PRBC-absorbed sera listed in Table 2.2. Table 5.3 
shows the results. PRBC absorbed antisera were all negative against pig 
lymphocytes 43, 44 and 46. Only the absorbed antisera 22a was positive (5.6%) 
whilst serum 26 was probably weakly positive against pig lymphocytes 38. Sera 
22a was also positive (5.6%) against pig lymphocytes OxA. PRBC absorbed 
antisera 24 were weakly positive and 31 was strongly positive (11.1%) against 
pig 42 lymphocytes.
From the above results any residual anti-Di or Penta antibody, as 
discussed in Sections 4.2 and 4.3, did not cause positive reactions against pig 
lymphocytes. Therefore, any reactivity by the PRBC-absorbed antisera with pig 
lymphocytes was caused by other IgG antibodies.
While only a limited number of PRBC-absorbed antisera in Series 1 and 
2 were tested against pig lymphocytes, with a small number of sera reacting 
with the pig lymphocytes, a larger study was carried out in the Series 3 
experiments. This was to observe if this trend continued or was there more 
‘cross-reactivity’ than seen in Series 1 and 2,
5.4 SERIES 3: PRBC ABSORBED HUMAN SERA VERSUS PIG
LYMPHOCYTES
Pig lymphocytes 43a, 46, 47, 48, 51, 52, 53, 54, 55, 56, 59, 60, 64, MPcc 
and MPdd obtained from pig spleen were tested by flow cytometry against 
PRBC absorbed sera listed in Table 2.3 for bound IgG as described in Section 
2.5.
The viability of pig splenocytes from 57 and 58 was too low to be 
analysed and were not included in the analysis. Regrettably, there was an 
insufficient lymphocyte sample from pigs OxA, 38,41,42, 43, 44 and 46 to be 
tested. This would have provided additional information as the antisera in Series 
1 and 2 did not react with many of these pig cells.
As expected the AB negative controls did not react with any of the pig 
lymphocytes and 45.5% of the HLA sera were negative as seen in Table 5.4. 
This table also shows that PRBC-absorbed sera, which are HLA antibody 
positive, do not necessarily react with all pig splenocytes. The number of 
positive reactions against each pig splenocyte range from 7.5 -  37.5%, seen in 
Figure 5.2. This figure displays the number of times (as percentages) a given
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TABLE 5.4 Results showing PRBC-absorbed sera (Series 3) against
PRBC-absorbed HLA anti-sera were tested for reactivity against a panel
Blood group of pigs
Pig cell number
Serum
no. Name
Ln HLA class 1 antibody speclflty i|u HLA class II antibody specifity3-3 Ashdown 14 Cwl 41 DQ2
6-3 R.B. (patient) 32 A2wk 28 DR15.16
8-3 W.B-1 (patient) 30 B57.58 0 Negative
9-3 W.B-2 (patient) 30 B57.58 0 Negative
10-3 W.B. (patient) 2 B13 90 DR52,DQ2,DR15,16
11-3 J.C. (patient) 90 A2,3,11.23,24,28.657,58,++ 98 DR52.+
16-3 W.G. (patient) 64 A25,26wk,32,B49,52,44wk.57wk.58wk. 62v/k. 63wk,+ 0 Negative
19-3 HGH (patient) 90 A2,B44,57.++ 100 DR52,DQ2,+
20-3 Hutchings 20 B8.59 78 DR52,DQ2
21-3 JAM (patient) 0 GDC negative: FlowPRA positive 26 DR11,13wk,+
22-3 M.J. (patient) 64 B51,52,57,58,49.62wk.44wk 56 DR17.18,13,14,8
2-3 AW (patient) 90 A1.2,649,61,++ 78 DR11,12,17,1,+
25-3 LA (patient) 68 A2,28,24,23wk 28 DR4.53
26-3 LL. (patient) 25 B7,27wk,13vwk,60vwk 75 DR15.16.1,103.10,+?4
30-3 MU (patient) 82 67,13,27,60,61,41,55, A25,29,32,+ 100 DQ7,8,9, DR1.10,103,15,16,17,18
35-3 Pugh 21 B55,56,13.35wk 75 DR15.16,4,7,9,+
36-3 R A . (patient) 53 B51,52,49,50,57,58wk,62wk,35wk,71 vwk, 44wk 70 DR15.16,51,+
38-3 D.S. (patient) 11 A30wk,31wk 22 weak?
43-3 H.W. (patient) 39 A1,11wk,24wk 72 DR15,16,+?1,10,103,+
44-3 R.W. (patient) 50 B14,8wk,+ 100 DR53,DQ3,+
7-3 G.B. (patient) 25 A3,B13,18,60vwk 13 DR4
12-3 Ching 50 A23,24,32,25wk, B51,57wk 88 DQ2,DR17,18wk,13,14wk,1,10,103
24-3 A.J-2 (patient) 25 844,45,50 100 DR52,DQ1,2
28-3 Lynch 25 844,45 78 DR15,16.51,DQ7,8,9,+
37-3 J.R. (patient) 53 B14,44,45,35,57,58,62,63,49,50, Owl.+ 81 DQ4,DR8,11,12,13,14,+72,+
41-3 Welsh 50 A1,11,25,26 88 DR52.+
14-3 Gaffney 25 B44,45wk,50 0 Negative
31-3 OK (patient) 25 A1 (ntA36) 63 DQ2
33-3 P.P. (patient) 80 A1,2,28,68,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+
40-3 R.V. (patient) 0 Negative 88 DR53,DQ3v/k
18-3 Holt-2 46 A1,11.23,26, BSvwk 56 DR15.16,17.18,11,12
32-3 Parsons 86 A23,24,25,32,B51,52,49,57,27,44wk 0 Negative
1-3 Abrahams 90 Bw6 72 DR52,(13)
17-3 Hoit-1 43 A1.11,26 (nt813) 53 DR15,16,51,11,12, +?52
5-3 B.B. (patient) 100 A1.2.3,11.28,++ 56 DR1,4,103,(10),Q2wk
13-3 CT (patient) 90 87,+++ 99 Muiti; ?DR15,16,51,13,14,++
27-3 M.L (patient) 20 88 0 Negative
29-3 R.M. (patient) 90 A2.3,23,24,B44,45,57,58,+ 75 DQ2,DR1,15,16
23-3 A.J-1 (patient) 75 844,45,49.50,60,61.62,27,13 100 DR52,DQ1,2
34-3 M.P. (patient) 10 B44wk,(45,49,50) 0 Negative
42-3 A.W. (patient) 90 A2.+++ 100 DR15,16,11,12,DQ2,+
39-3 8.8. (patient) 100 A2, +++ 100 Multi; ? DQ5,6,7,8,9,+
15-3 R.G. (patient) 90 A2,87,44,45,++ 53 DR1,10,103,15,16,(51)
4-3 J.B. (patient) 100 A1.B35, +++ 100 Muiti ??
45-3 AB serum 0 Negative 0 Negative
46-3 AB serum 0 Negative 0 Negative
47-3 Q-sera AB control Negative Negative
48-3 AB pre-absorp Negative Negative
45-3 AB pre-absorp Negative Negative
positive results are highlighted in red (RMdx >2.50). Results underlined maybe weakly positive as judged by histogram
data. HLA class I antibodies highlighted in pink are IgM only
All results are expressed as RMdx(relative medium fluorescence) MR = minipig
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various pig lymphocytes.
of 12 outbred and 2 inbred minipigs by flow cytometry as
43a 46 47 48 51 52 53 54 55 56 59 60 64 MPcc MPdd
RMdx RMdx RMdx RMdx RMdx RMdx RMdx
Serum no.
"ÔT TJT T T I T TT TT TT TT TT TT TT TT TT W 1.1
63 1.0 1.2 0.9 1.2 1.0 0.9 1.0 0.9 1.0 1.0 1.0 1.0 0.7 0.9 1.1
8-3 0.8
T 3
0.7 0.6 1.1 0.9 1.0 1.0 1.0 1.2 1.3TT 0.8 1.5 0.5 0.8 1.40.7 0.7 0.6 1.2 0.9 1.0 1.0 0.9 1.1 0.8 1.4 0.5 0.8 1.2
10-3 0.8 1.1 1.0 1.4 0.9 0.9 1.6 1.0 1.2 1.0 1.0 1.5 1.1 1.3 1.4
11-3 1.5 0.8 0.8 1.8 0.9 0.9 1.1 0.9 1.2 1.3 1.2 1.4 0.7 0.9 1.4
16-3 0.7 0.8 1.2 1.1 1.0 1.0 1.1 1.0 1.0 1.3 0.8 1.1 0.7 1.2 1.1
19-3 1.1 0.8 0.8 1.1 1.3 1.3 1.0 1.3 1.2 1.5 1.5 1.3 0.5 1.0 1.1
20-3 0.9 0.8 0.9 1.3 nt 1.0 1.0 0.9 1.1 1.1 0.9 1.4 0.6 1.0 1.1
21-3 0.8 0.7 1.0 1.7 1.4 1.3 1.1 1.1 1.5 1.9 1.3 1.6 0.5 1.2 1.4
22-3 0.8 0.8 1.2 2.0 1.4 1.3 1.2 1.0 1.6 1.7 1.3 1.9 0.6 1.3 1.7
2-3 1.1 0.9 1.0 1.7 1.5 1.3 1.3 1.0 2.0 1.4 1.1 1.6 0.7 1.3 1.5
25-3 1.2 0.9 1.7 1.4 1.3 1.1 1.1 1.3 1.6 1.8 1.0 1.3 0.6 1.2 1.3
26-3 1.1 0.8 0.9 1.4 1.3 1.1 1.1 1.1 1.2 1.1 0.9 1.8 0.6 1.0 1.4
30-3 0.8 2.0 1.0 1.2 1.2 1.3 1.0 0.9 1.4 1.6 1.1 1.5 0.6 1.6 1.1
35-3 1.0 1.0 0.7 1.4 1.3 1.6 1.0 1.3 1.4 1.5 1.4 1.6 0.6 1.0 1.2
36-3 1.0 0.8 0.7 1.4 1.2 1.3 1.1 0.9 1.2 1.2 1.1 1.4 0.7 1.1 1.2
38-3 0.9 1.0 0.8 1.4 1.1 1.0 1.0 0.9 1.3 1.1 0.7 1.4 0.8 1.2 1.1
43-3 1.6 1.0 2.9 2.1 1.7 1.6 2.0 1.3 1.8 1.5 1.5 1.9 1.0 1.3 1.9
44-3 1.0 0.9 1.6 1.4 1.2 1.1 1.7 0.9 1.1 1.4 1.1 1.3 0.7 1.1 1.2
7-3 1.8 1.2 1.2 1.8 1.3 1.4 1.3 2.1 1.9 1.8 2.0 0.8 2.1 1.4
12-3 1.4 0.9 1.0 1.6 1.4 1.4 1.5 1.1 1.6 1.7 1.9 0.7 1.3 1.6
24-3 1.0 0.9 1.5 1.9 1.3 2.0 1.1 1.1 2.0 2.3 2.1 0.8 1.3 1.6
28-3 0.7 0.7 0.6 1.4 0.9 1.2 0.9 1.7 1.8 0.7 1.1 0.8 0.8 0.7
37-3 1.6 1.2 nt 2.2 1.6 1.5 1.1 1.0 1.5 1.8 1.8 2 â 0.9 1.4 2.3
41-3
14-3 1.0 0.7 1.3 1.0 2.4 1.0 1.0 0.90.7 0.7 1.4 1.1 2.3 1.7 1.0 1.8:4 1.1 1.5 0.71.7 2.2 0.9 1.20.8 0.91.3
31-3 1.0 0.8 1.4 2.3 1.5 1.1 1.2 0.9 1.2 1.7 1.1 0.7 1.1
33-3 1.0 0.9 1.1 2.0 1.7 1.8 1.5 1.7 2.3 1.1 1.9 0.8 1.7
42-3 2 s
B D IK E I
45-3 0.8
Orange boxes indicate RMdx between 2.5 and 5.0. Red box indicates a RMdx >5.0. The underlined values 
maybe weakly positive when viewed on histogram overlays.
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Chapter 5:_____________________ Analysis of Anti-Piq-Absorbed Sera Against Pig Lymphocytes
pig will react with the human sera tested. For example, pig 48 and 60 reacts 
more frequently with the anti-HLA sera than pig 46 or 47. This would be 
expected since the pigs probably have different SLA types and probably reflects 
the different HLA specificities of the antisera. However, out of 46 serum 
samples (including four samples with IgM anti-HLA and two AB negative control 
sera) 54.5% of the PRBC-absorbed HLA sera were positive by flow cytometry 
against some or all of the pig lymphocytes (see Table 5.4) and no two serum 
samples had the same reaction pattern. Of the 690 flow cytometric analyses 
only 19.4% of the tests were positive. Table 5.4 also demonstrates that with 
increasing HLA class I PRA, up to 100%, there is increasing reactivity with the 
15 different pig splenocytes. Figure 5.3a illustrates this more clearly and if this 
data is broken down further, of the 39 samples with an IgG HLA class I 
antibody, 44.8% of samples with a PRA >70% were positive. Those sera that 
had a PRA of <70%, 8.8% were positive. It is of note that there were two 
instances where antisera from patient samples 2-3 and 19-3, both of which 
have an HLA class I PRA of 90%, did not react with any of the pig lymphocytes. 
Figure 5.3b Illustrates that the trend of Increasing HLA class I PRA reacting with 
more pig lymphocytes is not seen for the antisera with HLA class II specificity. 
There were 37 samples that had an IgG HLA class II antibody, and 27.8% of 
these samples with a PRA >70% were positive compare to 20.5%with a PRA of 
<70%.
It is evident that HLA antisera with the same HLA class I specificity 
reacted against some but not always the same pig lymphocytes as seen in 
Table 5.4. In addition, sera that did not have any IgG HLA class II antibodies, 
but which had HLA class I specific antibodies reacted with various pig 
lymphocytes such as;
serum 32-3 reacted with pig lymphocytes 43a, 51, 55 and 59.
serum 14-3 reacted with pig lymphocytes 55 and 59
serum 34-3 reacted with pig lymphocytes 43a, 48, 51, 52, 55, 56, 59, 60, 64,
MPcc and MPdd.
All these antisera contained an anti-HLA-B44. However, other antisera 
with the B44 specificity, such as 19-3, failed to react with any of the pig 
lymphocytes tested. Other sera with an HLA-B44 antibody reacted with different 
pig lymphocytes, such as, serum 24-3 reacted with pig 59, serum 28-3 reacted
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Chapter 5:_____________________Analysis of Anti-Pia-Absorbed Sera Against Pig Lymphocytes
with pig 52 and serum 37-3 reacted with pig 60. Of interest is serum 34-3 (anti- 
644 weak, negative HLA class II), which reacts with 11 of the panel of 14 pig 
lymphocytes. Other sera that also have anti-844 (22-3, and 36-3) were negative 
with all 14 of the cell panel. This observation is not surprising as these sera are 
polyclonal in nature.
Serum samples 23-3 and 24-3 are from the same patient but samples 
were taken 10 years apart and have different HLA class I specificity and the 
same HLA class II specificity. Serum 23-3 (taken 1988) reacted with many 
more pig lymphocytes (48, 52, 56, 59, 60, 64, MPcc and MPdd) than serum 24- 
3, which reacted with pig 59 only. A similar result was seen with sera 17-3 and 
18-3. These patients’ serum samples were also taken 9 years apart and show 
different reaction patterns from each other. In this case the HLA class I and II 
antibody specificity of the sera are similar, although serum 17-3 (taken 1989) 
reacted with pig 48, 52, 55, 56, 60 and MPdd, whereas serum 18-3 (taken 
1998) only reacted with pig 48, 60 and MPdd.
Patient serum 40-3 that did not have any anti-HLA class I specific 
antibody reacted with pig lymphocytes 48 and 60. The HLA class II specificity of 
this serum was very similar to serum 44-3, which did not react with any of the 
pig lymphocytes.
Serum samples 14-3, 32-3 and 34-3 did not have any HLA class II 
reactivity but reacted against pig lymphocytes, which would indicate that HLA 
class I antibody may be the reason for the IgG antibody/antigen reaction seen.
Serum 27-3 reacted with pig lymphocytes 48, 56, 59, 60, 64, MPcc and 
MPdd. The flow cytometric assay detects IgG antibodies only, and this serum 
has an IgM anti-HLA-B8 only. These positive reactions are obviously not due to 
any HLA antibody as this serum was tested for the presence of any IgG HLA 
antibody as demonstrated in Section 4.3.2.1, Table 4.2.
From the results in this chapter, it was evident that these anti-pig 
antibodies, which were not xenoreactive in the sense of natural carbohydrate 
antibodies, would require further investigation. Using human EBV and pooled 
human platelets, HLA specific antibodies were absorbed from the PRBC- 
absorbed antisera and re-tested against pig splenocytes. This work was carried 
out with serum samples from Series 2 and 3 only. The results of this work are 
described in Chapter 6.
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CHAPTER 6: ABSORPTION OF HLA ANTIBODIES
6.1 INTRODUCTION
As the supposition is that anti-HLA can cross-react with SLA, any HLA- 
antisera that reacted with pig lymphocytes may be due to this phenomenon. To 
investigate whether or not the positive reactions against the pig lymphocytes 
described in the previous chapter were due to HLA-specific antibody, pig 
lymphocytes were used in an attempt to absorb out the anti-HLA activity from 
the serum samples in Series 2. Section 6.1 of this chapter describes the results 
obtained from these experiments.
Human major histocompatibility class I molecules are expressed on the 
surface of nearly all nucleated cells and platelets, whereas HLA class II 
molecules are expressed on selected cells such as B cells, APC and thymus 
epithelial cells. Another approach to explore whether or not reactivity against 
the pig lymphocytes were due to HLA-specific antibody. Series 3 serum 
samples were absorbed with various targets that express HLA molecules. One 
such target was human EBV transformed lymphoblastoid cells lines, which 
express both HLA class I and II antigens. These cell lines are used routinely for 
the detection of HLA class I and class II antibodies in the clinical setting, and 
thus would be useful to remove both HLA class I and II specific antibody 
reactivity (Sutton et al., 1995). Human platelets express only HLA class I and 
not class II antigens and as such they were used to absorb out anti-HLA class I 
specific antibody, leaving HLA class II specific antibody.
6.2 ABSORPTION OF ANTISERA WITH PIG LYMPHOCYTES TO
REMOVE ANTI-HLA REACTIVITY
If HLA specific antibodies can cross-react with SLA antigens, some of this 
reactivity should be removed by some pig lymphocytes. These experiments 
were performed over two days, as fresh pig lymphocytes were required for the 
GDC assay. HLA antisera that were pre- and post- PRBC-absorbed as 
described in Section 2.3.1 were tested by GDC for the presence of IgG and IgM 
pig reactive antibody (Section 2.6.2 and 2.6.3). The PRBG-absorbed sera were 
absorbed with pig 46 lymphocytes and examined for removal or reduction in
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reactivity against human splenocyte 147. These PRBC and/or pig lymphocyte 
absorbed sera were also tested with lymphocytes from pig 46 by flow cytometry 
for IgG antibody (Section 2.5).
6.2.1 Test Antisera Pre- and Post-PRBC-Absorbed Against Pig 
Lymphocyte 46 by GDC
Serum samples from Series 2 were tested pre- and post-PRBC-absorption 
with and without DTT for the presence of IgG and IgM antibody. Table 6.1 
demonstrates that an IgG antibody was present in all samples pre-PRBC- 
absorption. The majority of serum samples agglutinated (shown by an asterix) 
indicating IgM antibody was also present. After absorption with PRBC, the 
results were all negative with pig lymphocyte 46 by cytotoxicity as shown in the 
post-PRBC-absorption column. These negative results indicated that either the 
PRBC had successfully absorbed out the anti-pig reactivity or that the assay 
was not sensitive enough.
6.2.2 PRBC and Pig Lymphocyte Absorbed HLA Antisera Tested 
for Removal of HLA Activity by Flow Cytometry Against Human 
Splenocyte
PRBC-absorbed antisera were absorbed with pig 46's lymphocytes as 
described in Section 2.8.3. These sera were tested back against human 
splenocyte 147 (tissue type A l l ,  26; B18, 44; Cw5, 7; DR12, 14,52; DQ5, 7) for 
HLA reactivity by flow cytometry (Section 2.5). Table 6.2 shows PRBC- 
absorbed antisera from Series 2, pre- and post- pig lymphocyte absorption. The 
RMdx values post-pig lymphocyte absorption had fallen, probably due to the 
dilutional effects of the absorption process. Serums 26, 31, 34 and 35 were 
negative pre- and post-pig lymphocyte absorption. This was not surprising as 
none of these antisera contained HLA-specific antibodies that would react with 
the HLA antigens expressed on cell 147s surface. Sera 24 and 37 were 
negative post-lymphocyte absorption, but were weakly positive pre-lymphocyte 
absorption. This variation in the RMdx is due to dilution effects as mentioned 
above.
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Chapter 6: Absorption of HLA Antibodies
TABLE 6.2 investigation of the removal of HLA specific antibody by pig 
lymphocytes. PRBC-absorbed anti-sera (Series 2) tested pre- and post- pig 46 
lymphocyte absorption back against human splenocyte 147by flow cytometry 
(Section 2.5) for IgG HLA antibody.
Human splenocyte 147
No. Name HLA class 1 antibody specificity
Pre-pig
lymphocyte
absorption
Post-pig
lymphocyte
absorption
21a Cutting A2 7.2 5.5
22a I.F. (patient) A1,2,11,28, B8,13,+ 48.3 47.4
23 Gaffney B44,45wk,50 14.8 9.5
24 Hutchings B8.59 3.2 2.3
25 A.J. (patient) B44,45,13,7wk,60wk ,61 wk,49wk, 50wk 41.4 21.7
26 L.L. (patient) B7,27wk,7wk,60wk,42wk 1.2 0.9
27 M.L. (patient) A2,B35wk,53wk,+ 5.2 3.6
28 S.L. (patient) A llw k 16.7 12.3
29 Lynch B44,45,+?Cw1 20.1 16.1
30 J.R. (patient) B14,44,45,35,57,58,62,63,49,50,Cw1,+ 23.6 27.6
31 Roper A23wk 1.5 1.2
32 McColl A25,26,66,29,43,34wk 22.5 14.9
33 C.S. (patient) A1 ,B44wk,45wk 9.2 6.3
34 D.S. (patient) A30,31,26vwk 1.5 1.0
35 B.S. (patient) B8 1.5 1.2
36 Welsh A1,11 41.8 27.3
37 Ashdown Cwl 2.7 1.5
38 AB SERUM Negative 1.0 1.0
Positive control 29.1 23.0
Positive results are highlighted in red (RMdx >2.5).
All values are given in RMdx (relative medium fluorescence).
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6.2.3 Flow Cytometric Analysis of PRBC-Absorbed Sera Against 
Pig Lymphocyte 46 for the Presence of IgG Antibody
Since PRBC-absorbed HLA sera were negative against pig 46 
lymphocytes by CDC, indicating either and or IgM/IgG reactivity, a flow 
cytometric assay was performed. Table 6.3 demonstrates all the RMdx values 
were <2.5, therefore, there was no IgG reactivity of any of the PRBC-absorbed 
sera against pig 46's lymphocytes. Although these sera obviously still retained 
anti-HLA reactivity post- pig lymphocyte absorption as shown previously in 
Table 6.2, unfortunately none of the sera reacted against the pig 46's 
lymphocytes post-PRBC-absorption. Thus, this experiment was not carried any 
further as negative results would have been obtained.
There were insufficient sera to repeat this experiment or develop any 
further experiments using these HLA antisera. As such, using the PRBC- 
absorbed sera from Series 3 a different approach was taken. This was to use 
other targets to absorb out the HLA specific antibody.
6.3 PRBC AND HUMAN EBV TRANSFORMED CELL LINES ABSORBED 
SERA RESULTS -CYCLE 1
Initially only six antisera from Series 3 were investigated (cycle 1 ) and 
subsequently a further 22 sera (cycle2) were also analysed to examine if human 
EBV transformed cell lines could remove the reactivity of the human antisera 
against pig lymphocytes.
Six PRBC absorbed sera (7-3, 13-3,14-3, 32-3, 34-3 and 41-3) were 
selected that had reacted against pig lymphocytes and had different PRAs and 
HLA antibody specificity. Table 6.4 shows the flow cytometric results of the 
above sera against the various pig lymphocytes. Four EBV transformed cell 
lines were pooled and used for the absorptions. They had the following tissue 
types:
a) A2, 66; B41, 44, Cw5,17 ; DR7 ,13, 52, 53; Q6, 9
b) A36,68; B53, 58; Cw4, 7 ; DR13,15, 51, 52; Q2, 6
c) A25, 32; B39, 61; Cw2,12; DR7 ,11, 52, 53; Q2, 7
d)A1 , 25; B18, 57; Cw6,12; DR7 ,12, 52, 53; Q2, 7
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TABLE 6.3 Investigation of PRBC human anti-sera against pig 
lymphocyte 46. PRBC-absorbed anti-sera (Series 2) was tested 
against pig lymphocyte 46 by flow cytometry(Section 2.5) for IgG HLA 
antibody.
Pig 46
No. Name HLA Class 1 antibody specificity
Post-PRBC-
absorption
21a Cutting A2 1.2
22a I.F. (patient) A1,2.11,28, 88,13,+ 1.2
23 Gaffney B44,45wk,50 1.1
24 Hutchings 88,59 1.2
25 A.J. (patient) B44,45,13,7wk,6Gwk,61wk,49wk,50wk 1.1
26 L.L. (patient) B7,27wk,7wk,60wk,42wk 1.0
27 M.L. (patient) A2,B35wk,53wk,+ 1.1
28 S.L. (patient) A llw k 0.9
29 Lynch B44,45,+?Cw1 1.1
30 J.R. (patient) B14,44,46,35,57,58,62,63,49,50,Cw1,+ 1.3
31 Roper A23wk 1.7
32 McColl A25,26,66,29,43,34wk 1.2
33 C.S. (patient) A1 ,B44wk,45wk 1.4
34 D.S. (patient) A30,31,26vwk 1.0
35 B.S. (patient) B8 1.0
36 Welsh A1,11 1.1
37 Ashdown Cwl 0.9
38 AB SERUM Negative 1.0
Positive control 15.1
Positive results are highlighted in red (RMdx >2.5).
All values are given in RMdx (relative medium fluorescence).
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Chapter 6___________________________________ Absorption of HLA Antibodies
The PRBC-absorbed sera were tested by flow cytometry as described in 
Section 2.5. PRBC-absorbed sera were tested pre- and post-EBV-pool-1 
absorption for the presence IgG antibody back against both EBV pools-1 and - 
2. Table 6.5 show the results in RMdx, of these experiments and positive 
results are shown in red. Serum samples 7-3 and 34-3 were negative against 
the EBV pooI-1 pre-absorption of the antisera. All the EBV-absorbed antisera 
were negative against both the EBV pool-1 and -2 for the presence of any IgG 
antibody. Serum 7-3 was diluted 1:20 as there was insufficient sample to test 
pre-EBV-absorption and consequently it gave a negative result. It was expected 
that serum 34-3 (anti-B44) would be positive pre-EBV-absorption against the 
EBV pool-1 as this pool contains two cells that express HLA-B44. This serum 
34-3 clearly contains an anti-HLA class I antibody as when screened for HLA 
specific antibody by CDC after PRBC-absorption a weak anti-B44 was still 
present (see Section 4.3.1). Furthermore, FlowPRA™ class I screening beads 
show the presence of an IgG HLA class I antibody in this serum post-PRBC- 
absorption as illustrated in Figure 6.1. This histogram clearly shows a shift to 
the right along the X-axis indicating IgG (FL-1) binding to the beads. This 
negative result using the EBV pools either reflects the antigen being ‘diluted’ as 
there are 10 cells in each pool, or the B44 expression on the cells is too low to 
able to detect antibody binding (Liebert and Aster, 1977).
The EBV pools-1 and -2 used to screen for the presence of HLA 
antibodies did not include the same cells as those used for the EBV 
absorptions. Table 6.6 shows the HLA class 1 and II types for the human EBV 
transformed B cell lines used in pool-1 and -2. Some HLA antigens were not 
contained in these pools. Many of them were uncommon and included: HLA- 
A31, 34, B47, 48, 56, 67, 71 and 72.
From these experiments, the EBV cells used for the absorptions had 
removed the presence of HLA specific antibody. Therefore, these PRBC and 
EBV-absorbed sera were tested against pig lymphocytes to evaluate if the ‘anti­
pig’ reactivity had been removed.
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Chapter 6: Absorption of HLA antibodies
FIGURE 6.1 Investigation of HLA class I specific antibody by FlowPRA™ 
class I screening beads. Histogram of the results from serum 34-3-post-RBC 
absorption tested with FlowPRA™ beads for the presence of IgG (FL-1) 
antibody. Multiple peaks indicate the presence of an HLA class I antibody.
oCO
LU
O
FL1 LOG
Negative control 
Positive control 
Serum 34-3
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TABLE 6.6 Tissue types of the human EBV transformed lymphoblastoid cell 
pools. These cell lines were used for absorptions (Section 2.8.2) and screening 
for the presence of IgG HLA antibody by flow cytometry (Section2.5).
EBV cell pool 1
H
cell line name A A B B Cw Cw DR DR DR DR DR DQ DQ
1 LUTELILY 2 66 41 44 6 17 7 13 52 63 6 9
2 SAUJUL 24 11 50 60 3 6 4 7 63 2 3
3 WATIAN 11 32 52 35 4 12 4 103 53 5 8
4 M0LT-4 1 25 57 18 6 12 7 12 52 2 7
5 LUCVER 3 25 45 62 3 6 4 53 7
6 NAWALIZO 36 68 58 53 4 7 15 13 52 51 2 6
7 6513 2 23 44 38 4 5 17 4 52 53 2 3
8 KHA-MOH 36 30 7 78 7 9 13 52 53 6 7
9 BOTTGER 23 30 13 49 6 11 7 52 53 2 2
10 AP 2 33 46 58 1 3 17 8 62 2 6
■A type
EBV cell pool 2
H
cell line name A A B B CwCw DR DR DR DR DR DQ DQ
11 VOO 9241 1 3 8 56 1 7 1 17 52 2 5
12 HRC-2 25 28 39 62 10 12 15 11 52 51 6 7
13 ODOC 25 32 39 61 2 12 7 11 52 53 2 7
14 SPR-NF 2 26 38 63 7 12 12 17 52 2 7
15 LWAGS 3 64 8 1 5
16 WILLERRO 29 68 61 73 8 15 15 13 52 51 6
17 COLROY 1 29 8 51 7 12 1 4 53 5 7
18 RSH 68 30 42 2 18 52 4
19 DJS 9269 2 3 35 37 4 6 1 16 51 5 5
20 JJO-A 1 2 55 27 2 9 13 14 52 5 6
LA type
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6.4 HLA ANTISERA ABSORBED WITH EBV-TRANSFORMED CELL
POOLS AGAINST PIG LYMPHOCYTES - CYCLE 1
The six antisera 7-3, 13-3, 14-3, 32-3, 34-3 and 41-3 in cycle 1 had no 
residual anti-HLA specific antibody when tested against EBV cells as previously 
shown in Table 6.5, and so these sera were tested against a panel of three pig 
lymphocytes. Results in Table 6.7 show the flow cytometric results, in RMdx, of 
these sera tested against pig lymphocytes 43a, 52 and 59 pre- and post-EBV- 
absorption. It can be seen from this table that absorption with human EBV- 
transformed cell lines has removed the pig-reactive antibody (serum 13-3 
versus pig 52 and 59, serum 32-3 versus pig 43 and 59 and serum 41-3 versus 
pig 43). Serum 34-3 post-EBV-absorption still reacted with the three pig 
lymphocytes tested. This suggested that an antibody other than HLA was 
present in this serum sample.
The results from this experiment showed that absorption with EBV cell 
lines did appear to remove HLA reactivity when EBV-absorbed antisera were 
tested back against EBV pools-1 and -2. It was decided that these experiments 
should be repeated but with a larger number of serum samples and to expand 
the screening for the presence of HLA antibodies. Not only were the EBV- 
absorbed antisera back tested against the EBV pools-1 and -2 but they were 
also screened with FlowPRA™ screening beads for the presence of HLA class I 
and II antibodies. The results of these experiments are discussed in Section
6.5.1
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Chapter 6___________________________________ Absorption of HLA Antibodies
6.5 PRBC AND HUMAN EBV-TRANSFORMED CELL LINES ABSORBED
SERA RESULTS -CYCLE 2
In cycle 2 twenty-two PRBC-absorbed antisera and two AB negative 
controls were selected and absorbed with EBV transformed cells to remove 
anti-HLA specific antibodies. The EBV pool-1 was used for the absorptions and 
the HLA types of this pool are shown previously in Table 6.6. PRBC-absorbed 
serum samples were tested by flow cytometry (Section 2.5) with EBV pool-1 for 
IgG antibody as shown in the first column in Table 6.8. Most of the PRBC- 
absorbed antisera were positive against the EBV pool-1 pre-absorption with this 
pool, shown in red. Serum 27-3 was negative as expected as this serum only 
contains IgM anti-B8. Once again serum 34-3 was negative but as previously 
mentioned, Figure 6.1 demonstrates an IgG HLA class I specific antibody was 
clearly present in this serum sample.
The PRBC-absorbed sera were absorbed with EBV cells and back tested 
with EBV pool-1 cells for the presence of any remaining IgG HLA antibody as 
shown in second column in Table 6.8. The results show two sera remained 
positive (5-3 and 28-3), although the RMdx post-absorption for both had fallen 
(129.5 to 3.8 and 41.5 to 26.6 respectively). The histogram in Figure 6.2 
illustrates these results very clearly as there is a definite shift to the right along 
the X-axis indicating IgG binding and not all anti-HLA specific antibody had 
been removed.
These twenty-two PRBC and EBV pool-1-absorbed sera were further 
tested against the EBV pool-2 cells to investigate if all HLA specific antibodies 
had been removed as the cells in this pool had different HLA types (see Table 
6.6). Results of the flow cytometric experiments show serum samples 5-3, 12- 
3, 17-3,28-3, 29-3, and 33-3 still had activity versus EBV pool-2 as seen in 
Table 6.9. Therefore, all the antisera were subsequently absorbed with the 
EBV pool-2 in an attempt to remove all residual HLA specific antibodies 
present. The PRBC, EBV pool-1-and -2-absorbed sera were tested back 
against the EBV transformed cell pool-2, and serum 17-3 and 28-3 continued to 
remain positive as can been seen in the second column in Table 6.9. The 
RMdxs on these two sera pre-and post-absorption with the EBV pool-2 did not 
alter appreciably. The histograms in Figures 6.3a and b plainly illustrate that 
there
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Chapter 6: Absorption of HLA antibodies
FIGURE 6.2 PRBC and EBV pool-1 absorbed antisera tested back against 
the EBV pool-1. Histogram result demonstrating serum absorbed with PRBC 
and a pool of EBV cells, when tested back against the EBV pool-1 by flow 
cytometry (Section 2.5) for IgG (FL-1) antibody. Two sera remain positive post­
absorption, indicating that not all anti-HLA specific antibody had been removed.
CO
1010 1 O^ 
FITC-FL1
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Positive control 
Serum 5-3 (RMdx 3.8) 
Serum 28-3 (RMdx 26.6)
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Chapter 6: Absorption of HLA antibodies
FIGURE 6.3a PRBC and EBV pool-1-absorbed sera test against EBV pool-
2. Histogram result demonstrating serum absorbed with PRBC and EBV pool-1 
cells, when tested back against the EBV pool-2 for IgG antibody (FL1), two sera 
remained positive post-absorption.
1 o
Negative control 
positive control 
Serum 17-3 (RMdx 3.9) 
Serum 28-3 (RMdx 4.2)
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FIGURE 6.3b PRBC and EBV pool-1 and 2-absorbed sera test against EBV 
pool-2. Histogram result demonstrating serum absorbed with PRBC and both 
EBV pools -1 and -2. Upon testing back against the EBV pool-2 for IgG antibody 
(FL1), two sera continued to remain positive post-absorption.
CO
1 0 10 1 0 ^
FITC-FL1
1 0
Negative control 
positive control 
Serum 17-3 (RMdx 6.0) 
Serum 28-3 (RMdx 3.8)
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was an IgG antibody still present in these sera post-PRBC, EBV pool-1 and -2 
absorptions.
The EBV pooI-2 cells that were used for the first and second absorptions 
were tested for the presence of bound IgG. Those EBV cells used for the 
absorption of antisera 17-3 and 28-3, did have IgG antibody bound on them 
(RMdx 4.7 and 5.1; RMdx 5.4 and 11.9 respectively), indicating the HLA specific 
antibody titre was high and thus more cells would have to be used to remove all 
the HLA reactivity.
The PRBC, EBV pool-1-and 2- absorbed sera (5-3, 17-3, 28-3, 29-3 and 
34-3) were subjected to another round of absorptions with the EBV pool-2 cells. 
These sera were selected as it was considered at this point that any RMdx >1.5 
could probably be positive. Since it was central to this work all HLA reactivity 
was removed, an extra quantity of EBV-transformed cells were used for the 
absorption of serum samples 17-3 and 28-3 as all these sera had a RMdx of 
>2.5. This was an attempt to ensure all HLA specific antibodies would be 
removed.
All the PRBC and EBV absorbed sera were tested by the FlowPRA™ 
screening test to examine if any residual HLA class I and/or class II antibody 
remained in the sera.
6.5.1 PRBC and EBV Pool-1 and -2 Absorbed Sera Tested by the
FlowPRA *^  ^ Screening Test
The FlowPRA™ screening results cannot be interpreted as RMdx (see 
section 2.7.5.1) but on the shape of the histogram and the shift of the histogram 
to the right along the X-axis (FL-1). Nonetheless, this assay is semi-quantative 
and the amount of antibody can be compared to the negative control. There 
were no single peak that shifted to the right along the X-axis, and accordingly 
control beads were not used to determine if a shift was due to ‘non-specific’ 
binding. PRBC-absorbed sera were tested by FlowPRA™ beads after 
absorption with EBV pool-1 and after absorption with EBV pool-2. Table 6.10 
shows the flow cytometric results post-absorption with EBV cells lines, and in 
the majority of cases HLA class I and II antibodies were removed as shown in 
the third and sixth column. As a comparison, results for the presence of IgG 
HLA class 1 and II antibody post-PRBC-absorption is also shown in the first and
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TABLE 6.10 Results from screening PRBC and EBV-absorbed anti-sera tested by the 
FlowPRA™ screening test. Flow cytometric results showing that HLA class I and II 
antibodies were removed in most cases after absorption with with EBV cells lines. The anti­
sera were tested for the presence of IgG anti-HLA by FiowPRA™ beads. As a comparison, 
results for the presence of IgG HLA class I and II antibody is also shown after absorption 
with PRBC.
Positive results are highlighted in red 
* samples that were absorbed twice with EBV pool-2 
nt = not tested
FlowPRA™ class 1 FlowPRA™ class II
Serum post-PRB-
post PRBC & 
EBV-1
post PRBC & 
EBV-18.2 post-PRB-
post PRBC & 
EBV-1
post PRBC & 
EBV-1 &2
no. Name absorpt" absorpt" absorpt" absorpt" absorpf absorpt"
1-3 Abrahams <..5.4. nt - 4 .4.,}. nt -
2-3 AW (patient) 4.4 .4 . nt nt 4 .4 ,4. nt nt
3-3 Ashdown nt nt 4 .4 . nt nt
4-3 J.B. (patient) 4 .4 .4. - .{.4.4. 4 ,4. -
5-3 B.B. (patient) <.,^ 4. » 4.4 .4. 4.4. . *
6-3 R.B. (patient) nt nt 4.4 .4 . nt nt
7-3 G.B. (patient) +/. - 4.4 .4. - -
8-3 W.B-1 (patient) - nt nt - nt nt
9-3 W.B-2 (patient) - nt nt - nt nt
10-3 W.B. (patient) nt nt 4 .4 .4. nt nt
11-3 J.C, (patient) 4*4^ 4* nt nt 4..Î.4 . nt nt
12-3 Ching •[.4. - 4,4 .4 . 4 .4 . +/-
13-3 CT (patient) - ,{.4,4. - -
14-3 Gaffney - - - - -
15-3 R.G. (patient) - •5- -
16-3 W.G. (patient) - nt nt - nt nt
17-3 Holt-1 4 .4.4. 4. 4 _*
18-3 Hoit-2 nt nt .{,4 .4. nt nt
19-3 HGH (patient) 4 ,4.4 . nt nt nt nt
20-3 Hutchings 4- nt nt nt nt
21-3 JAM (patient) 4 .4 . nt nt nt nt
22-3 M.J. (patient) nt nt 4 .4 .4. nt nt
23-3 A.J-1 (patient) 4. - +/- -
24-3 A.J-2 (patient) 4' - 4..Î.4. - -
25-3 LA (patient) 4 .4 .4 . nt nt 4 .4 , nt nt
26-3 L.L. (patient) .J4 .4 . nt nt 4,4 .4 . nt nt
27-3 M.L. (patient) - - - - - -
28-3 Lynch 4.4 . i- 4.4.4 , 4 .4. 4. *
29-3 R.M. (patient) 4 .4.4. 4.4. 4 .4.4. +/- - *
30-3 MU (patient) 4 ,4. kg. nt nt 4.4.4. nt nt
31-3 OK (patient) 4 .^4. nt nt 4 .4.4. nt nt
32-3 Parsons 4.4.4. - - - - -
33-3 P.P. (patient) '!■'!■ "S* ❖ - .{,4.4 . 4.4 ,4. - *
34-3 M.P. (patient) 4 .4.4. - - - +/- -
35-3 Pugh 4 .4.4 . nt nt 4.4.4. nt nt
36-3 R A . (patient) 4. .^ 4. nt nt nt nt
37-3 J.R. (patient) 4«4**j* +/- - 4 .4 .4. +/- -
38-3 D.S. (patient) nt nt 4 ,4 .4 . nt nt
39-3 B.S. (patient) 4.4 .4. - - 4,4.4, 4, -
40-3 R.V. (patient) - nt nt .},4. nt nt
41-3 Welsh 4 .4.4 . - - 4 .4 ,.(, 4- +/-
42-3 A.W. (patient) 4.4.4. - - 4 .4.4. - -
43-3 H.W. (patient) 4 .,}. 4 . - 4 .4.4 . - -
44-3 R.W. (patient) 4.4.4 . nt nt 4 .4.4 . nt nt
45-3 AB serum - - nt - - nt
46-3 AB serum - nt nt - nt nt
180
Chapter 6___________________________________ Absorption of HLA Antibodies
fourth column. Serum samples 5-3,17-3, 28-3, and 29-3 still contained a trace 
of HLA class I specific antibody, shown with a red cross. This is probably due to 
the high titre of antibody present in antisera 5-3,17-3 and 29-3. Serum 28-3 
HLA class I antibody was probably not completely absorbed out using the EBV 
pool-2, as this pool does not contain any cells expressing B44 and 45. Only 
serum 28-3 still retained a small amount of HLA class II specific antibody after 
all the absorptions. Once again this maybe due to the EBV pool-2 not 
containing any DQ8 and 9. Serum 28-3 has an anti-DQ7, 8, 9 plus other class II 
antibodies. Figure 6.4 illustrates the histogram overlays of the FlowPRA™ class 
I beads of serum 17-3 through the stages of absorption using the EBV cells.
The strength of IgG antibody binding to the beads is reduced after each 
absorption step but still has HLA class 1 specific antibody after the final with 
EBV pool-2. All the other absorbed-sera (apart from 5-3, 17-3 and 28-3 as 
discussed above) did not contain any HLA class I or II specific antibody.
It was decided not to continue with any further absorptions with those sera, 
which contained some residual HLA specific antibody, as the quantity remaining 
was small. These PRBC and EBV-absorbed sera were now tested against a 
panel of pig lymphocytes, in order to examine if the reactivity against these cells 
had been removed by the EBV-absorptions.
6.6 HLA ANTISERA ABSORBED WITH EBV POOLS VERSUS PIG
LYMPHOCYTES-CYCLE 2
In cycle one, only a few samples had been tested post- human EBV cell 
line absorption (to remove HLA-specific antibody) and tested back against the 
small number of three pig lymphocytes. Thus, in cycle 2, six pig lymphocytes 
were tested against a variety of EBV-absorbed antisera.
In all of the samples, absorption with the EBV pools not only removed 
HLA class I and II specific antibody in most of the sera as discussed in Section 
6.5 and shown in Table 6,10, but also the reactivity against most of the pig 
lymphocytes. Table 6.11 shows the results of the PRBC, EBV pool-1 and -2 
absorbed sera tested for IgG binding by flow cytometry against pig 43a, 47, 52, 
53, 54 and 59 lymphocytes. Only serum 34-3, remained positive versus pig 43a 
and 59 lymphocytes. Those sera with residual HLA specific antibody (5-3,17- 
3,28-3 and 32-3) were also negative after EBV-absorption against the pig
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FIGURE 6.4 Histogram of FlowPRA™ class I beads tested with absorbed 
anti-sera. This histogram demonstrates that PRBC-absorbed serum 17-3 still 
retains some weak IgG HLA antibody after absorption with EBV pool-1 and 
twice with EBV pool-2. The titre of this antibody fell and further absorptions with 
the EBV cells would probably remove all IgG HLA antibody.
CO
101010 10 1 0 ^  
FL1 LOG
Negative control 
Positive control
Serum 17-3 post- PRBC- absorption
Serum 17-3 post- PRBC and EBV pool-1- absorption
Serum 17-3 post- PRBC and EBV pool-1 and 2- absorption
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lymphocytes. This indicates that the HLA antibody remaining was not reactive 
against the pig cells demonstrating that the anti-HLA/SLA crossreactivity is a 
subset of the total anti-HLA in these sera. However, the reactivity of serum 34-3 
against pig 52 was absorbed out by the EBV cells, which was inconsistent with 
the results obtained in cycle 1 where the antibody was not removed, although 
reduced as shown previously in Table 6.7. In addition, post-PRBC and EBV- 
absorption, serum 34-3 was now positive (RMdx 2.6) against pig 54 
lymphocytes whereas this serum was negative (RMdx 2.1) against this cell 
when absorbed with PRBC only. Pig 54 was not tested with the sera in cycle 1. 
The RMdx value of 2.6 is just above the cut-off value and the difference 
between 2.1 and 2.6 is within a reproducibility range. For example, if the RMdxs 
of Table 6.5 and 6.8 are examined (PRBC-absorbed sera against EBV pool-1), 
the differences between cycle 1 and 2 for serum samples 13-3 is 22.0 and 21.8; 
serum 14-3 is 3.0 and 2.8; serum 32-3 is 10.5 and 8,2; serum34-3 is 1.8 and 1.9 
and serum 41-3 is 11.5 and 9.2. Thus, the results from serum 34-3 against pig 
54 would be considered equivocal.
Interestingly, serum 27-3, which has an IgM anti-HLA-B8, which was 
positive for an IgG antibody versus pig 59 lymphocyte post-PRBC-absorption 
(RMdx 4.3), was negative against this cell after EBV-absorptions (RMdx 2.0). 
This would suggest that the cells in EBV pool and pig 59 might have a shared 
antigen on their cell surfaces. However, this serum was negative against the 
EBV pools pre-and post-PRBC-absorption as seen previously in Table 6.8.
Given that the EBV cell lines, (which express both HLA class I and II) do 
remove reactivity from the human PRBC absorbed sera, further absorptions 
were carried out using human platelets (which express HLA class I) to study if 
this antibody reactivity could be due to either HLA class I or class II.
6.7 ABSORPTION OF HLA CLASS I ANTIBODY USING POOLED HUMAN
PLATELETS
All PRBC-absorbed antisera (except 8-3, 16-3, and 38-3) were treated as 
described in Section 2.8.1. The PRBC and platelet absorbed sera were tested 
back by flow cytometry (Section 2.5) against the pooled platelets. The results of 
this assay are shown in Table 6.12. All the RMdx values were below 2.5, thus 
Indicating that any reactivity against the platelets had been absorbed out. To
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TABLE 6.12 Flow cytometric analysis of PRBC and platelet-absorbed sera versus 
pooled platelets for IgG antibody.
No. NAME
linHLA class 1 antibody specificity ILÛÎHLA class II antltxxly specificity RMdx1-3 Abrahams 90 Bw6 72 DR52,(13) 1.3
2-3 AW (patient) 90 A1,2,B49,61,++ 78 DR11,12,17,1,+ 1.1
3-3 Ashdown 14 Cwl 41 DQ2 1.0
4-3 J.B. (patient) 1 0 0 A1.B35, +++ 1 0 0 Multi ?? 1.1
5-3 B.B. (patient) 1 0 0 A1,2,3.11,28,++ 56 DR1,4,103,(10),Q2wk 1.1
6-3 R.B. (patient) 32 A2wk 28 DR15,16 1.0
7-3 G.B. (patient) 25 A3,B13,18,60vwk 13 DR4 1.0
8-3 W.B-1 (patient) 30 B57.58 0 Negative nt
9-3 W.B-2 (patient) 30 B57.58 0 Negative 1.0
10-3 W.B. (patient) 2 B13 90 DR52,DQ2,DR15,16 0.9
11-3 J.C. (patient) 90 A2,3,11,23,24,28,B57.58.++ 98 DR52.+ 0.9
12-3 Ching 50 A23,24,32,25wk,B51,57wk 8 8 DQ2,DR17,18wk,13,14wk,1,10,103 0.9
13-3 CT (patient) 90 B7.+++ 99 Multi; ?DR15,16,51,13,14,++ 0.9
14-3 Gaffney 25 B44,45wk,50 0 Negative 0.9
15-3 R.G. (patient) 90 A2,B7,44,45,++ 53 DR1,10,103,15,16,(51) 1.0
16-3 W.G. (patient) 64
A25,26wk,32,B49,52,44wk,57wk,58wk,
62wk,63wk,+ 0 Negative nt
17-3 Holt-1 43 A1,11,26 (nt B13) 53 DR15,16,51,11,12, +?52 1.2
18-3 Holt-2 46 A1,11.23,26,B8vwk 56 DR15,16,17,18,11,12 1.0
19-3 HGH (patient) 90 A2,B44,57,++ 1 0 0 DR52,DQ2,+ 1.2
20-3 Hutchings 2 0 88,59 78 DR52.DQ2 1.1
21-3 JAM (patient) 0 Negative 26 DR11,13wk,+ 0.8
22-3 M.J. (patient) 54 B51,52,57,58,49,62wk,44wk 56 DR17,18,13,14,8 1.0
23-3 A.J-1 (patient) 75 844,45,49,50,60,61,62,27,13 1 0 0 DR52,DQ1,2 1.0
24-3 A.J-2 (patient) 25 844,45,50 1 0 0 DR52,DQ1,2 0.9
25-3 LA (patient) 6 8 A2,28,24,23wk 28 DR4.53 1.0
26-3 L.L. (patient) 25 B7,27wk, 13vwk,60vwk 75 DR15,16,1,103,10,+?4 1.1
27-3 M.L. (patient) 2 0 8 8 0 Negative 0.9
28-3 Lynch 25 844,45 78 DR15,16,51,DQ7,8,9,+ 1.0
29-3 R.M. (patient) 90 A2,3,23,24,B44,45,57,58,+ 75 DQ2.DR1,15,16 0.8
30-3 MU (patient) 82 87,13,27,60,61,41,55, A25,29,32,+ 1 0 0 DQ7,8,9,DR1,10,103,15,16,17,18 0.7
31-3 OK (patient) 25 A1 (ntA36) 63 DQ2 1.0
32-3 Parsons 8 6 A23,24,25,32,B51,52,49,57,27,44wk 0 Negative 1.0
33-3 P.P. (patient) 90 A1.2,28,88,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+ 0.9
34-3 M.P. (patient) 1 0 B44wk 0 Negative 1.0
35-3 Pugh 2 1 855,56,13,35wk 75 DR15,16,4,7,9,+ 0.8
36-3 R A . (patient) 53
B51,52,49,50,57,58wk,62wk,35wk, 
71vwk,44wk 70 DR15,16,51,+ 0.9
37-3 J.R. (patient) 53 814,44,45,35,57,58,62,63,49,50, Cwl,+ 81 DQ4,DR8,11,12,13,14,+?2,+ 1.0
38-3 D.S. (patient) 1 1 A30wk,31wk 2 2 weak ? nt
39-3 B.S. (patient) 1 0 0 A2, +++ 1 0 0 Multi; ? 005,6,7,8,9,+ 1.0
40-3 R.V. (patient) 0 Negative 8 8 DR53,DQ3wk 1.2
41-3 Welsh 50 A1,11,25,26 8 8 DR52.+ 1.0
42-3 A.W. (patient) 90 A2.+++ 1 0 0 DR15,16,11,12,002,+ 1.1
43-3 H.W. (patient) 39 A1,11wk,24wk 72 0R15,16,+?1,10,103,+ 1.1
44-3 R.W. (patient) 50 B14,8%rk,+ 1 0 0 0R53,003,+ 0.9
45-3 AB serum 0 Negative 0 Negative nt
46-3 AB serum 0 Negative 0 Negative 1.0
Positive control 131.9
Positive results are highlighted in red (RMdx >2.5).
All values are given in RMdx (relative medium fluorescence). 
HLA class I antibodies highlighted in pink are IgM only
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ascertain if any HLA specific antibody remained in this platelet absorbed 
antisera, they were tested against EBV pool-1 and -2 by flow cytometry as 
described in Section 2.5.
6.7.1 PRBC and Human Platelet-Absorbed Sera Versus Human
EBV Transformed Cell Lines
Table 6.13 demonstrates the results of the PRBC and human platelet- 
absorbed sera tested against the human EBV pools. Many of the absorbed sera 
show reactivity with EBV cell pools (RMdx >2.5) indicating residual IgG 
antibody, except sera 6-3, 7-3, 9-3, 14-3, 15-3, 21-3, 26-3, 27-3, 32-3, 34-3, 43- 
3 and 45-3. It was not surprising that serum samples 9-3,14-3, 27-3, 32-3, 34-3 
and the AB negative serum 45-3 were negative as none of these contained any 
HLA class II reactivity as demonstrated by testing with FlowPRA™ class II 
screening beads in the sera after absorption with PRBC (Section 6.5.1). This 
suggests that the platelets had removed the HLA class I activity in these sera. 
However, PRBC plus platelet-absorbed sera (namely 6-3, 7-3,15-3, 21-3, 26-3, 
and 43-3 that had HLA class II specific antibodies) were negative against the 
EBV pools. It had been demonstrated that the platelets had adsorbed out the 
HLA class I activity as demonstrated when the platelet absorbed sera were 
back against the pooled platelets (results shown in Table 6.12). Four of these 
platelet-absorbed sera, (namely 6-3,15-3, 26-3, and 43-3) had an anti-HLA- 
DRI 5, 16 specificity, serum 7-3 had an anti-HLA-DR4 and serum 21-3 had an 
anti-DR 11 and weak 13. The antigens DR4, 15,16, 11 and 13 to which these 
antibodies should react are well represented in both EBV pools (see Table 6.6 
for HLA types of cell lines). Thus these antisera, which contained HLA class II 
specific antibody, should have been positive. It is possible that the HLA 
expression on some of the EBV cell lines have been reduced during cell culture 
or that the presence of other cells in the pool has ‘diluted’ out the antigen 
sufficiently to cause insufficient antibody binding to be detected by the flow 
cytometer.
6.7.2 PRBC and Human Platelet Absorbed Sera Versus Pig 64 
Lymphocytes
Although many of the antisera retained reactivity against the EBV pools, 
the platelet-absorbed sera were tested against pig lymphocyte 64. Table 6.14 
shows the results of the PRBC and platelet-absorbed sera tested for any IgG
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TABLE 6.13 Analysis of PRBC and platelet-absorbed sera for IgG HLA antibody activity.
Flow cytometric analysis of PRBC and platelet absorbed sera were tested against human EBV 
pool-1 and 2 for IgG antibody by flow cytometry (Section 2.5) for IgG antibody. FlowPRA class 
II results pre-platelet-absorption is shown for comparison.
No. NAME
S5
I
80
1
S
HLA class 1 antibody 
specificity
I
1
Sr
HLA class II antibody 
specificity IEBVpool-1 EBVpool-2
1-3 Abrahams 90 Bw6 72 DR52,(13) +++ 2.2 5.0
2-3 AW (patient) 90 A1,2,B49,61,++ 78 DR11,12,17,1,+ +++ 3.1 4.2
3-3 Ashdown 14 Cw1(A30,B27) 41 DQ2 ++ 4.9 10.1
4-3 J.B. (patient) 1 0 0 A1.B35, +++ 1 0 0 Multi ?? +++ 16.8 31.2
5-3 B.B. (patient) 1 0 0 A1,2.3,11,28,++ 56 DR1,4,103,(10),Q2wk +++ 17.8 41.5
6-3 R.B. (patient) 32 A2wk 28 DR15,16 +♦+ 1.3 1.3
7-3 G.B. (patient) 25 A3,B13,18,60vwk 13 DR4 +++ 1.3 1.4
8-3 W.B-1 (patient) 30 B57.58 0 Negative - nt nt
9-3 W.B-2 (patient) 30 B57,58 0 Negative - 1.0 0.9
10-3 W.B. (patient) 2 B13 90 DR52,DQ2,DR15,16 +++ 57.0 107.7
11-3 J.C. (patient) 90 A2,3,11,23,24,28,857,58,++ 98 DR52,+ +++ 12.0 21.3
12-3 Ching 50 A23,24,32,25wk,B51,57wk 8 8 103 +++ 8.0 13.6
13-3 CT (patient) 90 87,+++ 99 Multi; ?DR15,16,51,13,14,++ +++ 6.4 10.8
14-3 Gaffney 25 B44,45wk,50 0 Negative - 0.9 1.0
15-3 R.G. (patient) 90 A2,B7,44,45,++ 53 DR1,10,103,15,16,(51) 1.2 1.4
16-3 W.G. (patient) 64
A25,26wk,32 tj49,62,44wk, 
57wk,58wk, 62wk,63wk,+ 0 Negative nt nt
17-3 Hott-1 43 A1.11,26 (ntB13) 53 DR15,16,51,11,12, +?52 ++ 3.2 4.3
18-3 Holt-2 46 A1.11,23.26,B8vwk 56 DR15,16,17,18,11,12 +++ 4.9 5.0
19-3 HGH (patient) 90 A2,844,57,++ 1 0 0 DR52,DQ2,+ ++ 3.8 5.0
20-3 Hutchings 2 0 88,59 78 DR52,DQ2 +♦+ 2.8 4.3
21-3 JAM (patient) 0 CDC negative; FlowPRA positive 26 DR11,13wk,+ ++ 1.1 1.2
22-3 M.J. (patient) 54 851,52,57,58,49,62wk,44wk 56 DR17,18,13,14,8 +++ 11.2 14.6
23-3 A.J-1 (patient) 75 644,45,49,50,60,61,62,27,13 1 0 0 DR52,DQ1,2 +++ 50.9 84.6
24-3 A.J-2 (patient) 25 844,45,50 1 0 0 DR52,DQ1,2 ♦++ 4.8 6.4
25-3 LA (patient) 6 8 A2,28,24,23wk 28 DR4.53 ++ 3.0 3.9
26-3 L.L. (patient) 25 B7,27wk,13vwk,60vwk 75 DR15,16,1,103,10,+?4 +++ 1.6 2.3
27-3 M.L. (patient) 2 0 8 8 0 Negative - 1.6 1.0
28-3 Lynch 25 844,45 78 DR15,16,51,DQ7,8,9,+ +++ 22.0 9.9
29-3 R.M. (patient) 90 A2,3,23,24,B44,45,57,58,+ 75 DQ2.DR1,15,16 +++ 14.9 15.1
30-3 MU (patient) 82
87,13,27,60,61,41,55,
A25,29,32,+ 1 0 0
DQ7,8,9,DR1,10,103,15,16, 17, 
18 +++ 8.8 15.1
31-3 OK (patient) 25 A1 (ntA36) 63 DQ2 +++ 18.2 49.0
32-3 Parsons 8 6 4wk 0 Negative - 0.9 1.0
33-3 P.P. (patient) 90 A1,2,28,68,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+ +♦+ 4.9 10.1
34-3 M.P, (patient) 1 0 B44wk 0 Negative - 1.1 1.0
35-3 Pugh 2 1 855,56,13,35wk 75 DR15,16,4,7,9,+ +++ 5.2 10.1
36-3 R A . (patient) 53 wk, 71vwk,44wk 70 DR15,16,51,+ ♦++ 6.9 8.4
37-3 J.R. (patient) 53 ,Cw1,+ 81 DQ4,DR8,11,12,13,14,+?2,+ ♦++ 15.9 21.7
38-3 D.S. (patient) 1 1 A30wk,31wk 2 2 vi/eak ? +++ nt nt
39-3 B.S. (patient) 1 0 0 A2, 23,24,29,844,+ 1 0 0 Multi; ? DQ5,6,7,8,9,+ +♦+ 65.8 75.7
40-3 R.V. (patient) 0 Negative 8 8 DR53,DQ3wk ++ 3.1 1.6
41-3 Welsh 50 A1.11,25,26 8 8 DR52.+ ♦++ 4.3 6.6
42-3 A.W. (patient) 90 A2,28,23,24,B44,+ 1 0 0 DR15,16,11,12,DQ2,+ +++ 11.6 14.6
43-3 H.W. (patient) 39 A1,11wk,24wk 72 DR15,16,+?1,10,103,+ +++ 1.5 1.8
44-3 R.W. (patient) 50 B14,8wk,+ 1 0 0 DR53,DQ3,+ +++ 3.7 1.5
45-3 AB serum 0 Negative 0 Negative - nt nt
46-3 AB serum 0 Negative 0 Negative - 1.0 0.8
Positive control +++ 90.0 133.2
Positive results are highlighted in red (RMdx >2.5).
All values are given in RMdx (relative medium fluorescence). 
HLA class I antibodies highlighted in pink are IgM only
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TABLE 6.14 Platelet and/or PRBC-absorbed sera tested against pig 
lymphocyte. Sera were absorbed with pooled platelets and/or PRBC (Section2.3.1 
and 2.8.1)and tested by flow cytometry (Section 2.5) against lymphocytes from pig 64 
for IgG antibody.
pig 64 lymphocytes
No. NAME
s«gg1
i HLA Class 1 antibody specificity
t
LLL
u
HLA class II antit>ody 
specificity
po*t-PRBC-
abiorpt"
poct-PRBC 
and human 
platelet- 
absorpt"
1-3 Abrahams 90 Bw6 72 DR52,(13) 0 . 6 0.9
2-3 AW (patient) 90 A1.2,849,61,++ 78 DR11,12,17,1,+ 0.7 1.4
3-3 Ashdown 14 Cw1(A30,B27) 41 DQ2 0.5 1 . 2
4-3 J.B. (patient) 1 0 0 A1,B35, +++ 1 0 0 Multi ?? 10.3 1.9
5-3 B.B. (patient) 1 0 0 A1,2,3,11,28,++ 56 DR1,4,103,(10),Q2wk 0 . 8 1.3
6-3 R.B. (patient) 32 A2wk 28 DR15.16 0.7 1 . 0
7-3 G.B. (patient) 25 A3,B13,18,60vwk 13 DR4 0 . 8 2.7
8-3 W.B-1 (patient) 30 857,58 0 Negative 0.5 nt
9-3 W.B-2 (patient) 30 857,58 0 Negative 0.5 0.9
10-3 W.B. (patient) 2 B13 90 DR52,DQ2,DR15,16 1 .1 0.9
11-3 J.C. (patient) 90 A2,3,11,23,24,28,857,58,++ 98 DR52.+ 0.7 0.9
12-3 Ching 50 A23,24,32,25wk,B51,57wk 8 8 10,103 0.7 1.3
13-3 CT (patient) 90 B7,+++ 99 Multi; ?DR15,16,51,13,14,++ 2.7 7.2
14-3 Gaffney 25 B44,45wk,50 0 Negative 0,9 1 .1
15-3 R.G. (patient) 90 A2,67,44,45,++ 53 DR1,10,103,15,16,(51) 2 . 8 1 . 0
16-3 W.G. (patient) 64 ÀiS,i?éwk,32.è4Ô,52,44wk, 57wk,58wk, 62wk,63wk,+ 0 Negative 0.7 nt
17-3 Holt-1 43 A1,11,26 (nt 813) 53 DR15,16,51,11,12, +?52 0 . 8 2 . 6
18-3 Holt-2 46 A1,11,23,26,B8vwk 56 DR15,16,17,18,11,12 0.7 2 . 1
19-3 HGH (patient) 90 A2,844,57,++ 1 0 0 DR52,DQ2,+ 0.5 0.9
20-3 Hutchings 2 0 B8,59 78 DR52.DQ2 0 . 6 1 .1
21-3 JAM (patient) 0 CDC negative; FlowPRA positive 26 DR11,13wk,+ 0.5 1.4
22-3 M.J (patient) 54 B51,52,57,58,49,62wk,44wk 56 DR17,18,13,14,8 0 . 6 1.5
23-3 A.J-1 (patient) 75 644,45,49,50,60,61.62,27,13 1 0 0 DR52,DQ1,2 1.9 3.5
24-3 A.J-2 (patient) 25 844,45,50 1 0 0 DR52,DQ1,2 0 . 8 1 . 2
25-3 LA (patient) 6 8 A2,28,24,23wk 28 DR4,53 0 . 6 1.3
26-3 L.L. (patient) 25 B7,27wk, 13vwk,60vwk 75 DR15.16,1,103,10,+74 0 . 6 1 . 2
27-3 M.L. (patient) 2 0 8 8 0 Negative 2.3 1.5
28-3 Lynch 26 844,45 78 DR15,16,51,DQ7,8,9,+ 0 . 8 1 .1
29-3 R.M. (patient) 90 A2,3,23,24,B44,45,57,58,+ 75 DQ2.DR1,15,16 4.7 1.4
30-3 MU (patient) 82 87,13,27,60,61,41,55, A25,29,32,+ 1 0 0 18 0 . 6 1 . 0
31-3 OK (patient) 25 A1 (ntA36) 63 DQ2 0.7 14
32-3 Parsons 8 6 A23,24,25,32,B51,52,49,57,27, 44wk 0 Negative 0.7 1 . 0
33-3 P.P. (patient) 90 A1,2,28,88,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+ 0 . 8 1.9
34-3 M.P. (patient) 1 0 B44wk 0 Negative 2 . 0 3.3
35-3 Pugh 2 1 B55,56,13,35wk 75 DR15,16,4,7,9,+ 0 . 6 1 . 2
36-3 RA. (patient) 53 wk,44wk 70 DR15,16,51,+ 0.7 1 .1
37-3 JR. (patient) 53
814,44,45,35,57,58,62,63,49,50,
Cw1,+ 81 DQ4,DR8,11,12,13,14,+?2,+ 0.9 2 . 2
38-3 D.S. (patient) 11 A30wk,31wk 2 2 weak ? 0 . 8 nt
39-3 B.S. (patient) 1 0 0 A2, 23,24,29,844,+ 1 0 0 Multi; ? DQ5,6,7,8,9,+ 3.1 4.0
40-3 R.V. (patient) 0 Negative 8 8 DR53,DQ3wk 0 . 6 1 . 2
41-3 Welsh 50 A1,11,25,26 8 8 DR52.+ 0.7 1 . 0
42-3 A.W. (patient) 90 A2,28,23,24,B44,+ 1 0 0 DR15,16,11,12,DQ2,+ 2 .1 2.9
43-3 H.W. (patient) 39 A1,11wk,24wk 72 DR15,16,+?1,10,103,+ 1 . 0 1.4
44-3 R.W. (patient) 50 B14,8wk,+ 1 0 0 DR53,DQ3,+ 0 7 1 3
45-3 AB serum 0 Negative 0 Negative 1 .1 nt
46-3 AB serum 0 Negative 0 Negative 1 . 0 1 . 0
Positive control 57.2 70.2
Positive results are highlighted in red (RMdx >2.5).
All values are given in RMdx (relative medium fluorescence). 
HLA Class I antibodies highlighted in pink are IgM only
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reactivity against the lymphocytes of pig 64 by flow cytometry. Absorption with 
human platelets did remove reactivity against pig 64 lymphocytes in sera 4-3, 
15-3 and 29-3 only (RMdx fell 10.3 to 1.9; 2.8 to 1.0 and 4.7 to 1.4 respectively). 
This would indicate that these reactions against pig lymphocytes were due to 
HLA class I antibody. Two sera remained positive, 13-3 and 39-3, suggesting 
that this maybe due to HLA class II antibody. However, a number of sera (7-3, 
17-3, 23-3, 34-3, 42-3) that were negative prior to platelet absorption against pig 
64 gave a positive reaction to pig 64 lymphocytes. This would imply that the 
human platelets might have removed an IgM antibody, thus allowing the 
reactive IgG antibody to be detected.
The above set of experiments has demonstrated that absorption with 
EBV cells and pooled platelets not only remove HLA specific antibodies but also 
reactivity against the pig lymphocytes in most instances. As such, another 
approach was taken. The antibody that reacted against the pig lymphocytes 
would be eluted from the cell surface and characterised. These experiments 
and results are discussed in Chapter 7.
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CHAPTER 7: CHARACTERISATION OF ANTIBODY ELUTED 
FROM PIG LYMPHOCYTES
7.1 INTRODUCTION
Buffers of extreme pH disrupt ionic and hydrogen bonds of protein-to- 
protein interaction. Since the anti-HLA/SLA interaction is probably of high 
affinity, harsh conditions are required to dissociate the two proteins. Therefore, 
a low pH elution method was chosen to remove the bound anti-pig reactive 
antibody from the surface of a pig lymphocyte. However, this method may 
destroy the protein’s physiological activity as the elution conditions often 
irreversibly denature it. As such, once the antibody has been eluted, the eluate 
must be neutralised as soon as possible in order to prevent any further 
dénaturation of the antibody.
Sera were selected for absorption and elution experiments on the basis 
of their reactivity against pig 64 and MPcc lymphocytes. Also included were 
sera that were thought to be weakly positive. In addition, other sera were 
included that had high panel reactive antibodies but which were negative 
against the pig lymphocytes. These two different groups of selected sera, i.e. 
reactive and non-reactive against pig lymphocytes, are separated by a gap in 
the following tables, with the negatively reactive sera at the bottom. The 
antisera were incubated with the pig lymphocytes and the antibody eluted off as 
described in Section 2.9, which was then followed by experiments to identify the 
antibody.
7.2 EVALUATION BY CDC AND FLOW CYTOMETRY OF HUMAN SERA
PRE- AND POST- PIG 64 LYMPHOCYTE ABSORPTION
A number of different PRBC-absorbed sera were selected for these 
experiments. Sera positive against pig 64 lymphocytes (blood group O) were 4- 
3, 13-3, 15-3, 23-3, 27-3, 29-3, 34-3 and 39-3, and also included was sera 42-3, 
which was thought to be weakly positive as described earlier in Table 5.4. Three 
antisera (5-3, 32-3,33-3) with a high panel reactive antibodies for HLA class I 
and class II, but negative with pig 64 lymphocytes were selected as control sera 
for the elution experiments. Also included were the two AB negative controls
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sera 45-3 and 46-3. The sera were absorbed as described in Section 2.8.3. The 
pig 64-absorbed sera and pre-lymphocyte absorbed sera were examined for 
reactivity by CDC and flow cytometry against the pig 64 lymphocytes (Sections
2.6.2 and 2.5). Results are shown in Table 7.1. Positive results are highlighted 
in red. It can be seen that only pre-pig 64 absorbed sera 27-3, 29-3, 33-3 and 
39-3 were positive when tested back against the lymphocytes from pig 64 by 
CDC, indicating an IgM or high titre IgG antibody. All other samples were 
negative pre-and post-pig 64-absorption. Flow cytometric analysis was 
performed on the post-pig 64-absorbed supernatant by testing back against pig 
64 lymphocytes and examining for bound IgG antibody. Most samples were 
negative for the presence of IgG antibody to pig 64 as can be seen in Table 7.1, 
indicating that the antibody that reacts with pig 64 had been adsorbed onto the 
lymphocytes. Serum samples 27-3 and 39-3 post-pig 64-absorption continued 
to react with the pig lymphocytes indicating not all antibody had been removed 
by the pig lymphocytes.
The pre-and post-pig 64-absorbed sera were also examined for the 
presence of IgG HLA specific antibody by testing against EBV pools-1 and -2 
Table 7.2 shows that serum 27-3 was negative as expected as this serum 
contains an IgM HLA antibody and serum 34-3 was also negative (see Section
6.3 for fuller explanation). All other samples tested positive, as shown in red, for 
IgG antibody against the human EBV pools. Although the pig lymphocytes had 
absorbed out an IgG antibody, some HLA activity remained in the sera.
The antibodies bound to the pig lymphocytes were eluted as described in 
Section 2.9 and assessed for reactivity against the target lymphocytes, as the 
eluted antibodies should react back with these pig 64 cells.
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7.3 PIG 64 ELUATES ASSESSED FOR REACTIVITY AGAINST PIG
LYMPHOCYTES
All the eluates were tested back against the lymphocytes from pig 64 by 
flow cytometry (Section 2.5) to investigate if the eluted IgG antibody was still 
reactive against the pig 64 lymphocytes. Table 7.3 shows the examination of pig 
64 eluates tested back with pig 64 lymphocytes. As a comparison, results from 
the PRBC-absorbed sera against pig 64 lymphocytes are also included in this 
table. Positive results are shown in red. Two eluates (27-3 and 29-3) showed 
much less reactivity against pig 64 splenocytes compared the pre-absorption 
samples. It maybe there was insufficient antibody in the eluate or the antibody 
had denatured in the preparation. As expected, the negative control eluates did 
not react with the pig lymphocytes. The eluate from serum 42-3, which was 
considered possibly weakly positive (RMdx 2.4) against pig 64 post-PRBC- 
absorption, was now positive (RMdx 3.2). In addition, the eluates for sera 13-3, 
15-3, 23-3 and 39-3 now reacted more strongly against the pig 64 lymphocytes, 
whilst eluate 4-3 was weaker against pig 64 lymphocytes. These differences in 
reactivity may be due to the quantity of antibody present in the eluates.
The eluates were also tested against other pig lymphocytes (56, 59 and 
60) to which they had reacted against post-PRBC-absorption for the presence 
of IgG antibody by flow cytometry. Table 7.4 illustrates that only eluate 4-3 was 
reactive with all the pig lymphocytes tested. The RMdx values are also given 
post-PRBC-absorption, for comparison. Positive values are highlighted in red. 
Eluates 5-3, 32-3, 33-3, 45-3 and 46-3 are negative controls. The eluate from 
this serum shows a reduction in the amount of antibody binding to pig 56, 59 
and 60 lymphocytes. Eluates 13-3, 15-3, 27-3, 29-3 and 34-3 were negative. 
Eluates 23-3, 39-3 and 42-3 were not tested, as there was insufficient sample to 
perform the assay. Thus, the antibody present in the pig 64 eluate was not the 
same as that which bound to the pig lymphocytes (Section 5.3) whereas the 
antibody in eluate 4-3 may possibly be.
As the eluates reacted back against pig 64 lymphocytes, an antibody 
was obviously present. Given that the eluate antibody was derived from sera 
with HLA specific antibodies, the next step was to try and identify the antibody 
and its specificity.
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TABLE 7.3 Examination of pig 64 eluates tested back with pig 64 
lymphocytes. Selected HLA specific antisera were reacted with pig 64 
lymphocytes and eluted as described in Section 2.9. The eluates were tested 
back against pig 64 eluates for IgG antibody by flow cytometry (Section 2.5). 
As a comparison results from the PRBC-absorbed sera against pig 64 
lymphocytes are also included in this table. Eluates 5-3, 32-3, 33-3, 45-3 and 
46-3 are negative controls.
No. NAME
§LnHLA class 1 antibody specificity llc u. si HLA Class II antibody specificity post PRBC- absorpt" eluate from pig 64
4-3 J.B. (patient) 1(X) A1.B35, +++ 1 0 0 Multi ?? 10.3 2.8
13-3 CT (patient) 90 B7.+++ 99 ?OR15,16,51,13,14,++ 2.7 4.2
15-3 R.G. (patient) 90 A2,87,44.45++ 53 DR1,10,103,15,16,(51) 2.8 4.0
23-3 A.J-1 (patient) 75 644,45,49,50,60,61,62,27,13 1 0 0 DR52,DQ1,2 2.5 4.9
27-3 M.L. (patient) 2 0 8 8 0 Negative 2.5 1.2
29-3 R.M. (patient) 90 A2,3,23,24,844,45,57,58,+ 75 DQ2,DR1,15,16 4.7 2.1
34-3 M.P. (patient) 1 0 844wk 0 Negative 2.6 2.6
39-3 B.S. (patient) 1 0 0 A2,23,24,29,844,++ 1 0 0 Multi; ? 005,6.7,8,9,+ 3.1 4.3
42-3 A.W. (patient) 90 A2,28,23,24,844,++ 1 0 0 DR15,16,11,12,DQ2,+ 2.4 3.2
5-3 B.B. (patient) 1 0 0 A1,2,3,11,28,++ 56 DR1,4,103,(10),Q2wk 0.8 1.1
32-3 Parsons 6 6 A23,24,25,32,B51,52,49,57,27, 44\wk 0 Negative 0.7 0.9
33-3 P.P. (patient) 90 A1,2,28,88,35,+ 94
DQ7,8,9,DR15,16,+?10,
1 1 .+ 0.8 1.3
45-3 AB serum 0 Negative 0 Negative 1.1 0.9
46-3 AB serum 0 Negative 0 Negative 1.0 1.1
Positive control 7.2 45.6
Positive results are highlighted in red (RMdx >2.5).
All results are expressed as RMdx = relative medium fluorescence. 
HLA class I antibodies highlighted In pink are IgM only
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7.4 PIG 64 ELUATES EXAMINED FOR PRESENCE OF HLA CLASS I 
AND II ANTIBODY
In an attempt to evaluate if the specificity present in the eluates was due to 
IgG HLA specific antibody, they were initially tested against the EBV pools-1 
and -2 by flow cytometry to detect IgG antibody. Table 7.5 shows that eluate 4-3 
was negative against EBV pool-1 but weakly positive against EBV pool-2; 
eluates 23-3, 39-3 and 42-3 were strongly positive against both EBV pools, all 
with RMdx of >26.9. The eluates from 13-3, 15-3, 27-3 and 34-3 sera did not 
react with either/or EBV pool-1 or -2. This would indicate that only eluates 4-3, 
23-3, 39-3 and 42-3 had any HLA reactivity and eluates that 13-3, 15-3, 27-3 
and 34-3 did not. As expected the negative control eluates 5-3, 32-3, 45-3 and 
46-3 did not react with either of the EBV pools.
Since it had been demonstrated in Section 6.6 that the EBV pools 
sometimes fails to detect HLA specific antibody and in Section 6.7, human 
platelets were absorbing all HLA class I plus possible another antibody, a more 
precise method was employed, namely the FlowPRA™ class I and II screening 
assay. It was also thought that these beads might assist in identifying the 
specificity of any HLA antibody that may be present in the eluate.
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7.4.1 Assessment of Pig 64 Eiuates for Presence of HLA class I
Antibody
The eiuates were screened with the FlowPRA™ class I screening beads 
(Section 2.7.5) to examine if the antibody present was either an anti-HLA class I 
or II antibody. Figure 7.1 demonstrates the difficulty in interpreting these results. 
It can be seen that the eiuates from the AB sera negative controls (45-3 and 46- 
3) and negative control eluate 33-3 moved into the second log decade of the X- 
axis, which indicates that an IgG antibody has bound to the surface of the 
beads. However, the histograms do show a single peak, which may be 
indicative of some 'non-specific' IgG binding, or the FITC fluorochrome binding 
to the beads in a non-specific manner. However, the eluate from the other 
negative control 32-3 was probably negative and eluate 5-3 (also a negative 
control) showed an odd histogram profile. However, if the shape of the 
histogram curves are considered, eiuates 4-3 and 39-3, which show multiple 
peaks, may be positive and eiuates 13-3 and 42-3 possibly positive. Thus, 
eiuates 15-3, 23-3, 27-3, 29-3 and 34-3 would possibly be negative.
Since the results from this assay was considered unreliable, the eiuates 
were subsequently tested by ELISA for the presence of HLA class I antibody 
using QUIKScreen® as described in Section 2.7.4. This assay screens for all 
common HLA class I antibodies and the conjugate was an anti-IgG, IgM plus 
IgA. Table 7.6 shows the O.D values for this obtained for this assay and only 
eluate 4-3 was weakly positive (shown in red) and the other eiuates were 
negative.
The ELISA technique is not as sensitive as flow cytometric assays (van 
Dam et al., 2000), so the eiuates were tested by flow cytometry against the 
platelets from pig 64, which express MHC class I molecules (Lianes eta!.,
2001). Thus, the eiuates were tested against pig 64 and pooled human 
platelets. Table 7.7 demonstrates that none of the eiuates tested were reactive 
against the pig platelets.
From the ELISA results, an HLA class I specific antibody was only 
present in eluate 4-3. The result for the other eiuates were inconclusive when 
tested by FlowPRA™ class I beads. These results would also suggest that no 
HLA class I reactive antibody was present in any of the eiuates. As such, the 
possible presence of HLA class II antibodies was investigated.
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FIGURE 7.1 Pig 64 eiuates tested with FlowPRAclass I screening beads.
Eiuates were tested by flow cytometry as described in Section 2.7.5 for the 
presence of IgG HLA class I specific antibody.
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Fig 7.1
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TABLE 7.6 Presence of HLA class I antibody in eiuates as tested by 
ELISA. Eiuates prepared from pig 64 were tested against selected pig 
lymphocytes by GTI QuikScreen ELISA (Section 2.7.4) for the presence of 
antibody. Eiuates 5-3, 32-3, 33-3, 45-3 and 46-3 are negative controls.
No. NAME
ILU HLA class 1 antibody specificity i|Û HLA class II antibody specificity ELISA O.D.
4-3 J.B. (patient) 1 0 0 A1.B35, +++ 1 0 0 Muiti ?? 0.115
13-3 CT (patient) 90 B7.+++ 99 Multi; ?DR15,16,51,13,14,++ 0.041
15-3 R.G. (patient) 90 A2,87,44,45,++ 53 DR1,10,103,15,16,(51) 0.044
23-3 A.J-1 (patient) 75 644,45,49.50,60.61,62,27,13 1 0 0 DR52,DQ1,2 0.051
27-3 M.L. (patient) 2 0 8 8 0 Negative 0.032
29-3 R.M. (patient) 80 A2,3,23,24.844,45,57,58,+ 75 DQ2,DR1,15,16 0.056
34-3 M.P. (patient) 1 0 B44wk 0 Negative 0.072
39-3 B.S. (patient) 1 0 0 A2,23,24,29,B44.++ 1 0 0 Multi; ? DQ5,6,7,8,9,+ 0.047
42-3 A.W. (patient) 90 A2,28,23,24,844,++ 1 0 0 DR15,16,11,12,DQ2,+ 0.046
5-3 B.B. (patient) 1 0 0 A1,2,3,11,28,++ 56 DR1,4,103,(10),Q2wk 0.047
32-3 Pareons 8 6 A23,24.25,32,851,52,49,57,27,44wk 0 Negative nt
33-3 P.P. (patient) 90 A1.2,28,88,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+ nt
45-3 AB serum 0 Negative 0 Negative 0.036
46-3 AB serum 0 Negative 0 Negative nt
Positive conb'ol 0.664
Cutoff O.D = 0.095 
O.D. = opitical density 
Positive results are highlighted in red. 
nt = sample not tested
HLA class I antibodies highlighted in pink are IgM only
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TABLE 7.7 Investigation of pig 64 eiuates for reactivity against pig and 
fiuman platelets. Flow cytometric analysis of the eiuates tested against pig 64 
and pooled human platelets for IgG antibody. Eiuates 5-3, 32-3, 33-3, 45-3 and 
46-3 are negative controls.
No. NAME
i
L
n HLAotiiss-t4 intibody.spocificity - i l HLA Class II antibody specificity Pig 64 platelets pooled human flatelets -
4-3 J.B. (patient) 1 0 0 A1.B35, +++ 1 0 0 Muiti ?? 1.7 1.3
13-3 CT (patient) 90 B7.+++ 99
Multi;
?DR15,16,51,13,14,++ 1.9 1.2
15-3 R.G. (patient) 90 A2,87.44,45.++ 53 DR1,10,103,15,16,(51) 1.4 1.7
23-3 A.J-1 (patient) 75 B44,45,49,50,60,61,62,27,13 1 0 0 DR52.DQ1.2 nt nt
27-3 M.L. (patient) 2 0 B8 0 Negative nt nt
29-3 R.M. (patient) 90 A2,3,23,24,B44,45,57,58,+ 75 DQ2,DR1,15,16 1.1 1.3
34-3 M.P. (patient) 1 0 B44wk 0 Negative 1.3 1.2
39-3 B.S. (patient) 1 0 0 A2.23,24,29,844,++ 1 0 0 Muiti; ? DQ5,6,7,8,9,+ nt nt
42-3 A.W. (patient) 90 A2,28,23,24,844,++ 1 0 0 DR15,16,11,12,DQ2,+ nt nt
5-3 B.B. (patient) 1 0 0 A1.2.3,11,28,++ 56 DR1,4,103,(10),Q2wk 1.0 1.3
32-3 Parsons 8 6 A23,24,25,32,851,52,49,57.27, 44wk Q Negative nt 1.6
33-3 P.P. (patient) 90 A1,2,28,88,35,+ 94
DQ7,8,9,DR15,16,+?10,
1 1 ,+ nt nt
45-3 - ABaerum 0 Negative 0  ■Negative 1.X) nt
46-3 AB serum 0 Negative 0 Negative 1.0 1.0
Positive control 6.9 146.9
Positive results are highlighted in red (RMdx >2.5).
AH results are expressed as RWIdx- relative medium fluorescence, 
nt = not tested
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7.4.2 Assessment of Pig 64 Eiuates for Presence of HLA class II
Antibody
To detect the presence of HLA class II antibody, the FlowPRA™ screening 
test was used. All five eiuates (including two AB negative controls), which did 
not react with pig 64 lymphocytes, were negative for the presence of HLA class 
II antibody as expected. Only eiuates 23-3, 39-3 and 42-3 were positive and the 
other six, 4-3, 13-3, 15-3, 27-3, 29-3 and 34-3 were negative. Figure 7.2 shows 
the histograms results of the three eiuates that were positive for the presence of 
IgG antibody against the FlowPRA™ class II beads. There is clear shift to the 
right along the X-axis and multiple peaks can be seen.
As the presence of anti-HLA-class II antibody was established, additional 
examination of the positive eiuates was carried out to identify the antibody 
specificity.
7.4.2.1 Characterisation of HLA ciass il antibody in pig 64 eiuates
The three eiuates (23-3, 39-3 and 42-3) that were positive by the 
FlowPRA™ screening test were examined for HLA class II antibody specificity 
by the FlowPRA™ specific test as described in Section 2.7.2.2. These results 
were compared to the results of the PRBC-absorbed antisera. The HLA class II 
antibodies in the PRBC-absorbed serum 23-3 reacted against DR52, DQ5, 6 
and 02. Figure 7.3 shows the raw data demonstrating the dot plots of FL-1 (IgG 
antibody) versus FL-2 (various bead populations within the bead groups) of the 
four groups of beads, comparing the PRBC-absorbed serum and the eluate 
sample. This particular eluate has a ‘shorter’ and weaker HLA-DR52 specificity. 
As described in Section 4.4.1.1 and seen in Table 4.3, each bead population 
RMdx was calculated and sorted in order of highest values to the lowest. This 
can be seen in Table 7.8. The serum donors’ antigens have been crossed out, 
because individuals do not raise antibodies against their own HLA antigens.
This reactivity is similar to that of the eiuates from the serum samples 39- 
3 and 42-3. Figures 7.4 and 7.5 show dot plots of FL-1 against FL-2 and 
although the eiuates show a reduction in specificity, it is not as marked as that 
seen in eluate 23-3. Tables 7.9 and 7.10 shows the RMdx values of these sera 
and their eiuates sorted in order of reactivity. Serum 39-3 had an HLA class II 
panel reactive antibody of 100% demonstrating reactivity towards HLA-DQ5, 
6,7,8 and 9 (and
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FIGURE 7.2 Determination of the presence of HLA class II antibody in 
eiuates by flow cytometry. Histogram results of eiuates tested against 
FlowPRA™ class II beads (Section 2.7.5) for IgG antibody (FL1).
CO
o
FL1
Neg control 
Pos control 
Eluate 23-3 
Eluate 39-3 
Eluate 42-3
905
Chapter 7: Characterisation of Antibody Eluted From Pig Lvmphocvtes
FIGURE 7.3 Dot plot results of serum and eluate 23-3 by the 
FlowPRA’^ “  class II specific test. PRBC-absorbed serum 23-3 and the 
eluate was tested for HLA class II specificity by FlowPRA™. Each group 
of beads are shown as FL-1 (IgG) against FL-2 (separates each bead 
population) for PRBC-absorbed serum 23-3 and the eluate of 23-3.
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FIGURE 7.4 Dotpiot results of serum and eluate 39-3 by the 
FlowPRA™ class II specific test. PRBC-absorbed serum 39-3 and 
the eluate was tested for HLA class II specificity by FlowPRA™. Each 
group of beads are shown as FL-1 (IgG) against FL-2 (separates each 
bead population) for PRBC-absorbed serum 39-3 and the eluate o f 39-
PRBC-absorbed 39-3 ELUATE 39-3
#
a
lo*
Group 1
w 10*FL1
a
"ID* W 10*FL1
Group 2
w 10*
a
FU
Group 3
FL1
a
FU
Group 4
1'0*
208
X
oc
o>.
5
h.
Ri
oai o co «o o» IO (M 00o po 00O) co<ji co(O fso> OO) (O mlO colO
— I—
CM 1 co lf> l '^
1
p coro mco OCO M.CM M;CM M. p
§ o> h- IO (£> o r- 00 CD 00 o> <o N. 00 CD m 00 <o liol
IO CD o> IO IO N IO IO
g IO c£> "» \u> IO to <o IO N IO « \ CM IO \ \IO IO\\\\\
oc
Q ZÔ 5 5 E E E E u> I e1
g s S 2 S s S R S s !"2 s s 2
g HHHH\HH\ HHHHH
g w w w Hg w M- CD\-4" o CM wHM. o CM h- 1 lO" f HM.HHCMH
g m S 00 00 00 - - O) - O) ro 00 M- , U ° - - - co CM O)
a
1O
? % 9CM s 2 % °?CM °?TT 9CM T % CM 2 CM%4 2 4 %$
1
cô 5 5 CM (? 2 5
«?
Ul
<
liJ
01
0:a.
%I
«?
%
3OCLUCO
5   ^
I  s  ;
*: p  T
f  % f
- 'T f' 
? 2  ?
0 CV 0 
\i r  c 
0  co c^  8  g
0 ^  C 
? 8  ?
D IO c
3 N ?
B CD c
3 S ?
3 C
li RI f
B -» 0 
- O 0 
M CM T
B o  ir 
0 OC) cc
) «J Cl
> co c) CM C
- CM 0 
M ^  C
=> p  0 
2 °  h
B CD co
g  “> r> oo 0> h- oo üB OP U0 h B CO ClB h. h IO IIB O» 0p IO IIB Cl? f^  IO h.
g  ^ \w N0 IO w0 IO 0D IO II0 ^ r U ^ N. »^■ h» h
■ lO \ ^  CD Ci, y ^  IO IIB
\ Y r \
g  5 0 IO E E E 1B E s t
g  2 2 2 2 2 co c IO u? 2  S? S? S sB CO B lO 2 ?
g  \
\  ^ \  ^ \  )
ï
Q£ (O T
û  ^
4 '
> o  ■";  ' f  $0  «  cü p IO c2 «  \ p ^  r
V  '
M IO W» M u îi c- ;:  c- \
\ Y
g  ^  "0 00 ^t O) 00 ^  I^  CJ) î:  ï2 CJ) h'  ^  52 M- -,t  00 h■•0 4 ^  CB V- ,- -p- cl «  r- Ri 2
û tç c 
5 CM c
o
0 IO 0
> '«— c
) co hl % c0  oo li M c? «p •»[ % : > IO u B co ^? T't CM -,M -,}■ Cl r CM -,p OO OCr co ^) N -, • -M- ^ :  :- CM r  ^ CM %• P: :- ^  ?   ^ V- ^
g
3  O111 
c ^ "O o =  C % w (0
i n
I s
UJ c
o
CO
EE0)(0
gill
0)20 
c1 8
I
-H2II3
T3 .O ^  OJ to P  00
.2 lo
« ^II
I f
li8
CO
600
0 :CL
i lilIII f 8 8
E
o>êII
S , :
Î îCO C
1 1  8 ^
co o  
1 1
CD
J(0 i
co
c  (0  
co CD
co 3  c  0X0(0
€ . s
m
CD
2CO
30
81
2  (0
O) J5 00 ^
^  c  (O (D in .g>§1
gc
8
O
if
l iill
III
CDx :i.8
1  s
(D CO
!O ^  T3 COn oCSJ
Chapter 7: Characterisation of Antibody Eluted From Pia Lvmphocvtes
FIGURE 7.5 Dotpiot results of serum and eluate 42-3 by the 
FlowPRA™ class 11 specific test PRBC-absorbed serum 42-3 and 
the eluate was tested for H1_A class II specificity by FlowPRA™. Each 
group of beads are shown as FL-1 (IgG) against FL-2 (separates each 
bead population) for PRBC-absorbed serum 42-3 and the eluate of 42-3.
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possibly) DR51. Elution of this antibody from pig 64 lymphocytes has altered the 
specificity to an HLA-DR15, (+/-16), 51 with a weaker DQ5, 6,7,8,9.
Serum 42-2 also had an HLA class II panel reactive antibody of 100% and in 
this case the specificity was possibly anti-HLA-D02, 5,6,11,12,13,14 (and 
possibly) DR51. The eluate shows a slightly weaker antibody with a probable 
reactivity to HLA-DRI 5, (+/-16), 51,11,13,14 plus a weaker DQ5, 6 and others. 
The determination of these antibody specificities was aided by the knowledge of 
these patients HLA class II type and of their failed grafts and/or partner’s tissue 
type. Since these experiments had shown that an HLA class 11 (and possibly an 
HLA class I) antibody could be eluted from pig lymphocytes, it was thought the 
use of SLA typed inbred NIH minipig could help determine the epitopes that 
may be involved in these cross reactions.
7.5 ABSORPTION AND ELUTION OF ANTIBODIES FROM NIH MINIPIG 
OF THE cc (MPcc) HAPLOTYPE
The absorption and elution experiments of HLA antibody were repeated 
using the NIH minipig. As shown earlier in Table 5.4 a number of PRBC- 
absorbed sera reacted with MPcc splenocytes. These PRBC-absorbed sera 
were 5-3, 15-3 27-3, 33-3, 34-3, 39-3 and 42-3, which reacted weakly, whereas 
sera 4-3 and 23-3 reacted strongly. Eiuates were prepared from serum 
samples 4-3, 5-3, 15-3, 23-3, 27-3, 33-3, 34-3, 39-3, and 42-3 and also from 
two sera, 7-3 and 29-3, which may have been weakly positive. PRBC-absorbed 
sera (2-3, 11-3 and 13-3) that did not react with MPcc but had high HLA class I 
and II panel reactive antibodies were included as negative controls. Also 
included was PRBC-absorbed AB serum 45-3 and 46-3, as these samples did 
not have any HLA reactivity.
7.5.1 MPcc eiuates Assessed for Reactivity Against MPcc
Lymphocytes by GDC and Flow Cytometry
All the prepared eiuates (Section 2.9) were tested against fresh MPcc 
lymphocytes by CDC. The negative control was pig serum and the positive 
control was pre-PRBC-absorbed AB serum 45-3 (as it still contained 
xenoreactive antibodies). All the eiuates reacted strongly against the MPcc 
lymphocytes as shown in Table 7.11. All the eiuates showed 100% cell kill
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TABLE 7.11 Investigation of MPcc eiuates tested by CDC. MPcc 
eiuates were tested back against MPcc splenocytes by CDC as 
described in Section 2.6.2. The last 5 eiuates (including two eiuates 
prepared from AB sera) are negative controls.
No. NAME
i
B01
HLA Class 1 antibody specificity
s«J
If HLA Class II antibody specificity Eluate
4-3 J.B. (patient) 1 0 0 A1.B35, +++ 1 0 0 Multi ?? 8
5-3 B.B. (patient) 1 0 0 A1,2.3,11.28,++ 56 DR1,4,103,(10),Q2wk 8
7-3 G.B. (patient) 25 A3.B13.18.60vwk 13 DR4 8
15-3 R.G. (patient) 90 A2.B7.44.45.++ 53 DR1,10,103,15,16,(51) 8
23-3 A.J-1 (patient) 75 844.45.49,50.60.61.62,27.13 1 0 0 DR52,DQ1,2 8
27-3 M.L. (patient) 2 0 B8 0 Negative 8
29-3 R.M. (patient) 90 A2.3.23.24,844.45,57,58,+ 75 DQ2,DR1,15,16 8
33-3 P.P. (patient) 90 A1.2.28.B8.35.+ 94 DQ7,8,9,DR15,16,+?10,11,+ 8
34-3 M.P. (patient) 1 0 B44wk 0 Negative 8
39-3 B.S. (patient) 1 0 0 A2.23,24,29,844.+ 1 0 0 Multi; ? DQ5,6,7,8,9,+ 8
42-3 A W (patient) 90 A2.28.23.24.B44.+ 1 0 0 DR15,16,11,12,DQ2,+ 8
2-3 AW (patient) 90 A1.2,849.61,++ 78 DR11,12,17,1,+ 8
11-3 J.C. (patient) 90 A2.3.11,23,24,28,857,58,++ 98 DR52,+ 8
13-3 CT (patient) 90 87,+++ 99 Multi; ?DR15,16,51,13,14,++ 8
45-3 AB serum 0 Negative 0 Negative 8
46-3 AB serum 0 Negative 0 Negative 8
Positive control 8
MPcc cells plus PCS 2
Positive results are highlighted in red 
8 = 100% cell death 
PCS = foetal calf serum
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(scored as 8). This result was unexpected, as the negative control eiuates 2-3, 
11-3, 13-3, 45-3 and 46-3 were also positive (scored as 8). The reason why all 
the eiuates were cytotoxic is unclear. It is possible that despite dialysing 
overnight, not all the chemicals were removed. Alternatively, the eiuates may 
have become hypertonic, thus rupturing the cells. However, if this were the 
case, the flow cytometric assays would also have been affected and as 
described below this was not the case.
Therefore, another method was used to detect the MPcc eluate reactivity 
against the MPcc splenocytes. The eiuates were tested against MPcc 
splenocytes by flow cytometry (Section 2.5) for IgG antibody. Table 7.12 
demonstrates that eiuates from the ‘negative control’ eiuates (2-3, 11-3, 13-3, 
45-3, 46-3) were negative as expected. Only eiuates 15-3, 33-3, 39-3 and 42-3 
were positive when tested against pig MPcc lymphocytes. For comparison, the 
RMdx values of the PRBC-absorbed sera against pig MPdd is shown in the first 
column. Eluate 4-3 was bordering on weakly positive. All the other prepared 
eiuates were negative. Perhaps it was not surprising that eiuates 7-3 and 29-3 
were negative as these sera were chosen for the experiment as they could have 
been weakly positive (RMdx 2.1). Nonetheless, the other eiuates (5-3, 23-3, 27- 
3 and 34-3) should have been positive since there was an antibody present in 
these sera that was reactive against MPcc cells.
Since it was expected that the majority of the eiuates should react against 
the pig MPcc lymphocytes further work was carried out to investigate if indeed 
these eiuates contained any HLA antibody at all.
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TABLE 7.12 Investigation of MPcc eiuates tested back against MPcc 
lymphocytes by flow cytometry. This table demonstrates the reactions of 
the MPcc eiuates when tested back against MPcc cells. As a comparison 
the RMdx values are given for the sera after PRBC-absorption. The last 5 
eiuates (including two eiuates prepared from AB sera) are negative controls.
Pig MPcc
No. NAME
ê
§1
i f HLA class 1 antibody specificity
11 
T ih
HLA class II antibody 
specificity
PRBC-
absorbed
sera eluate
4-3 J.B. (patient) 1 0 0 A1.B35, +++ 1 0 0 Multi ?? 7.5 2.3
5-3 B.B. (patient) 1 0 0 A1,2,3.11,28,++ 56 DR1,4,103,(10),Q2wk 3.3 1.3
7-3 G.B. (patient) 25 A3,B13,18,60wyk 13 DR4 2.1 1.2
15-3 R.G. (patient) 90 A2,B7,44,45,++ 53 DR1,10,103,15,16,(51) 4.2 2.7
23-3 A.J-1 (patient) 75 844,45,49,50,60,61,62,27,13 1 0 0 DR52,DQ1,2 23.3 2.0
27-3 M.L. (patient) 2 0 B8 0 Negative 4.1 1.2
23-3 R.M. (patient) 90 A2,3,23,24,B44,45,57,58,+ 75 DQ2,DR1,15,16 2.1 1.2
33-3 P.P. (patient) 90 A1,2,28,B8,35,+ 94 DQ7,8,9,DR15,16,+?10,11,+ 3.8 5.7
34-3 M.P. (patient) 1 0 B44wk 0 Negative 3.1 2.0
39-3 B.S. (patient) 1 0 0 A2,23,24,29,B44,+ 1 0 0 Muiti; ? 005,6,7,8,9,+ 3.0 3.8
42-3 A.W. (patient) 90 A2,28,23,24,B44,+ 1 0 0 DR15,16,11,12,002,+ 3.2 2.5
2-3 AW (patient) 90 A1,2,B49,61,++ 78 0R11,12,17,1,+ 1.3 1.2
11-3 J.C. (patient) 90 A2,3,11,23,24,28,857,58,++ 98 0R52.+ 0.9 1.2
13-3 CT (patient) 90 87,+++ 99 Multi; ?0R15,16,51,13,14,++ 1.2 1.1
45-3 AB serum 0 Negative 0 Negative 1.0 1.2
46-3 AB serum 0 Negative 0 Negative 1.0 1.2
Positive control 45.7 108.8
Positive results are highlighted in red (RMdx >2.5).
All results are expressed as RMdx = relative medium fluorescence. 
HLA class I antibodies highlighted in pink are IgM only.
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7.5.2 Assessment of Pig MPcc Eiuates for the Presence of HLA
Antibody
The MPcc eiuates were screened by flow cytometry (Section 2.5) using 
EBV pools-1 and -2 for the presence of IgG antibody. These eiuates were also 
screened for the presence of HLA class II antibody using FlowPRA™ class II 
screening beads (Section 2.7.5). Table 7.13 illustrates that all the MPcc eiuates 
failed to react with the human EBV pools-1 and-2 for IgG antibody. However, 
three eiuates 33-3, 39-3 and 42-3 reacted with the FlowPRA™ class II 
screening beads indicating that there was an HLA class II antibody present. The 
presence of HLA class I antibody was not screened for by FlowPRA™ class I 
screening beads. The last 5 eiuates (including two eiuates prepared from AB 
sera) are negative controls. Unfortunately, there were insufficient eluate 
samples, to carry out further work.
From the above results from Section 7.4, the presence of an HLA class II 
antibody that cross-reacts with pig lymphocytes was confirmed.
The next step was to attempt to sequence the SLA antigens of the outbred 
pigs, particularly pig 64, and try to identify any epitopes, which could account for 
this cross-reactivity between HLA class II and SLA class 11 antigens.
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7.6 SEQUENCING OF SLA CLASS I GENES
The initial strategy was to use cDNA to sequence the MHC class I region 
of pig 64. A method was developed using human lymphocytes, however, it was 
decided after a meeting with Dr Paul Dunn (UKTSSA, Bristol) that a sequence 
based typing (SBT) approach would be as effective. Paul Dunn was consulted 
as he has vast experience using this method and has developed it for routine 
use for sequencing the human HLA class I and II genes.
The primers were based on a SBT method developed by Dr Doug Smith 
(Oklahoma City, USA; personal communication) for typing the inbred Yucatan 
minipig (Section 2.12).
7.6.1 Isolation and Amplification of Porcine DNA
Pig DNA was prepared as described in Section 2.10 and the concentration 
measured (Section 2.11). Table 7.14 gives the O.D. of the pig DNA from pigs 
43, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 59, 60, 61,62 and 64. From these 
results, the DNA samples were diluted to a concentration of 50ng/pl.
Pig 62 DNA was selected (as it was high-quality and quantity of DNA) for 
the first amplification cycle with primers listed in Section 2.12. After the 
amplification of the DNA with the primers, the amplified product was run on a 
0.8% agarose gel. After visualisation of the gel, no product bands could be 
seen. The process was repeated with DNA from pig 47, 48 and 56, as the DNA 
was high quality. Once again, no amplified products could be seen.
The DNA samples and primers were sent to Paul Dunn (UKTSSA, Bristol) 
and again no amplified product was visualised.
Doug Smith (Oklahoma City, USA) was contacted regarding the lack of 
amplification of the porcine DNA. His response was that the SLA1 and SLA7 
primers used do not always amplify with every pig breed, as some do not have 
these alleles. The NIH minipig haplotype aa do not have a SLA7 (PD14) allele 
at this locus and the NIH minipig cc do not have the SLA1 (PD1) allele. Thus, it 
would appear that all the pigs tested did not have the SLA1 or SLA7 allele.
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TABLE 7.14 Measurment of porcine DNA concentration. O.D. at 
26Gnm measures the DNA and at 260nm measures any contaminating 
protein. In general highly pure DNA has an A260/A280 ratio >1:8
pig DNA 
No. Voi ul
O.D.
280nm
O.D.
260nm
A26o/A20o
ratio
Total 
DNA ug
Total 
DNA ug/ul
43 100 0.112 0.193 1.72 38.6 0.386
47 50 0.031 0.064 2.06 6.4 0.128
48 50 0.014 0.031 2.21 3.0 0.060
49 100 0.116 0.197 1.70 39.4 0.394
50 100 0.649 1.039 1,60 207.8 1.078
51 200 0.089 0.132 1.48 52.9 0.264
52 450 0.176 0.305 1.73 274.5 0.610
53 200 0.163 0.291 1.79 116.4 0.582
54 250 0.157 0.234 1.49 117.0 0.468
55 300 0.184 0.331 1.80 198.0 0.660
56 250 0.205 0.379 1.85 189.5 0.759
59 1200 0.395 0.662 1.68 1588.8 1.324
60 450 0.133 0.257 1.93 231.3 0.514
61 700 0.103 0.179 1.74 250.6 0.358
62 300 0.351 0.663 1.89 397.8 1.326
64 350 0.309 0.603 1.95 361.8 1.206
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CHAPTER 8; DISCUSSION
8.1 OVERVIEW AND AIMS
Solid organ transplantation is often the only option for those patients who have 
reached end stage illness; without a transplant, such a patient would either die or 
have a poor quality of life. Transplant success rates are steadily improving with the 
application of increasingly successful immunosuppressive agents and continued 
development in our understanding of the mechanisms that causehyperacute rejection 
and acute rejection. However, more and more patients have to wait longer for a 
transplant, as the supply of human organs is limited. Unfortunately those patients 
who have become sensitised to the polymorphic HLA antigens by either transfusion, 
pregnancy or failed transplants, may wait decades for a suitable organ. To tackle this 
problem in the future the use of animal organs may be a viable way to supplement or 
replace allografts. For a variety of reasons (see Section 1.7.1 ) the pig has been 
selected as the preferred species for xenotransplantation. However, when species 
barriers of widely disparate species are crossed, hyperacute rejection occurs, which 
is dominated by naturally occurring xenoreactive antibody mediated mechanisms 
(Perper and Najarian, 1966). There are various potential therapeutic measures that 
can be used to control/overcome hyperacute rejection, resulting from xenoreactive 
antibodies. In allotransplantation, the importance of allo-HLA antibodies in transplant 
rejection in heart and renal transplants has been widely acknowledged and the 
detection of circulating HLA specific antibodies prior to transplantation is a major 
requirement to avoid hyperacute rejection of the graft (Kissmeyer-Nielsen ef a/., 1966; 
Mullins et al., 1989; Ogura et al., 1992; Patel and Terasaki, 1969; Singh et al., 1983). 
In xenotransplantation, a positive crossmatch due to preformed antibodies would also 
be a contraindication to successful transplantation.
Polyclonal HLA antibodies with polyspecific reactivity often are ‘cross 
reactive' with HLA antigens, which share either a common or similar epitopes. As
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there is approximately 75 - 87% homology between HLA and SLA it might be 
expected that some HLA antibodies would react with certain SLA antigens.
To examine this possible occurrence, well characterised HLA specific sera 
were selected from highly sensitised patients (panel reactive antibodies >85%), 
antisera with limited specificity, and sera without any HLA reactivity were used in 
this current study. The aims of this study were to remove all anti-pig reactive 
antibodies by using PRBC and to demonstrate that any remaining XNA in the HLA 
specific antisera was not the cause of reactivity against pig lymphocytes. All sera 
were comprehensively tested to demonstrate that this was the case. The HLA 
antisera (some with the same/similar HLA specificity) were tested against a panel 
of pig lymphocytes to examine if there was any pattern of reactivity of the HLA 
antisera against these cells. To prove that the reactivity against the pig 
lymphocytes was due to HLA specific antibodies, the HLA antibodies were 
absorbed out of the sera by the use of pooled human EBV cell lines and pooled 
human platelets and reactivity against the pig lymphocytes were studied. Those 
antibodies that bound to the pig lymphocytes were eluted and assays were carried 
out to characterise the specificity of the eluted antibody. If this eluted antibody were 
shown to be HLA, this specificity would be established and investigated for 
possible epitope matches between HLA and SLA.
Several groups have shown that highly HLA-sensitised human sera can 
have non-Gala1-3Gal reactivity against pig lymphocytes (Naziruddin etal., 1998; 
Oostingh et al., 2002; Taylor et al., 1998). H LA-specific sera can cross-react with 
HLA that have common or similar epitopes. Also it is known that SLA has 80% 
homology with HLA. The data from the research in this thesis indicates that 
particular HLA class II antibodies will bind to cross-reacting epitopes on particular 
pig lymphocytes. However, a few sera with the 'same' anti-HLA class I specificity 
did not always react with the same pig lymphocytes, highlighting the polyclonal 
nature of HLA antibodies.
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8.2 REMOVAL OF ANTI-PIG REACTIVITY
The results from these studies show that the use of PRBCs to remove IgG 
anti-pig specific antibody was successful. This observation was based on the fact 
that after absorption with PRBCs all IgG anti-pig reactivity against PRBC and/or pig 
lymphocytes was eliminated. In all of the sera pre-PRBC-absorption, XNA was 
detected either by CDC or flow cytometry when tested against PRBC and pig 
lymphocytes. However, serum 28 did not react against pig lymphocytes by flow 
cytometry but was positive against PRBCs by CDC. This indicates that this 
patient’s serum contained only IgM anti-pig antibody. A very small number 
individuals do not have IgG anti-Gala1,3Gal, but have IgM only (J.Lee, personal 
communication).
Since it is known that human anti-pig natural antibodies are specific for the 
Gala1,3Gal epitope that causes hyperacute rejection, all samples were tested by 
specific Di- and Penta-Gala1,3Gal ELISAs (Good ef a/., 1992). Although a very 
small number of the antisera were positive for the presence of anti-Di- and Penta- 
Galal ,3Gal-saccharide post-PRBC-absorption, the presence of this antibody did 
not interfere with any of the subsequent assays against pig lymphocytes. However, 
it could be argued that serum 20, which was Di- and Penta-saccharide positive by 
ELISA, was also positive against the two pig lymphocytes tested. These reactions 
may be due to residual anti-pig reactivity. In the Series 1 experiments, 15 of the 20 
sera were anti-Penta-saccharide positive. This was in contrast to the Series 2 
samples, where only 5 out of the 18 samples were positive. Since in the first 
Series the Penta-saccharide was conjugated to BSA, this discrepancy between 
Series 1 and 2 may reflect the presence of anti-BSA antibodies that are 
occasionally present In normal human serum (Falchuk and Isselbacher, 1976). 
Another contributing factor could be that the antisera were diluted 1:2 with PBS. A 
dilution of 1:4 is optimum, which prevents a high background due to any anti-BSA 
antibodies that may be present in the antisera (McKane ef a/., 1998). Of the 13 
sera that were negative for anti-Penta-saccharide in Series 2 by ELISA, 16 sera 
(including the AB negative control) were positive when tested against RRBCs for 
IgG reactivity. Serum sample 29, which contained an anti-Penta antibody, was
222
Chapter 8:__________________________________________________________________ Discussion
negative against the RRBCs. These results would suggest that these sera contain 
a specific anti-rabbit antibody, which did not cross-react with pig lymphocytes. 
Furthermore, the presence of residual Penta-saccharide antibody in any sample 
did not react with RRBCs. The removal of the anti-Penta activity by absorption with 
RRBCs did not diminish the sera’s reactivity against pig lymphocytes. Moreover, 
serum 16, which was anti-Di- and Penta-saccharide negative, was positive against 
pig 41 lymphocytes, indicating that HLA antisera, negative for XNA, still reacted 
against pig lymphocytes. Despite any residual anti-Galal ,3Gal activity in some 
sera, the majority did not react with most of the pig lymphocytes tested. Since 
these results show the effectiveness of PRBCs to absorb out anti-pig reactivity due 
to XNA, further tests to confirm this in the Series 3 experiments was considered 
unnecessary. Other groups have also used this method to remove XNA, and 
showed that by using a specific Galal ,3Gal ELISA that 95% or more of the XNA 
was removed (Oostingh et al., 2002; Taylor et al., 1998). These groups have 
suggested that the residual Galal ,3Gal antibody was probably of low affinity, which 
bound to the aGal substrate in the ELISA but not to the membrane Gal epitopes. 
Whilst this may be so, it has been demonstrated that in some individuals, who have 
anti-Penta reactivity detected by ELISA, the Penta specific antibody fails to bind to 
pig lymphocytes (McKane et al., 1998). This would imply this phenomenon might 
be occurring in the serum samples of the current study, indicating the polyclonal 
nature of the XNA repertoire in normal human serum.
8.3 EFFECT OF ABSORPTION ON HLA ANTIBODIES
The use of RRBCs and/or PRBCs to absorb out XNA antibody did not affect 
the HLA antibody specificity in the antisera. There was a small dilutional effect 
post-absorption, which could be seen in the flow cytometric experiments but not 
CDC. However, serum 19 did show that PRBC appeared to remove an anti-HLA- 
A2 when tested against two human PBLs. Serum from this individual was tested by 
flow cytometry in the Series 2 experiments (serum 22a) and was positive against a 
human splenocyte. In the latter situation, the serum was taken on a different date 
and the positive reaction against the human splenocyte could have been due to
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other HLA antigens on the ceil. Unfortunately, this experiment was not repeated 
using the same cells and PRBC-absorbed serum. Nevertheless, in Series 3 this 
situation was not seen in any of the 39 PRBC-absorbed sera tested by GDC (to 
confirm HLA reactivity was still present). Thus, it is likely, the negative result seen 
with serum 19 may be an experimental error, but this would require confirmation.
8.4 HUMAN HLA REACTIVITY AGAINST PIG LYMPHOCYTES
The PRBC-absorbed sera, when tested against a panel of pig lymphocytes, 
showed distinctive reaction patterns in the Series 3 experiments. This was an 
attempt to evaluate if any of the human antisera and/or pig lymphocytes would give 
the same reaction pattern. The results show that no two sera reacted with the 
same pigs. Only 19.4% of the flow cytometric data resulted in a positive reaction. 
This figure is similar to recently published data showing that 20% of the sera tested 
reacted with the pig lymphocytes used (Oostingh et a/., 2002). However, in this 
study the authors had included many more sera that did not have any HLA 
antibody present. This is in contrast to data from another study, where 67% of their 
patient's sera with a high HLA class I panel reactive antibodies reacted against the 
pig panel used (Taylor et al., 1998). Taylor et al. used four unrelated large white 
pigs, which were tested against 13 highly sensitised patient sera. However, in the 
current study (Series 1 and 2), when small numbers of serum samples and a panel 
of pig lymphocytes were used, this high frequency of positive reactions against pig 
lymphocytes was not seen. This was probably due to the serum selected, as not all 
samples were from highly sensitised patients. This is in contrast to Taylor et al.,
(1998) who selected sera only from highly sensitised patients.
Oostingh et al. (2002) used a similar number of human serum samples and 
pigs as in the current study, and the same percentage of positive reactions was 
found. In their case, they used the pigs from an Imutran hOAF transgenic herd.
This implies that this herd, which probably has a smaller genetic pool than the 
outbred pigs used for the current study (which came from an abattoir, supplied 
from different farms) probably have similar SLA alleles.
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In a study by Naziruddin et ai, (1998) purified anti-HLA serum from nine 
patients with varying panel reactive antibodies were all positive with a minipig, 
haplotype dd. In the study described in this thesis (Series 3), only 12 (30.8%) of the 
39 sensitised patients for IgG HLA class I antibodies were positive. This difference 
may reflect the different techniques used. Naziruddin efa/., (1998) used purified 
HLA serum, which probably had a higher titre of antibody than the serum used in 
the current study, which was unmodified. Therefore, they may have detected the 
presence of very weak antibodies that bound to the pig lymphocytes. This group 
also showed that the 9 purified HLA antisera reacted (with varying degrees of 
binding) against all the 6 pigs used in their study. The XNA IgG antibody was 
removed by passing the IgG fraction down a melibiose and porcine thyroglobulin 
column. Melibiose does not bind with a high affinity to XNA, and thus would not 
remove all antibody (Thibaudeau et al., 1994). In addition the ELISA used to test 
for the absence of XNA was performed using Griffonia simplicifolia type I lectin, 
isolectin B4 (GS-IB4). Although this lectin recognises the Gala1,3Gal epitope, it is 
not reactive with all XNA (Lin et al., 1998b). Many different molecules are 
galactosylated by the a1,3- galactosyltransferase on the porcine endothelium, and 
the polyclonal nature of the XNA has been demonstrated in normal human serum 
(McKane eta!., 1998; Vaughan, McKenzie and Sandrin, 1995). Thus a single 
assay to detect the presence of XNA would be insufficient. The results obtained by 
Naziruddin et al., (1998), which demonstrated 100% binding of ‘anti-HLA’ antibody 
to pig lymphocytes, may be due to some residual XNA that was reacting against 
pig lymphocytes. On the other hand, these authors demonstrated by Western 
blotting of purified SLA antigens that the HLA-purified sera recognised a 45kd 
band, which is indicative of an SLA heavy chain, whilst the negative controls did 
not.
This wide variation in the results seen in the published data and in this 
current study probably reflects the antisera selected, the breed of pig used and the 
methodology used to absorb out the Galal ,3Gal specific XNA. The work in this 
current thesis has proven that PRBCs are an excellent matrix to use to absorb out
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the Galal ,3Gal specific XNA and moreover, this was rigorously tested to ensure 
this was the case.
8.5 POTENTIAL ROLE OF IgG NON-HLA ANTIBODIES
The role of IgM-HLA antibodies in allo-transplantation outcome remains 
controversial. Thus, for this study only IgG was Investigated in any depth. 
However, four serum samples that had IgM HLA class I only, were included since 
initially it had not been determined whether or not a low titre of IgG anti-HLA was 
also present in these sera. From the screening data, using both EBV-transformed 
cell line pools and Flow PRA™ screening, the presence of IgG anti-HLA was not 
detected. Surprisingly one (27-3) of the four IgM anti-HLA sera reacted with 46.7% 
of the pig lymphocytes. The antibody detected was IgG, as the presence of IgM 
was not tested for. In addition, this serum did not contain any HLA class ll-specific 
antibody. The IgG antibody in the eluate prepared from this serum, failed to react 
back against the pig lymphocytes to which the antibody originally bound. This may 
be due to dilution or dénaturation of the antibody in the eluate. Nonetheless, this 
serum contained an IgG anti-pig antibody and whether this antibody would be 
deleterious in transplantation remains to be evaluated.
From the above data there appears to be some epitopes recognised on 
porcine lymphocytes by certain of the anti-HLA sera that may not be anti-species. 
Alternatively, it may be that some pig lymphocytes present a target for an antibody 
other than anti-HLA.
8.6 NON-HLA CLASS I REACTIVITY OF SERA
A small panel of human lymphocytes were treated with a low pH solution to 
remove the HLA class I molecule and were tested against the Series 3 sera pre- 
and post-PRBC-absorption. The majority of results were negative supporting the 
premise that the positive reactions prior to low pH treatment of the cells were due 
to HLA class I antibody/antigen reactions. However, there were 15 instances were 
there was a positive reaction after acid treatment of the cells, indicating another 
target, other than HLA to which the IgG antibodies were reacting. In 7 cases
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(15.2%), this non-HLA antibody was removed by PRBC absorption and in 7 
instances it was not. In the cases where the non-HLA antibody was removed by 
the PRBCs, it may be that an IgG specific or polymorphic pig antibody present in 
the human serum reacts with some human PBLs and pig lymphocytes. Since 
heterogeneity of carbohydrate moieties expressed on cells from different lineages 
has been reported, it may be that some of these antibodies present in some human 
serum recognise a determinant on PRBCs (Barclay et al., 1976). Certainly there is 
heterogeneity within the xenoreactive natural anti-carbohydrate antibodies, which 
always include the IgM isotype and that bind in a temperature dependant fashion 
and with similar functional avidity (Economidou, Hughes-Jones and Gardner, 1967; 
McKane et al., 1998; Parker et al., 1994). The IgG component of these antibodies 
is obviously not autoreactive in vivo (as no pathogenesis was reported) but may 
also bind in a temperature dependant fashion or may be reactive in vitro only.
There was one case (serum 15-3), which gave discrepant results. In this 
situation post-acid treatment abrogated the reaction, (signifying an HLA class I 
antibody) but after PRBC absorption there was a strong positive reaction. This may 
be due to either experimental error or perhaps to a high titre, non-HLA antibody, 
which was non-complement fixing or was inducing a prozone effect and that was 
absorbed by PRBCs. After absorption with PRBCs, a ‘third’ complement fixing, 
non-HLA antibody may recognise a non-HLA determinant or a cryptic antigen 
exposed by acid-treatment.
There were three sera that appeared to have non-HLA antibodies, which 
were reactive against some pig lymphocytes. These were: I) serum 27-3, which 
only has an IgM HLA-B8 antibody, reacted against 46.7% of the pig lymphocytes. 
The eluate prepared from this serum failed to react back against the pig 64 
lymphocyte as discussed earlier. This serum also showed that absorption with EBV 
cells removed an antibody that was reactive against pig lymphocytes. However, 
this serum did not have any IgG reactivity against the EBV pools. It was confirmed 
that there was no IgG HLA antibody present in this serum by flow cytometry, it is 
possible that the absorption with the EBV pools diluted the antibody, resulting in a 
negative result. This data was only shown against a single pig and thus this work
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should be repeated not only against the same pig but also with other pigs the 
antibody was binding to. ii) Serum 34-3, which has a limited IgG HLA-class I 
antibody only, reacted against 80% of the pig panel. Although the eluate prepared 
from this serum reacted back against the pig lymphocyte, no HLA class I or II 
antibody could be detected in it. Since it could be argued that the detection of an 
antibody reactive against HLA class I was flawed in this study (due to the eluates 
showing an unusual histogram profile by flow cytometry, being toxic by CDC and 
possible dilutional effects) the presence of a reactive HLA class I antibody still has 
to be considered. Furthermore, when all the anti-HLA class I antibody was 
removed from this serum, it continued to react (albeit weaker) against pig 
lymphocytes, iii) Serum 13-3, which reacted against 46.7% (but not the same pigs 
as serum 27-3) showed that in the platelet absorption experiments this reactivity to 
pig 64 could be due to an HLA class II antibody. However, an HLA class II specific 
antibody was not detected in the eluate although the RMdx was of a similar value 
to those eluates that did have HLA class II antibody detected. Once again, the 
presence of an HLA class I antibody in this eluate cannot be ruled out. Other sera 
that showed an increase in IgG binding post-platelet-absorption may also indicate 
the presence of another non-HLA antibody present in these antisera.
There are reports that human non-a-galactosyl antibodies are reactive 
against porcine tissue (Macchiarini etal., 1998; C.Taylor personal communication). 
It Is evident that further work is required to elucidate the target or targets these 
antibodies may recognise, although there are issues of Incomplete removal of 
Galal ,3Gal antibody. If these antibodies activate the complement system, promote 
neutrophil adhesion on endothelial surfaces, and cause IL-1a synthesis, this would 
have an undesirable outcome on the transplant (Vercellotti et al., 1991). IL-1a 
synthesis would mediate endothelial activation and the loss of heparan sulphate, 
which is critical for endothelial function (Ihrcke and Platt, 1996; Platt et al., 1990). It 
is also possible that non-HLA antibodies binding to the endothelium may promote 
the action of NK (or other cells expressing Fc receptors) and T cell responses 
(Brouard etal., 1999b; InverardI etal., 1992).
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8.7 CORRELATION OF HLA PANEL REACTIVE ANTIBODIES WITH
REACTIVITY AGAINST PIG LYMPHOCYTES
A number of antisera were selected for the work described in this current 
study as they had similar anti-HLA class I or II specificity and variable panel 
reactive antibodies. Upon analysing the HLA panel reactive antibodies, it was 
found that there was increasing reactivity with the pig lymphocytes as the HLA 
class I panel reactive antibodies increased, which was not found for those sera 
with a high (>70%) HLA class II panel reactive antibodies. The data for HLA class I 
was similar to that found by Oostingh et al., (2002). They showed that those sera 
with panel reactive antibodies >64% had a higher incidence of reactivity against 
the pig panel. This was similar to that which was found in this current study. 
However, Oostingh et al., (2002) showed that of those sera with panei reactive 
antibodies <64%, only 0.75% were positive against the pig panel. This is in 
contrast to the current study where it was 8.8%. This variation of results is probably 
due to a number of reasons such as; i) Oostingh et al., (2002) included a higher 
number of sera that were negative for HLA class I antibodies, whereas in this 
current study most of the sera had either a HLA class I and/or class II antibody, ii) 
screening techniques vary between laboratories such as incubation times and cell 
panel used, iii) number of cells and tissue type of the cell panel used and iv) the 
patient population are certainly different, which would denote that the tissue types 
would vary between the different ethnic groups, iiv) the variation between the 
different pigs used in the studies. There is no data on SLA class II antigen 
expression, and limited work regarding SLA class I expression, but there does 
appear that there is variable MHC expression between different breeds and also 
pigs of the same breed but different herds (Velten et al., 1999; Renard et al.,
2001 ). This may account for why some HLA antibodies bind to certain pig’s 
lymphocytes and not to others in an outbred pig population.
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8.8 EPITOPE RECOGNITION BY HLA ANTIBODIES
It is probable that some HLA antibodies recognise either a single amino acid 
residue whilst others recognise conformational epitopes. This can be shown in a 
limited way in HLA antisera 3 and 16, both of which have anti-Bw4 activity. The 
sequence of the Bw4 epitope in humans involves the determinants at positions 79- 
83. Positions 82 and 83 are probably the most critical residues for the Bw4 
specificity (Wan et al., 1986). As both sera 3 and 16 had antl-HLA-Bw4, and 
reacted with pig lymphocytes 41 and not the other pig lymphocytes, it is possible 
that there was a similar epitope present on this pigs lymphocytes.
Although sera 6, 19, 20 and 21 also reacted with pig 41 lymphocytes, it is 
possible the antibodies were recognising other polymorphic residues on the 
porcine cell surface within SLA. In the study by Taylor et al., (1998) they also 
showed an anti-Bw4 serum reactive with one pig lymphocyte and not another. In 
addition, their anti-Bw6 antisera failed to bind to either pig lymphocyte. The Bw6 
epitope is present on >90% of human lymphocytes and the serum (1-3), which had 
an anti-Bw6 specific antibody, failed to react with all 15 pigs, demonstrating the 
pigs used in this study did not have the Bw6 epitope. Sequence data from NIH 
minipigs with the PA1, PCI and PD1 alleles have the Bw6 motif (Leucine81, 
Arginine82, and Glycine83) and not the Bw4 (Alanine81, Leucine82, and 
Arginine83) amino acid sequence. Since most of the pigs tested in this study were 
outbred pigs, it may be that some pig breeds do not express the Bw6 epitope. 
Intriguingly, the anti-Bw6 sera also failed to react with the two minipigs, cc and dd 
haplotypes. This would suggest that the Bw6 epitope in the minipIgs, and possibly 
the outbred pigs, couldn’t be recognised by the human Bw6 specific antibody. This 
may indicate a conformational difference between the HLA and SLA class I 
molecules.
In Series 2 and 3, none of the sera with similar HLA class I specificity 
showed a similar reaction pattern to the pig lymphocytes. This is particularly seen 
with serum samples 14-3 and 34-3, both of which contain anti-HLA-B44 and 45 
(negative anti-HLA class II). The serum sample 34-3, reacted against 80% of the 
pig panel whereas serum 14-3 only reacted with 20% of the pigs tested. However,
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it is clear that despite some antisera having very similar anti-HLA specificity, they 
did not react with the same pig lymphocytes. The antisera used in these 
experiments are polyclonal in nature and it is probable that the antibodies are 
recognising subtly different human MHC residues and by extension different 
epitopes on the SLA antigen.
Human monoclonal antibodies (MoAb) have been used in the past to 
determine SLA types. The human MoAb that is reactive with HLA-A28, 33 and 34 
(5959, 2380 and 2384) reacts against porcine lymphocytes, obviously recognising 
determinants on pig cells (Lunney, 1994; Lunney and Sachs, 1978 and D.Smith, 
unpublished data 1996, Oklahoma, USA). Data also indicates three HLA-B44, 45 
MoAb (1659, 4514 and 7622) also react with pigs. Other MoAb reactive against 
other HLA-A, B, DR and DO antigens have also shown to be reactive against pig 
PBLs. However, another group has demonstrated that a MoAb against a single 
HLA specificity did not cross react with pig lymphocytes whilst those MoAb with 
broad specificities did (Mulder, Kardol and Niterink, 2000). This would indicate that 
it there is public epitopes shared between the HLA and SLA molecules.
Studies have demonstrated that many HLA antibodies can be accounted for 
by recognition of a single amino acid residue (Park etal., 1995). This premise is 
supported by the observation in which two monoclonal antibodies produced 
mutually exclusive reactions, explainable by a single specific residue (Salter and 
Parham, 1989b). Park et al, (1995) demonstrated that allogenic antibodies also 
reacted in a similar fashion. As much as 32% of the HLA-A locus and 13% of the 
HLA-B locus comprised polymorphic residues that functioned as a single epitope 
and to which HLA antibodies reacted. Thus, they found antibodies to antigens, 
HLA-A2, A3, A29, A30, A33, A68, B7, B8. B13, B14, B18, B27, B37, B44, B46,
B54 and B57 that might be controlled by a single amino acid residue. Park et al, 
(1995) also proposed that many multispecific HLA antibodies might also be 
determined by a single amino acid. For example, HLA antibodies that react with all 
A-locus specificities, except HLA-A23 and 24, could be due to the single amino 
acid arginine at position 65 of the a1 helix of the HLA class I molecule.
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Even when a single residue can be identified as the critical epitope for an 
antibody, it is debatable that this is the structure of a serological determinant. Since 
the antibody-binding sites of an immunoglobulin molecule comprise six 
hypervariable loops that make contact with the antigen, the paratope/epitope 
interface involves 3-8 residues (Behoofs et al., 1988). It is possible that in some 
cases only one CDR plays a primary role in binding to the HLA molecule 
(antibodies that recognise a single residue), whilst the other CDRs bind to distinct 
sites on the molecule. Data reveals that this is indeed the case (McCutcheon et al., 
1993). The recognition sites can be made up of sequential residues (continuous 
epitope), or of non-sequential amino acids that are in close proximity to each other 
(discontinuous epitope). For example, each turn of the a-helix of the HLA molecule 
is composed of 3-4 residues that would bring close together the amino acids of 
consecutive turns of the helix. It is proposed that an HLA antibody probably 
recognises discontinuous epitopes more frequently than continuous (Colombani, 
1990). In addition, conformational determinants also play a role in antibody 
recognition (Bluestone etal., 1992; Sherman etal., 1993).
The amino acids exposed at the surface of the molecule are accessible to 
antibody contact. Most of the single polymorphic residues are on the a-helices 
(positions 1-90 for a1 and 91-182 for oc2) on the HLA heavy chain. The 
polymorphic residues in the (3 sheet are probably not directly accessible for 
antibody binding but may play a role in altering conformation of the molecule via 
the peptide (Domena et al., 1993; McCutcheon et al., 1993). The loops connecting 
the a-helices and p-strands can be exposed and as such, involved in antibody 
binding. For example, the loop between the a1 and a2 domains (residues 84-94) 
forms an open structure on the top surface flanking the peptide-binding groove.
Single determinants have been identified and/or unique combinations of 
several amino acids exist, which can be contiguous or recognised by 
conformational changes. In the latter situation, one or several residues may not be 
unique but shared between other molecules as described in the situation of 
recognised public epitopes or CREGs. Allo-antisera are generally polyclonal, 
containing several antibody populations that may be capable of binding to two or
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more epitopes on the same molecule. Several MHC molecules may share these 
epitopes, so called public determinants. Although HLA specific antibodies may be 
accounted for by recognition of a single epitope (private epitope) and certainly the 
literature demonstrates instances of antibodies recognising single amino acid 
residues, the data herein demonstrates that the HLA antisera, despite often having 
the same HLA specificity, rarely (if at all) recognise the same epitope(s) on the pig 
lymphocytes. Thus, predicting amino acid residues on an MHC molecule to which 
polyclonal HLA allo-sera may bind may be problematic.
8.9 REMOVAL OF HLA ANTIBODIES ABROGATES REACTIVITY AGAINST
PIG LYMPHOCYTES
It was evident that IgG HLA class I and/or class II antibodies present in the 
sera of individuals react against pig lymphocytes. The removal of these HLA 
antibodies by absorption with the EBV pools did remove the majority of the HLA 
class I and II antibody reactivity in the sera. This was confirmed by testing the 
absorbed sera back against the EBV pools and also using FlowPRA™ class I and 
II screening beads. In most cases the reactions against the pig lymphocytes were 
abrogated, which strongly suggests that the reaction were due to the presence of 
HLA-specific antibody. Only serum 34-3 (that had all HLA-specific antibody 
removed) still retained reactivity against pig lymphocytes after EBV absorptions, 
indicating that an IgG antibody other than HLA was causing the reaction. As 
mentioned above, this serum also reacted with 80% of the pig panel despite having 
limited HLA class I specificity. Five sera still retained some anti-HLA activity after 
absorptions with the EBV pools. Four had some HLA class I reactivity and one 
serum had HLA class II. Nonetheless, these sera and the others were negative 
when tested back against lymphocytes from a panel of 6 different pigs, indicating 
these residual antibodies did not recognise an epitope(s) on the various pig 
lymphocytes tested.
Absorption of the antisera with human platelets removed IgG reactivity 
against pig 64 lymphocytes in three sera only (4-3,15-3 and 29-3). This suggests 
these reactions against pig lymphocytes were due to the presence of HLA class I
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antibody. Only one of the eluates (4-3) prepared from pig 64 lymphocytes was 
confirmed as containing HLA class I specific antibody by the QuikScreen® ELISA. 
Unfortunately there was insufficient eluate to identify the HLA class I specificity, 
which would have clarified if the reaction in the screening method was indeed due 
to HLA class I antibody. A key weakness of this assay is that a test sample control 
well was not included. Thus, this positive reaction may be due to ‘background 
noise’, which is occasionally experienced by this and other ELISA methods.
Two sera (13-3 and 39-3) remained positive against the pig 64 lymphocyte 
post-platelet-absorption, suggesting that this may be due to HLA class II antibody. 
However, it cannot be ruled out that an HLA class I antibody was not completely 
absorbed out by the platelets. Indeed, If the FlowPRA™ results are to be believed 
for the eluates of these sera, there was HLA class I antibody in the eluate of 39-3. 
Serum 13-3 RMdx was more than twice as high post-absorption with platelets. This 
was also seen in other sera (7-3, 17-3, 23-3, 34-3, 42-3), which were negative prior 
to platelet absorption against pig 64 lymphocytes. This could be due to a non-HLA 
IgM antibody (or antibodies) being removed by the human platelets allowing a 
reactive IgG antibody to be detected. The IgM antibody is fives times larger than 
IgG, which can cause steric hindrance of the IgG antibody.
Taylor et al., (1998) showed a reduction in the antibody binding to pig and 
human PBLs after sera were absorbed with pooled human platelets in three of the 
six sera tested. These authors proposed that in the 3 cases where antibody was 
not reduced, it was probably due to inadequate absorption of the HLA class I 
antibody due to high titres. The presence or absence of HLA class II specific 
antibody was not examined.
Using platelets to absorb out HLA class I reactivity was successful in only 
three instances in the current study. Not all HLA reactivity was removed as when 
these platelet-absorbed sera were tested against pooled EBV cells, they were 
positive. Six sera (6-3, 7-3, 15-3, 21-3, 26-3, and 43-3) that had HLA class II 
specific antibodies were negative against EBV cell post-platelet-absorption. This 
suggests that the EBV pools used were inadequate at detecting some HLA class II 
specificities.
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A number of reasons may account for this occurrence such as i) the 
expression of HLA class I molecules on EBV transformed B cell lines show 
differential expression of the loci (Johnson, 2000), ii) it is known that long-term 
cultures of EBV-transformed B cell lines undergo phenotypic drift (Niedobitek et al., 
1995), iii) the EBV pools in this current study is a combination often cells, which 
may have ‘diluted’ out the DR antigen causing insufficient FITC-binding to the cells 
or some of the cells have died. However, there were four DR4 positive cells In EBV 
pooll, and so this is unlikely. Another possibility is that the DR4 antibody was 
recognising some subtypes of the DR4 antigen and not others. Unfortunately 
these PRBC and platelet absorbed sera were not tested using FlowPRA™ class II 
screening beads, which may have confirmed the absence/presence of HLA class II 
antibody.
8.10 ELUTION OF ANTIBODY FROM PIG LYMPHOCYTES
Eluting an antibody from pig 64 lymphocytes proved to be successful in 
seven of the nine cases. When these eluates were tested for HLA class I reactivity 
only eluate 4-3 contained some HLA class I activity, as discussed previously. In 
addition, the HLA class I reactivity was also absorbed out using pooled human 
platelets. Although platelet absorption indicated two other sera (15-3 and 29-3) 
might have had an HLA class I antibody removed, this could not be confirmed by 
the elution studies. The eluate preparation from serum 39-3 showed a negative or 
very weak reaction when tested back against pig 64 lymphocytes. It is possible, (as 
in the case with eluate 27-3), that the eluates had deteriorated or that there was 
insufficient antibody to be detected. All the eluates were tested against three other 
pig lymphocytes and only eluate 4-3 was positive. The latter contained an HLA 
class I antibody and reacted against all three pig lymphocytes. Thus it is possible 
that the HLA class I antibody was recognising an epitope present on most outbred 
pig lymphocytes.
These results are in contrast to a previous study in which eluted HLA class I 
antibody was eluted from pig kidneys perfused with human plasma with a high 
panel reactive antibodies (Barreau et al., 2000). In this study, in eight of the ten pig
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kidneys, these workers demonstrated the presence of IgG HLA antibody by 
complement dependent cytotoxicity. In five of the eluates HLA class I specificity 
was determined. However, this study only used plasma from one low sensitised, 6 
highly sensitised patients and 5 negative control plasma samples. Data from the 5 
negative controls were not shown. Interpreting the data from this study is difficult, 
but nonetheless it is clear that the presence of HLA class I antibody was detected.
Unfortunately the eluates obtained from the minipig MPcc were all positive 
when tested by CDC back against the pig's splenocytes. A number of possible 
reasons may account for these results, i) buffers of extreme pH disrupt ionic bonds 
between proteins and although the Fab portion and the light chains of antibodies 
resist disruption down to a pH of 2.0 the conformation of the Fc portion deteriorates 
below pH 3.9 (Tigssen). Thus, an altered conformation of the Fc portion of the 
antibody could activate complement. However, the negative controls (negative 
reaction against the MPdd initially) were also positive and thus this theory would 
not apply, ii) The eluates themselves were toxic to live cells even though they were 
dialysed overnight. A pH of 2.3 was used in this study, whereas Barreau et al.,
(2000) used a pH of 3.0 and this may account for the CDC assay failing to work in 
this analysis, iii) The eluates were hypertonic and thus caused lysis of the cells, or 
iv) a more likely explanation is that the eluates contained IgM Galal ,3Gal antibody. 
The sera in this current study were not tested for the presence of any residual IgM 
Galal ,3Gal antibody post-PRBC-absorption and as such it cannot be ruled out that 
an IgM antibody reactive against pig lymphocytes was present in the eluates.
In three of the nine eluates from pig 64, HLA class II specific antibody could 
be detected. Sera 13-3 and 39-3 indicated there might be a HLA class II antibody 
present post-platelet-absorption when tested back against pig 64 lymphocytes. The 
FlowPRA™ class II screen did not detect the presence of HLA class II antibody in 
eluate 13-3, whereas an HLA class II antibody was detected in eluate 39-3. Sirice 
the eluate 13-3 did react back against pig 64 lymphocytes, it is possible that an 
antibody, other than HLA, was involved. The acid treatment of human PBLs 
indicated that all the reactions in this serum were due to the presence of HLA class 
I antibody, but the panel used was small. Therefore, either the methods used to
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detect the presence of HLA class I antibody were not sensitive enough or an 
antibody recognising another protein molecule was involved. Although no single 
HLA class II specificity could be determined in any of the three eluates, all eluates 
showed a reduction in the overall specificity of the antibody. Two of the eluates 
(39-3 and 42-3) both contained an anti-DR15, 51,plus a weak DQ5, 6. This may 
reflect that both the HLA antibodies in these sera are detecting the same epitope.
In the current study, 46% of the Series 3 sera with a HLA class II specific 
antibody included a DO specific antibody. The majority of those sera that included a 
DO specific antibody (67%) were positive against pig splenocytes, with a frequency 
ranging from 6.7 to 100%. Since there are a high sequence homology between the 
SLA-DOB sequences (80% in exon 2 and 87% in exon 3) and the HLA-DOB 
sequences, it was not surprising that certain human sera reacted against the porcine 
lymphocytes.
The majority of patients with failed transplants form either HLA class I and/or II 
specific antibodies (Lobashevsky et al., 2000). Of those patients who do form HLA 
class II antibodies, many contain DQ specificities.
Of the six sera that contained an anti-DRI, three of these reacted against 
minipig MPcc. Sequence data of SLA class II of the NIH minipig of the cc 
haplotype show amino acid homology between human DRB1*0101 and DRB1*0102 
alleles, differing by 29% in the hypervariable residues (Gustafsson etal., 1990). This 
value was 66.2% when compared to other human DRB1* alleles.
Only four of the eleven eluates prepared from the minipig MPcc reacted 
back against minipig MPcc lymphocytes. Three of the four reactive eluates 
contained DR15 and 16 specific antibodies in their sera, but screening for the 
presence of HLA class I and/or class II was not performed, as there was 
insufficient eluate. A high number of the same sera were positive with both pig 64 
and MPcc lymphocytes. Only the eluates 15-3, 39-3 and 42-3 derived from minipig 
MPcc were positive when tested back against the minipig MPcc lymphocytes. The 
eluates of these sera from pig 64 were the only sera that had an HLA class II 
antibody identified in them. It is possible that these three eluates were recognising 
similar epitopes on these two genetically different pigs.
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The expression of the SLA class I genes appear to vary. The PD7 gene was 
generally about a fifth of that of PD1 and 14 (Renard et al., 2001). It has been 
proposed that the minipig PD14 gene maybe an allele at the MHC B locus, PD7 an 
allele at the MHC A locus and PD1 an allele at the MHC C locus. Proposed alleles 
in the pig of HOI haplotype, SLA-2, SLA-3 and SLA-1 respectively, were all 
expressed at equal levels. Further analysis showed that the PD7 gene promoter 
region displayed point mutations, unlike the SLA-3 gene. As such, it is possible that 
other SLA genes may show variations in levels of expression. This maybe a reason 
why in the current study a limited amount of HLA class I antibody was recovered 
from the eluates.
The data from the study described herein shows that HLA class I antibody 
does not react against pig lymphocytes with the frequency indicated by other 
studies. However, the information from the eluate experiments may indicate that: i) 
there was insufficient HLA class I antibody present in the eluate, ii) that the 
antibody was denatured, or iii) that the antibody was recognising an antigen other 
than HLA class 1. The eluate 4-3 probably had an HLA class I antibody eluted from 
pig lymphocytes. From the FlowPRA™ class I beads it could be argued that 
eluates 13-3, 39-3 and 42-3 also had some HLA class I activity. However, the data 
from this screening method was difficult to interpret and was thus unreliable. HLA 
class II antibodies are undoubtedly involved in the cross reactivity between pig 
lymphocytes and HLA antibody because in three eluates HLA class II specific 
antibody was found.
8.11 ROLE OF HLA CLASS II ANTIBODIES IN TRANSPLANTATION
Without doubt the presence of IgG HLA class I specific antibodies is a 
contraindication to clinical allo-transplantation as they always cause hyperacute 
rejection and immunological difficulties. The presence of HLA class II antibodies can 
also contribute to acute humoral rejection (Jeannet, Benzonana and Arni, 1981; 
Nunez, McPhaul and Stastny, 1983; Scornik etal., 1992; ten Hoor, Coopmans and 
Allebes, 1993). While HLA class II specific antibodies may not always be 
detrimental for graft survival, data indicates that they have the potential to cause
238
Chapter 8:______________________________________________________________    Discussion
hyperacute rejection or acute graft loss due to cellular rejection (Itescu et al., 1998). 
The influence of matching for the HLA-DPB locus also appears to play a role in 
cadaver kidney re-transplantation (Mytilineos, Deufel and Opelz, 1997). In the most 
part, data suggests that the presence of IgG HLA class II antibodies do play a role, 
particularly when the same HLA-DR mismatch is subsequently transplanted (Fuller 
et al., 1999b). Highly sensitised patients, for whom allografts are not realistic due to 
their panel reactive antibodies, represent a possible candidate group for xenografts. 
In many cases, their high panel reactive antibodies are due to previous transplants 
that failed. For that reason, the selection of particular pig breeds that do not express 
private and public SLA epitopes to which HLA antibodies cross-react would be 
beneficial.
8.12 GENETIC MANIPULATION TO PREVENT TRANSPLANT REJECTION
Although genetic manipulation of the Galal ,3Gal antigen or transgenic 
animals with complement regulatory proteins certainly prevents hyperacute 
rejection in some animal models, the production of an animal deficient in MHC 
antigens to prevent the H LA/S LA cross reaction, which may lead to hyperacute 
rejection or delayed xenograft rejection, is evidently important. Research using 
MHC class I and/or class II deficient mice, has shown that these animals have very 
few CD8^ T cells and/or a decreased CD4’*' T cell population. Xenotransplantation 
experiments involving these animals have revealed that donor MHC deficiency 
offers no protection to the graft. Thus, strategies to remove MHC antigen 
expression may not be successful in generating "universal donors" (Chitilian and 
Auchincloss, 1997). However, other techniques might be successfully employed in 
the future, such as the manipulation of the SLA genes to insert specific sequences 
that do not express public cross-reactive epitopes. This method may have 
implications in breeding the relevant animals, as they may not be able to present 
peptide to T cells.
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8.13 RECOGNITION OF SLA BY HUMAN T CELLS
Although there is limited published data regarding the binding of HLA allo- 
antisera to porcine MHC molecules, studies have demonstrated that human T cells 
recognise and are activated by SLA class I and II directly (Bravery et al., 1995; 
Murray et al., 1994; Xu et al., 1999). It was proposed that human CD8^ T cells 
could not recognise MHC SLA class I molecules as the conserved threonine at 
position 228 in HLA class I molecules is absent in the SLA class I molecule. 
However, this would not appear to be the case as It has been demonstrated that 
human CD8^ T cells are cytotoxic after stimulation with SLA class I molecules via 
other molecular interactions (Murray et al., 1994; Shishido et al., 1997). Other work 
demonstrates that human CD8^ T cells recognise SLA class I/peptide complex 
directly (Xu et al., 1999). The presence of HLA antibodies in an Individual indicates 
primed T cells. Even in the absence of detectable HLA antibodies after an 
immunising event, memory B cells may be present. As such, transplantation with 
pig organs expressing SLA would probably induce both cellular and humoral 
responses leading to rejection of the organ.
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8.14 SUMMARY
In the clinical situation of xenotransplantation, highly sensitised patients who 
could have their anti-species antibodies removed by immunoabsorption (or by the 
use of transgenic or knockout pigs), would still have to be crossmatched prior to 
transplantation. Thus, in summary this thesis has shown that:
a) To study the reaction of HLA antibodies against pig lymphocytes, the use of 
PRBC to remove anti-pig antibodies was satisfactory. Even in the presence 
of residual Galal ,3Ga! antibodies, they did not cause any false positive 
reactions against the pig lymphocytes. These results in themselves support 
the finding that these antibodies are a heterogeneous population and not all 
bind to the same molecule (McKane et al., 1998).
b) The removal of HLA specific antibody from human sera precludes the 
reaction observed between HLA specific sera and pig lymphocytes. This 
demonstrates that IgG HLA specific antibodies do bind to pig lymphocytes.
c) That in human serum there are other IgG non-HLA antibodies that react 
against pig lymphocytes. In some cases this antibody is absorbed out by 
PRBC demonstrating a possible carbohydrate determinant on both human 
and pig lymphocytes.
d) The elution studies demonstrate that in certain cases IgG HLA class II 
antibodies cross-react with swine lymphocytes in vivo. In one case an HLA 
class I antibody was also eluted from pig lymphocytes. These results show 
that HLA antibodies do cross react with some pig lymphocytes.
241
Chapter 8:__________________________________________________________________ Discussion
8.15 FUTURE WORK
1) Re-evaluate the cross reactivity of HLA class I antibodies by more 
absorption and elution studies, but by using larger volumes of cells 
and sera. Since it was possible that the was insufficient antibody 
present in the eluates from the current study, the eluates could be 
concentrated and tested by flow cytometry against pooled EBV cells 
and by the FlowPRA™ test. Flow cytometry is the most sensitive 
assay available for the detection of HLA specific antibodies, but CDC 
may also give information if these antibodies fix complement. It Is 
probable that the CDC test may not work, as the quantity of antibody 
must be of a sufficient titre to fix complement. However, other 
workers have succeeded in performing this assay and thus this would 
require further evaluation.
2) Confirm that the cross reactivity is against a 45kd molecule. This 
would establish if HLA class I antibodies were involved with the sera 
used in the current study. This method should also confirm the 
presence of a 32 and 26kd bands indicating cross reactivity with 
MHC class II molecules.
3) Since the NIH minipigs SLA are sequenced, repeating the absorption 
and elution experiments and establish the specificity of any HLA 
specific antibody may resolve some epitopes that are involved in the 
anti-HLA/SLA reactivity. The data from the current study shows that 
there was an HLA class II antibody eluted from minipigs with the cc 
haplotype. This requires repeating to identify the specificity of the 
antibody involved.
4) Homogenise pig tissue and remove supernatant from the cell lysate 
and run this by Western blotting with the PRBC-absorbed sera and 
eluates. The results may establish if there was a non-HLA component 
in the sera that reacts with pig lymphocytes. The results from this 
assay may be variable. The cell lysate may have to be concentrated 
and/or the PRBC-absorbed sera.
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